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Abstract
In recent decades one of the major forces driving lower urinary tract research has been 
the aim of discovering the origins of bladder dysfunction and developing new therapeutic 
agents for treatment of conditions such as detrusor overactivity (DO). It is now becoming 
clear that the simplistic view of the control of detrusor function is far more complicated 
and involves complex interactions between various components of the bladder. With 
limited access to human tissue, animal models have been used for investigating the 
underlying mechanisms that control the detrusor function under pathological states.
The aim of this project was to investigate the physiology and pathophysiology of bladder 
function in the streptozotocin (STZ)-induced diabetic rat model, 1, 4, 8 and 12-weeks post 
STZ injection. This was achieved by a combination of pharmacological, molecular biology 
and immunostaining techniques.
Antimuscarinic drugs are the current pharmacological agents available for treatment of 
DO; however, there is much controversy surrounding the muscarinic mediated responses 
of the bladders from animal models of DO. Therefore, the muscarinic receptor mediated 
smooth muscle contractions were investigated in detrusor strips from the diabetic rat. An 
increased agonist mediated response was detected in detrusor strips from 1-week 
diabetic rats, which was mediated by M3-muscarinic receptor subtype.
Basal spontaneous activity (SA) was detected in detrusor strips from control (non­
diabetic) and diabetic but not in 12-week diabetic tissues. 1-week diabetic tissues 
showed increased amplitude of basal SA compared to all other groups. Since increased 
amplitude of SA of the bladder is thought to be associated with DO, the mechanisms that 
may be regulating these contractions were explored. SA could be induced/modulated by 
low concentrations of muscarinic receptor agonist carbachol (CCH). Once again, the 
amplitude of CCH-induced SA was significantly bigger in 1-week diabetic tissues 
compared to all other groups. No role for the mucosa in mediating the CCH-induced SA 
was demonstrated; however, the mucosa may have a role in 12-week diabetic tissues.
The role of various potassium (K+) channels in modulating the SA was also investigated. 
Results demonstrated that opening of large conductance calcium activated potassium 
channels (BKCa) reduced the amplitude of CCH-induced SA in both control (non-diabetic) 
and diabetic groups, whilst blocking these channels resulted in an increased basal SA in 
all groups except 12-week diabetic tissues. A decreased expression of BKCa channel 
subunits’ mRNA was detected in all diabetic bladders. Opening of ATP sensitive K+ 
channels ( K At p ) only decreased the frequency of CCH-induced SA. Blocking K At p  
channels had no effect on basal SA in all tissues. A reduced expression of KATP channel 
subunits’ mRNA was also detected in diabetic rat bladders.
Recently a specialised type of cell, termed interstitial cells (ICs) has become the focus of 
research. It is postulated that they are involved in mediating the mechanosensory 
function of this organ. In this study, ICs were also identified in the rat urinary bladder 
using molecular biology and immunostaining. ICs were shown to play a role in mediating 
the CCH-induced SA of detrusors from rats, since their inhibition resulted in reduced SA 
in both control (non-diabetic) and diabetic tissues.
Marked differences were seen between 1-week and 12-week diabetic rat bladders and it 
was concluded that 1-week diabetic rats can be used as a model of DO.
In conclusion, the data presented in this thesis, indicates that complex mechanisms and 
physiological processes are present in the urinary bladder. It is clear that little is known 
about the detailed integrated physiology of the bladder wall and the structures involved in 
mediating the detrusor contractility.
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Chapter 1: General
Introduction
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1.1 The structure and function of the urinary bladder
The urinary bladder is a hollow distensible muscular organ which has two 
important functions: to store urine and to void urine in a controlled way. The 
storage and periodic elimination of urine is dependent on the activity of the 
reservoir, the urinary bladder, and an outlet consisting of the bladder neck, the 
urethra, and the striated muscles of the urethral sphincter.
1.1.1 Anatomy of the urinary bladder
The bladder is situated in the pelvic cavity posterior to the pubic symphysis,
which in males is directly anterior to the rectum and in females is anterior to the 
vagina and inferior to the uterus. The shape of the urinary bladder alters 
according to the amount of urine that it contains. The empty bladder is
collapsed and lies entirely within the pelvis. As it fills it takes on a spherical or
pear shape and its superior wall rises into the hypogastric region (Tortora & 
Grabowski, 2003; Snell, 2004). The position of the bladder is stabilised by 
ligaments which connect the inferior and anterior surface of the bladder to the 
pubic and pelvic bones.
The urinary bladder can be divided into two pharmacologically and 
physiologically distinct regions. The first region is the bladder body or dome 
which is a hollow smooth muscle region lined by a mucous membrane and 
covered on its outer aspect by peritoneal serosa and partly by fascia (Gosling, 
1979). The second region of the bladder is a much smaller region extending 
from the ureters to the urethra called the bladder base or neck and consists of 
the trigone, urethrovesical junction, deep detrusor and the anterior bladder wall. 
A schematic drawing of the bladder can be seen in Figure 1.
1.1.2 The bladder wall
The wall of the urinary bladder comprises of three layers. The deepest is the 
mucosa which is a mucous membrane composed of urothelium and the 
underlying lamina propria. Below the mucosa is the intermediate muscularis or 
the detrusor muscle. The most superficial coat of the urinary bladder, on the
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posterior and inferior surfaces, is the adventitia or serosa, a layer of areolar 
connective tissue.
1.1.2.1 The detrusor
The main component of the wall of the bladder is the smooth muscle or the 
detrusor. The detrusor smooth muscle cells are arranged into fascicles or 
bundles which are organised in groups around the bladder. The orientation of 
the detrusor muscle fibres is neither circular nor longitudinal, rather the muscle 
bundles cross each other forming a meshwork, particularly at the sides of the 
bladder. The muscle bundles may interconnect and furthermore individual 
smooth muscle cells themselves are interconnected via gap junctions. The 
individual smooth muscle cells in the detrusor are typically long spindle shaped 
cells with a central nucleus. Interspersed between smooth muscle bundles is 
connective tissue, composed primarily of collagen and elastic fibres (reviewed 
by Andersson & Arner, 2004).
During the filling of the bladder, the smooth muscle cells have to relax and be 
able to stretch and rearrange themselves over a very large area to 
accommodate the increase in volume without a significant rise in pressure. In 
other words, the bladder wall must be extremely compliant. Thus, there must be 
a continuous contractile activity in the smooth muscle cells to adjust their length 
during filling (reviewed in Turner & Brading, 1997; Andersson & Arner, 2004). 
The bladder of many species, including man, is rhythmically active during the 
filling phase. It is believed that this activity, also called spontaneous activity 
(SA), autonomous activity or micromotions, is generated within the bladder wall 
and may be important in sensation of bladder fullness and maintaining bladder 
compliance. Recent work has shown that the SA involves waves of contraction 
and localised stretches of the bladder wall. The mechanisms generating these 
complex events are still unclear and they may involve a network of specialised 
cells known as interstitial cells (ICs) driven by excitatory and inhibitory neural 
inputs (Gillespie, 2004), which are discussed in more detail in Chapter 6.
During voiding, force generation and shortening of smooth muscle cells must be 
initiated relatively quickly to allow the shape of the bladder to conform to the 
minimum surface area/volume ratio possible. In the normal bladder, the smooth
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muscle possesses a unique structure and characteristics that allows these 
requirements to be fulfilled. This structure is composed of contractile proteins 
and filaments such as actin and myosin that are not arranged into distinct 
sarcomeres. Cyclic attachment and detachment of the globular portion of the 
myosin molecules to the actin filaments results in the sliding of the filaments 
past each other and smooth muscle contraction (reviewed by Adelstein & 
Eisenberg, 1980 & Andersson & Arner, 2004).
1.1.2.2 The urothelium
The urothelium, or transitional epithelium, is a specialised lining of the urinary 
tract, extending from the renal pelvis to the urethra. The urothelium is 
composed of three layers; a basal cell layer attached to a basement membrane 
which is germinal in nature; an intermediate layer; and a superficial apical layer 
with large hexagonal cells’with diameters of 25-250 pm, which are also termed 
"umbrella cells” (Figure 1) (reviewed in Lewis, 2000). The apical membrane of 
umbrella cells is covered with scalloped shaped plaques which are separated 
by plasma membrane domains called the “hinge”. High resistance tight 
junctions are found between the umbrella cells and effectively divide the cell 
surface into apical and basolateral membrane domains. These cells function as 
a barrier against most substances found in the urine thus protecting the 
underlying tissue. The apical membrane of the umbrella cells also has a unique 
lipid and protein composition that contributes to the low permeability of these 
cells (reviewed in Lewis, 2000 & Apodaca, 2004).
Historically, the bladder urothelium has been considered only as a passive 
barrier that prevents urine leakage. However, recent studies have shown that 
the urothelium is a highly specialised structure, involved in antigen presentation, 
physical protection, the micturition reflex, metabolic secretion, inflammatory 
regulation and mechano-sensory signal transduction (reviewed in Birder, 2004 
& Moore & Goldman, 2006). Studies over the last few years indicate that 
urothelial cells display a number of properties similar to sensory neurons. It is 
believed that the urothelium, when exposed to physiological and mechanical 
stimuli, receives and transmits signals to submucosal neurons. Specialised 
sensory and signalling properties that allow the urothelial cells to respond to 
different stimuli include the expression of nicotinic, muscarinic, tachykinin,
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adrenergic, bradykinin and transient potential receptors, including the vanilloid 
receptors, TRPV1, TRPV2 and TRPV4 etc. (Birder et al, 2001; Birder, 2004; 
Beckel et al, 2006). The sensory role of the urothelium is also suggested in its 
responsiveness to transmitters released from sensory nerves, close association 
with suburothelial afferent nerves and release of chemical mediators such as 
ATP (Ferguson et al, 1997), tachykinins (Lecci & Maggi, 2001); ACH (Yoshida 
et al, 2008) and nitric oxide (NO) (De Groat, 2004) allowing reciprocal 
communication with neighbouring urothelial cells as well as underlying 
components such as myofibroblasts.
The urothelium can also modulate the underlying smooth muscle tone and 
inhibit detrusor contractility in vitro. Substances such as NO released from the 
urothelium are able to alter smooth muscle tone by activating guanyl cyclase 
which increases cyclic guanosine monophosphate (cGMP) levels and causes 
smooth muscle relaxation (Persson et al, 1993). Endogenous prostaglandins 
are also released from the urothelium which are important in increasing detrusor 
tone (Pinna et al, 2000). The presence of an unidentified urothelium derived 
inhibitory factor (UDIF), which is released from the urothelium and can inhibit 
detrusor contraction in vitro, has also been reported by several groups 
(Hawthorn et al, 2000; Templeman et al, 2002; Chaiyaprasithi et al, 2003).
The mechanisms by which the urothelium modifies detrusor contractile 
responses may be important for normal bladder function and thus dysfunction of 
any of these mechanisms may well be involved in bladder disorders such as 
detrusor overactivity (DO).
1.1.2.3 Interstitial cells (ICs) I myofibroblasts
A recently identified population of cells, known as myofibroblasts or ICs, has 
been identified in the bladder of many species (McCloskey & Gurney, 2002; 
Shafik et al, 2004; Van der AA et al, 2004; Metzger et al, 2008). These cells are 
morphologically similar to interstitial cells of Cajal (ICCs) in the gut and are 
thought to be found immediately beneath the urothelium as well as on the outer 
detrusor layers and on the boundary of smooth muscle bundles, where they 
seem to play an important role in processing of sensory information, 
pacemaking and modulating detrusor contractility (Sanders, 1996; McCloskey & 
Gurney, 2002; Hirst & Ward, 2003; Shafik et al, 2004; Van der AA et al, 2004;
Metzger et al, 2008). Further analysis of the function and the location of these 
cells in the urinary bladder will be discussed in Chapter 6.
1.2 Innervation of the bladder and control of voiding
1.2.1 The micturition reflex
Storage of urine and voiding comprise the two phases of the micturition cycle. 
The bladder and urethra function reciprocally to maintain the cycle. As the 
bladder fills during the storage phase, the detrusor remains relaxed with little 
change in the intravesical pressure. The neural pathways that stimulate the 
bladder are quiescent during this phase, and inhibitor pathways are active. The 
urethral outlet stays closed, with progressively increasing external urethral 
sphincter contractions, which act as a guarding reflex. When the bladder 
volume reaches a critical threshold, the urethral sphincter relaxes and the 
detrusor engages in a series of contractions which result in opening of the 
bladder neck and elimination of urine (Hanno et al, 2001).
1.2.2 Autonomic Pathways
The control of the micturition cycle is dependent upon neural circuits located in 
the brain, spinal cord and peripheral ganglia. The bladder has dense innervation 
of autonomic parasympathetic (pelvic), thoracolumbar sympathetic 
(hypogastric) and somatic (pudendal) nerves (Reviewed in De Groat, 1997 & 
Andersson and Arner, 2004), which often have opposing functions (Figure 2).
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Figure 2) Efferent pathways of the lower urinary tract. Efferent pathways and 
neurotransmitter mechanisms that regulate the lower urinary tract. Parasympathetic 
postganglionic axons which arise from the S2-S4 spinal segments and travel in sacral roots and 
pelvic nerves (PNs) release acetylcholine (ACH), which produces bladder contraction by 
stimulating muscarinic receptors (M3-subtype) in the bladder smooth muscle. Sympathetic 
postganglionic neurons originating from the T11-L2 segments in the spinal cord and travelling 
through the inferior mesenteric ganglia and the hypogastric nerve (HGN), release noradrenaline 
(NA), which activates (33 adrenergic receptors to relax bladder smooth muscle and activates a1 
adrenergic receptors to contract urethral smooth muscle. Somatic axons which arise from the 
S2-S4 spinal segments and pass through the pudendal nerves, also release ACH, which 
produces a contraction of the external sphincter striated muscle by activating nicotinic 
cholinergic receptors. Adapted from Fowler et al, 2008.
1.2.2.1 Parasympathetic pathways
The parasympathetic outflow is the main provider of excitatory input to the 
bladder. It densely innervates the bladder, in a way that nerve fibres are 
intimately related to individual muscle cells. Parasympathetic postganglionic 
nerves arise from the S2-S4 spinal segments through the pelvic nerves where 
they release both ACH and non-adrenergic non-cholinergic (NANC) transmitters 
(Figure 2). Cholinergic transmission is the major excitatory mechanism in 
human bladder and results in detrusor contraction and micturition (reviewed by 
Bissada et al, 1977, Andersson, 1993, Andersson & Arner, 2004 & De Groat, 
2006). ACH, the primary neurotransmitter responsible for initiation of contraction 
in the detrusor, acts on the muscarinic receptors on the smooth muscle and
results in subsequent activation of the contractile machinery leading to 
micturition. Muscarinic receptors are also present on parasympathetic nerve 
terminals at the neuromuscular junction and in the parasympathetic ganglia. 
Activation of these receptors on the nerve terminals can inhibit (through M4- 
muscarinic receptors) or enhance (through M1 -muscarinic receptors) ACH 
release, depending on the intensity of neural firing (Somogyi et al, 1994; 
Inadome et al, 1998; Shen & Mitchelson, 2001). There is a small contribution 
from other neurotransmitters (NANC) and receptors towards bladder 
contraction. This NANC component seems to vary with species and the 
frequency of neuronal stimulation of bladder detrusor (reviewed by Andersson & 
Arner, 2004 & Canda et al, 2006). It is believed that contribution of NANC 
component can increase in conditions associated with DO (reviewed by Canda 
et al, 2006). NANC pathways involve the purinergic system/ATP, nitric oxide 
(NO), vanilloide, prostanoids, neuropeptides and their receptors (reviewed by 
Andersson, 1993, Burnstock, 2001 & Andersson & Arner, 2004).
1.2.3 Sympathetic Pathways
Sympathetic efferent innervation of the urinary bladder results in relaxation of 
the detrusor body and contraction of the bladder neck and urethra during the 
filling phase of the micturition cycle. Sympathetic nerves originate in T11-L2 
segments in the spinal cord and travel through the inferior mesenteric ganglia 
and the hypogastric nerve (HGN), and subsequently release noradrenaline (NA) 
(Figure 2). The bladder body contains a high density of (3-adrenoreceptors 
(mainly of (32 and (33 subtypes), stimulation of which results in relaxation and 
urine storage. NA also activates the a-adrenergic excitatory receptors (mainly of 
a1 subtype) in the urethra, resulting in smooth muscle contraction and 
subsequent closure of the bladder neck during the filling phase of the micturition 
cycle reviewed in Andersson and Arner, 2004 & De Groat, 2006; Yamaguchi & 
Chappie, 2007).
1.2.4 Somatic pathways
Somatic innervation of the urethral sphincter results in contraction of the 
external striated muscle and subsequent inhibition of voiding. Somatic efferent 
pathways arise in S2-S4 motor neurons in Onufs nucleus and reach the 
periphery through the pudendal nerves (Figure 2). The ACH released from
these nerves excites nicotinic receptors on the sphincter muscle and results in 
urethral contraction (reviewed in de Groat, 1993, 2006 & Yoshimura & 
Chancellor, 2003).
1.2.5 Afferent pathways
During storage of urine there is ongoing afferent signalling that allows 
continuous sensation of bladder fullness and stretch. Signals from the bladder 
body are transmitted to the spinal cord by the pelvic and HGNs, whereas 
sensory input from the bladder neck and urethra is carried in the pudendal and 
HGNs (reviewed by Fowler et al, 2008). The most important afferent 
components of these nerves are the small myelinated A-5 and non-myelinated 
C fibres. A-5 fibres, which are located primarily within the detrusor muscle layer, 
respond to passive distension and active contraction and thus convey 
information about bladder filling. On the other hand, C fibres reside in the 
muscle close to the urothelium and are insensitive to bladder filling under 
physiological conditions. It appears that C fibres are more important in signalling 
of inflammatory and noxious events in the bladder and are sensitive to many 
different substances including tachykinins, NO, ATP, prostaglandins, 
endothelins and other neurotrophic factors which are released in the bladder 
from the afferent nerves as well as urothelial cells (Habler et al, 1990; De 
Groat, 1993 ; Rong et al, 2002; De Groat et al, 2006).
Since the cholinergic neurotransmitter, ACH, is the main mediator responsible 
for detrusor and urethral smooth muscle contraction, it is therefore important to 
understand the structure and function of the muscarinic receptors involved in 
mediating the effects of ACH in urinary bladder smooth muscle (UBSM).
1.2.6 Muscarinic Receptors: characterisation of structure and 
function
The muscarinic ACH receptors are members of a family of plasma membrane 
receptors which mediate signal transduction by coupling with heterotrimeric 
guanine nucleotide binding proteins (G-proteins). There are five receptor 
subtypes (M1-M5) and they are known to share a similar three dimensional 
structure, consisting of a single protein with seven transmembrane domains 
(TM1-7) linked by three intracellular and three extracellular loops (Figure 3)
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(Burstein et al, 1995; Wess et al, 1995; Felder, 1995). A schematic structure of 
these receptors is illustrated in Figure 3. It is believed that the seven 
transmembrane domains of muscarinic receptors assemble in a packed ring-like 
structure to form the ligand binding pocket. The N-terminus of the muscarinic 
receptor resides on the extracellular side of the membrane and contains 
glycosylation sites. The C-terminus is located on the cytoplasmic domain and 
contains a cysteine residue which is highly conserved across G-protein coupled 
receptors. There is a high degree of conservation between the 5 different 
muscarinic receptor subtypes in the sequence of their 7 transmembrane 
domains. Marked differences are seen in the hydrophilic cytoplasmic domains 
and extracellular loops and tails and it has been shown that cytoplasmic 
domains are important for G-protein coupling (Felder, 1995).
N-G lycosylation
N
Extracellu lar
TM I TM II TM I I I TM  VTM  IV TM  VI TM  V II
M em brane
Intrace llu lar
Figure 3) Topology of a muscarinic acetylcholine receptor, i: intracellular loop. TM: 
transmembrane domain. Diagram produced from information given by Felder et al, 1995.
By a mechanism that is still unknown, ACH binding to the transmembrane core 
of the muscarinic receptors triggers conformational changes in the receptor 
proteins which enable distinct cellular receptor domains to recognise and 
activate specific sets of G proteins. Muscarinic receptors stimulate signalling by 
binding to a heterotrimeric G-protein complex consisting of a, (3 and y subunits 
which provide the specificity for coupling to an appropriate effector molecule.
Upon interaction with the muscarinic receptor, the a-subunit dissociates from 
the (3 and y subunits and then interacts with an effector protein or ion channel to 
stimulate or inhibit a cascade of intracellular signalling pathways (Felder, 1995).
An important molecular distinction between the different muscarinic receptor 
subtypes is their specific coupling preferences to G-proteins. Muscarinic 
receptors can be classified into two major functional categories: pertusis toxin 
sensitive and insensitive receptors. M1, M3, and M5 are coupled to the 
pertussis toxin insensitive Gq/Gn protein family. These are a class of G-proteins 
that are not susceptible to ADP-ribosylation by pertussis toxin (Caulfield, 1993; 
Kostenis et al, 1997; Longhurst and Uvelius, 2001). Stimulation of these 
receptors mediates the activation of several isoforms of phospholipase C-(3 
(PLCp) resulting in the breakdown of phosphatidyl inositol lipids (PI hydrolysis). 
The second group includes M2 and M4 receptors, which are linked to pertussis 
toxin sensitive G (Gj) proteins (G proteins that are susceptible to ADP- 
ribosylation by pertussis toxin), activation of which results in inhibition of 
adenylate cyclase (Felder, 1995; Wess et al, 1995).
1.2.7 Muscarinic receptors in the bladder
Cholinergic muscarinic receptors are found throughout the bladder and are 
found both prejunctionally and postjunctionally. Prejunctionally, they have been 
identified on parasympathetic and sympathetic nerve endings, where they 
regulate ACH and NA release. It is believed that M1 receptors at prejunctional 
sites on cholinergic nerve terminals in the bladder are facilitatory with activation 
resulting in ACH release, especially during voiding. However M2- and M4- 
muscarinic receptors are inhibitory receptors and their activation reduces the 
release of ACH (Braverman etal, 1998; Igawa, 2000). Postjunctional muscarinic 
receptors can be found in two locations: on the detrusor smooth muscle, where 
they mediate contraction and on the urothelium at a density twice that of the 
detrusor, where they cause release of UDIF which inhibits detrusor contraction 
(Chess-Williams, 2002). The presence of M2 and M3, but not M1, M4 or M5, 
has been confirmed at the postjunctional level by immunoprecipitation studies 
using human, rabbit, guinea pig and rat urinary bladder. Several studies have
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reported that the M2 receptor is the most abundant muscarinic subtype in the 
bladder, with a M2:M3 ratio of 9:1 in rat bladder and 3:1 in all other species 
studied. Despite the dominant presence of the M2 receptor, pharmacological in 
vitro characterisation of muscarinic receptors in rat (Wang et al, 1995; 
Longhurst et al, 1995), rabbit (Choppin et al, 1998), guinea pig (Noronha-Blob 
et al, 1989), pig (Sellers et al, 2000) and human (Chess Williams, 2001) 
bladders indicate that the direct contraction of detrusor is mediated by the MS- 
muscarinic receptor, with the role of the M2-muscarinic receptor remaining 
unclear.
1.2.7.1 M3 muscarinic receptor signalling pathways
M3-muscarinic receptors act via a variety of second messenger systems to 
cause direct smooth muscle contraction. In the bladder of several species, 
including human, the traditional signal transduction mechanism of the MS- 
muscarinic receptor is stimulation of phosphoinositide hydrolysis. It is generally 
accepted that the M3 muscarinic receptor activates phospholipase C (PLC) via 
pertusis toxin-insensitive Gq/Gn proteins. PLC in turn accelerates the rate of 
phosphatidyl inositol (4, 5) biphosphate (PIP2) hydrolysis. The breakdown of 
PIP2 results in formation of inositol triphosphate (IP3) and diacylglycerol (DAG) 
and these molecules act as the second messengers. IP3 mobilises calcium 
(Ca2+) from intracellular stores and DAG activates protein kinase C (PKC). Ca2+ 
is believed to bind to calmodulin, a 16.8kD protein containing four Ca2+ binding 
sites, and the Ca2+/calmodulin complex then activates myosin light chain kinase 
(MLCK) which catalyses transfer of phosphate from MgATP to a serine residue 
near the N-terminal of myosin regulatory light chains. Phosphorylation of myosin 
light chain allows cross-bridge cycling and smooth muscle contraction. The 
reverse reaction is catalysed by myosin light chain phosphatase type I (MLCP) 
(Figure 4) (reviewed by Gallagher et al, 1997; Sanders, 2001; Andersson & 
Arner, 2004;).
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Figure 4) Regulation of smooth muscle contraction via M3-muscarinic receptor 
stimulation: M3-muscarinic receptor contributes to smooth muscle contraction via Ca2+ 
dependent and independent mechanisms. ACH, acetylcholine; PIP2, phosphatidyl inositol (4, 5) 
biphosphate; PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; CPi-17 for 
PKC-potentiated inhibitory protein of 17 kDa; MLC, myosin light chain; IP3, inositol 
trisphosphate; SR, sarcoplasmic reticulum; RyR, ryanodine receptor. Adapted from Somlyo & 
Somlyo, 2000; Andersson & Arner, 2004.
Although elevation of intracellular Ca2+ concentration plays a central role in 
smooth muscle contraction, there is still much debate about the precise 
mechanism of intracellular Ca2+ release. It was originally thought that the MS- 
muscarinic receptor mediated contractile response in the bladder was mediated 
by intracellular Ca2+ mobilisation by IP3. This assumption has been re­
examined by studies which have shown that the M3-mediated response in the 
bladder of various species is mediated by an increase in intracellular Ca2+ 
through L-type voltage dependent Ca2+ channels (VDCCs), especially at low 
concentrations of muscarinic agonists, since force development is diminished in 
Ca2+ channel (CAv1.2) knockout mice or in the presence of VDCCs blocker 
nifepidine (Wu et al, 1999; Fry et al, 2002; Schneider et al, 2004a, Wegner et al, 
2004; Rivera & Brading, 2006; Wuest et al, 2007). Thus, M3-muscarinic 
receptor mediated detrusor contraction involves Ca2+ entry via VDCCs followed 
by uptake of Ca2+ into intracellular stores and subsequent release either via
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IP3-dependent or Ca2+-induced Ca2+ release processes via ryanodine 
receptors (Figure 4) (Wuest et al, 2008; Rivera & Brading, 2006; Christ & 
Hodge, 2006). It is believed that at high agonist concentration the release of 
Ca2+ from intracellular stores becomes increasingly important (Chess-Williams, 
2002; Schneider et al, 2004a, Schneider et al, 2004b).
Although Ca2+-dependent mechanisms are important in mediating MS- 
muscarinic receptor modulated smooth muscle contraction, recently secondary 
mechanisms have been identified that can modulate bladder contractility 
independently of Ca2+ (i.e. without necessarily changing the intracellular Ca2+). 
This process is called Ca2+ sensitisation. The small GTPase Rho and one of its 
downstream effectors, Rho-associated kinase (ROCK), have been shown to 
play an important role in this mechanism (Wu et al, 1999; Fry et al, 2002; 
Schneider et al, 2004a, Peters et al, 2006). Activated ROCK phosphorylates the 
regulatory subunit of MLCP and inhibits phosphatase activity, which results in 
prevention of myosin light chain dephosphorylation, resulting in Ca2+ 
sensitisation of the detrusor smooth muscle and contraction (Figure 4) 
(Wibberley et al, 2003). Ca2+ sensitisation by the Rho/ROCK pathway is 
believed to be important in regulating the tonic phase of agonist-induced 
contraction in smooth muscle.
1.2.7.2 M2-muscarinic receptor signalling pathways
The signalling mechanisms for the M2-muscarinic receptors are less clear than 
those for the M3-muscarinic receptor subtype. The M2-muscarinic receptor is 
not involved in direct contraction of the bladder smooth muscle. It is generally 
believed that the M2-muscarinic receptors are coupled through the inhibitory G 
protein to adenylate cyclase (AC) and aid bladder contraction by preventing (3- 
adrenoceptor-induced formation of cyclic adenosine mono phosphate (cAMP), 
thus reversing NA-induced relaxation. Therefore, activation of M2-muscarinic 
receptor during micturition may "switch off' the sympathetic inhibitory |3- 
adrenoceptor-mediated relaxation and result in more efficient emptying (Figure 
5) (Chess-Williams, 2002).
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Contraction
Figure 5) Regulation of smooth muscle contraction via M2-muscarinic receptor 
stimulation: M2-muscarinic receptor contributes to smooth muscle contraction by reversing the 
(3-adrenoreceptor mediated relaxation via cAMP. M2-muscarinic receptor also inhibits the BKCa 
channels thus enhancing the contraction initiated by M3 muscarinic receptor stimulation. ACH, 
acetylcholine; (3-Ar, (3-adrenoreceptors; AC, adenylate cyclase; BK, large conductance Ca2+- 
activated K+ channels. Diagram was produced from information given in review by Andersson & 
Arner, 2004, Chess-Williams, 2002 & Nakamura et al, 2002.
M2-muscarinic receptors can also activate smooth muscle cells by decreasing 
the probability of potassium (K+) channels opening. For example Nakamura et 
al (2002) have shown that M2-muscarinic receptor stimulation in rat bladder 
smooth muscle cells results in inhibition of large conductance Ca2+ activated K+ 
channels (BKCa) and subsequent contraction of UBSM cells. Since BKCa 
channels are important in modulation of UBSM excitability and restoration of the 
resting membrane potential, inhibition of these channels by M2-muscarinic 
receptors should result in increased action potential duration and prolonged 
contraction. However, M2-muscarinic receptor mediated smooth muscle 
contraction is contingent upon Ca2+ mobilisation by another receptor like the 
M3-muscarinic receptor (Nakamura et al, 2002). Thus, it has been suggested 
that the M2-muscarinic receptor may only enhance smooth muscle contraction
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which is initiated by the M3-muscarinic receptor (Heppner et al, 1997; Ehlert, 
2003).
It has also been demonstrated that under conditions where the M3-muscarinic 
receptor is inactivated and cAMP levels have been increased, the contractile 
responses of the bladder smooth muscle can be attributed to M2-muscarinic 
receptor activation (Yaminishi et al, 2000). For example, in pig bladder removal 
of the M3 receptor population with an alkylating agent e.g. 4-DAMP mustard (N- 
2-chloroethyl-4-piperidinyl diphenylacetate), a selective M3-muscarinic receptor 
antagonist, followed by elevation in cAMP levels can illicit a response to 
muscarinic receptor agonists that is at least partially mediated via the M2- 
muscarinic receptor subtype (Chess-Williams, 2002). The same type of 
mechanism has been demonstrated in rat urinary detrusor muscle (Hedge et al, 
1997). Thus, it has been suggested that the function of this muscarinic receptor, 
subtype maybe more important in disease states or conditions where the M3- 
muscarinic receptor is dysfunctional.
Other postulated mechanisms by which the M2-muscarinic receptor may 
mediate contraction include opening of non-specific cation channels resulting in 
depolarisation and Ca2+ influx which results in stimulation of Rho and Ca2+ 
sensitisation (Bolton & Zholos, 1997).
Since the major signalling cascade of M2-muscarinic receptor is dependent on 
(3-adrenoceptor mediated smooth muscle relaxation, then it is important to 
understand the role of adrenoceptors as part of sympathetic neurotransmitter 
pathway in mediating the UBSM contractility.
1.2.8 Adrenoceptors in the bladder
The urinary bladder has been shown to possess functional a- and (3-adrenergic 
receptors that are important in modulating bladder smooth muscle tone. 
Adrenergic mechanisms are especially important during the fiiiing phase of 
micturition cycle, where the bladder muscle needs to be relaxed and compliant 
to allow urine storage (Anderson & Marks, 1983; Michel & Vrydag, 2006). a- 
adrenoceptors are most prominent in the bladder base and neck and their 
stimulation results in smooth muscle contraction. However, the key 
adrenoreceptor involved in mediating detrusor relaxation is the (3-subtype ((32
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and (33) (reviewed in Andersson & Arner, 2004). (3-adrenoceptors mediate 
detrusor relaxation via coupling of Gs protein to AC, which once activated, 
catalyses the conversion of ATP to cAMP. cAMP in turn activates PKA, or 
alternative effector molecules, to mediate smooth muscle relaxation. (3- 
adrenoceptors can also activate BKca channels in the detrusor via modulation of 
localised Ca2+ signals and increasing VDCC mediated Ca2+ influx (Petkov & 
Nelson, 2005; Ferro, 2006).
Since both cholinergic and adrenergic receptors, as part of their signalling 
pathways, interact with various ion channels on the UBSM cell membrane, it is 
important to understand the role of these channels in mediating the detrusor 
excitability and contractility in normal and pathological conditions.
1.3 Ion channels involved in mediating bladder smooth muscle 
function
In smooth muscle, ion conductance across the membrane provides the main 
trigger for the regulation of cell contraction and excitability. Ion channels provide 
the major access route to alter the cytoplasmic Ca2+ and K+ concentrations. 
Various Ca2+ and K+ channels have been identified in UBSM, that play key roles 
in modulating cellular excitability, signalling and the response to external stimuli.
1.3.1 Role of Ca2+ channels in bladder smooth muscle
As described earlier, to activate the contractile apparatus, an increase in 
intracellular Ca2+ concentration must be initiated. The Ca2+ utilised for activation 
of the contractile apparatus enters the cytoplasmic compartment of the smooth 
muscle cell via at least four types of Ca2+ channels: voltage dependent (L-type 
or VDCCs), store-operated, IP3 receptor and ryanodine receptor channels.
VDCCs and store operated channels are important in influx of Ca2+ from the 
extracellular space and are found abundantly in the plasma membrane of the 
cell. VDCCs activate upon membrane depolarisation and mediate Ca2+ influx in 
response to action potentials and membrane depolarisation (Catteral, 2000).
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Ryanodine receptors (RyR) and IP3 receptors are important in mediating Ca2+ 
release from intracellular stores and are located in the membranes of the SR 
(reviewed by Sanders, 2001 & Fraizer et al, 2008). Ca2+ entry via VDCCs 
triggers Ca2+ induced Ca2+ release (CICR) from RyRs, resulting in localised 
Ca2+ release termed Ca2+ sparks (Collier et al, 2000; reviewed by Sanders, 
2001 & Chalmers et al, 2007). RyR inhibition has been shown to inhibit bladder 
contraction in rabbits (Zderic et al, 1994), guinea-pig (Buckner et al, 2002) and 
human bladder (Visser & Van Mastrigt, 2000), although other investigators have 
not reported such inhibitions in mouse, pig and human bladders (Wuest et al, 
2007).
The role of IP3 receptors (IP3-R) in muscarinic receptor mediated smooth 
muscle contraction was described earlier. IP3-R is the predominant Ca2+ 
release channel on the sarcoplasmic reticulum (SR). Ca2+ alone is not enough 
for IP3-R activation and both IP3 and Ca2+ are required for channel activation 
(Wray et al, 2005; Chalmers et al, 2007).
Figure 4 demonstrates the role of some of these channels in M3-muscarinic- 
receptor-mediated smooth muscle contraction.
1.3.2 Role of K+ channels in bladder smooth muscle
K+ channels belong to a diverse family of membrane proteins that play 
important roles in mediating smooth muscle cell excitability and tone. Various 
types of K+ channels exist, which are not only activated under distinct conditions 
but also mediate different physiological functions. The main K+ channels which 
have been investigated in the bladder include Ca2+-activated K+ channels (Kca), 
ATP-sensitive (KAtp) channels and voltage-gated (Kv) channels.
1.3.2.1 Ca2+-activated potassium (Kca) channels
Kca channels are activated by a local or global increase in the intracellular Ca2+ 
concentration. UBSM exhibits spontaneous action potentials which are related 
to the phasic nature of spontaneous contractions in this tissue. These phasic 
contractions depend upon Ca2+ entry via VDCCs and production of an action 
potential. Kca channels are important in restoration of the resting membrane
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potential by hyperpolarising the plasma membrane to reduce or inhibit Ca2+ 
entry via VDCCs (Herrera et al, 2000). Kca channels are classified by their 
conductance: small (SKca)(2-25 pS), intermediate (IKca)(25-100 pS) and large 
(BKCa)(100-300pS) (Ghatta et al, 2006).
Large Conductance Ca2+- activated potassium channels (BKrJ
BKca channels are also known as BK, Slo and MaxiK channels. These channels 
are activated both by changes in intracellular Ca2+ and by membrane 
depolarisation and play a significant role in mediating UBSM tone and 
excitability. The activation of BKCa channels results in membrane 
hyperpolarisation and inhibition of action potential firing.
BKca channels consist of two distinct subunits: a and (3, arranged in 1:1 
stoichometry. Each channel exists as a tetramer, composed of 4 a -subunits 
either alone or in association with (3-subunit pairs. The a-subunit, also termed 
Slo-1, is encoded by the KCNMA1 gene and is the pore-forming subunit of BKca 
channels, whereas the (3-subunit, also termed the Slop, is the regulatory part of 
these channels and is the protein product of the KCNMB gene.
The a-subunit is composed of 7 transmembrane spanning domains (S0-S6) at 
the N-terminus, the P-loop, which is the pore forming loop between S5 and S6 
domains, and four hydrophobic segments (S7-10) at the large intracellular C- 
terminus (Figure 6). The extracellular N-terminus of the a-subunit is important 
for binding of the p-subunit. The centre of the four a subunits is the potassium 
selective pore. The pore forming motif of each subunit consists of the P-loop 
and the S5-S6 domains. The P-loop also contains the binding site for the pore 
blockers such as iberiotoxin (IBTX) and charybdotoxin (CHTX). The S2, S3 and 
S4 domains are important in voltage sensitivity of this channel. The Ca2+ 
binding site is believed to reside between the S9 and S10 domains (Ca2+ bowl). 
The C-terminal region also consists of a regulator of conductance of K+ (RCK) 
(the S7 and S8 domains), which is important for the physiological regulation of 
BKca channels by Ca2+. However, further Ca2+ binding sites may also be 
present in other regions of this channel (Figure 6) (reviewed by Ghatta et al, 
2006).
2 0
There are four putative (3-subunit types : (31- (34. The (3-subunit is composed of 
two transmembrane (TM) units which are connected via an extracellular loop. 
The residues within this extracellular domain are important in inducing the 
appropriate conformational change within the a-subunit to promote IBTX or 
CHTX binding. The (3-subunit can also increase the sensitivity of the a-subunit 
to Ca2+. However, the association of the a-subunit with different (3-subunits can 
modify the pharmacological properties of these channels. The (31 -subunit in 
bladder smooth muscle is important in modulating BKCa activity and plays a 
major role in regulation of phasic activity in the detrusor (reviewed by; 
Andersson & Arner, 2004 & Ghatta et al, 2006).
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Figure 6) Schematic representation of the structure of BKCa channels. TM: transmembrane 
unit of p-subunit, P: pore-forming loop, S: transmembrane spanning domain of the a-subunit . 
Adapted from Ghatta et al, 2006.
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Intermediate conductance Ca2+ activated potassium (IKnJ  channels
IKca channels are not voltage sensitive and are activated only by an elevation of 
intracellular Ca2+ concentration which results in hyperpolarisation of the plasma 
membrane. It is believed that IKca channels in addition to BKca channels play an 
important role in the regulation of membrane potential and bladder smooth 
muscle tone (Ohya et al, 2000).
IKca channels are composed of four putative a-subunits only with no regulatory 
(3-subunit associated with these channels. The KCNN4 gene, the protein 
product of which is termed SK4, encodes the a-subunit of IKCa channels and 
has been found in mouse and human urinary bladders (Ishii et al, 1997; Ohya et 
al, 2000). The exact function of these channels in UBSM requires further 
investigation.
Small conductance Ca2+-activated potassium channels
SKca channels are activated by an elevation of intracellular Ca2+ concentration, 
but are not voltage sensitive. These channels are important determinants of 
UBSM excitability and contractility. They underlie the action potential after 
hyperpolarisation in UBSM. Blockade of these channels results in a substantial 
increase in action potential frequency and subsequent detrusor contractility 
(Fujii et al, 1990; Herrera et al, 2000; Chalmers et al, 2007).
The a-subunit of SKCa channels in the UBSM is encoded by either the KCNN2 
(the protein product of which is termed SK2) or KCNN3 (the protein product of 
which is termed SK3) genes (Wickenden, 2002) and it consists of six 
transmembrane segments (S1-S6) with the pore located between S5-S6. No 
regulatory (3-subunit is associated with the function of these channels. The Ca2+ 
sensitivity of SKca channels is derived from a calmodulin binding site on the 
intracellular C-terminal domain of the channel near the pore forming region 
(Stocker, 2004).
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1.3.2.2 ATP sensitive K (Katp) channels
K a t p  channels are inhibited by a rise in intracellular ATP and are very important 
in the regulation of UBSM excitability. Their activity may confer a voltage- 
independent brake which limits UBSM depolarisation and controls myogenic 
activity (Bonev & Nelson, 1993; reviewed by Teramato, 2006). K At p  channels 
are composed of four pore-forming, inwardly rectifying, channel subunits 
(Kir6.x) and four modulatory sulphonylurea receptor subunits (SUR.x) that are 
members of the ATP-binding cassette (ABC) super-family of proteins (reviewed 
by Aguilar-Bryan et al, 1998). So far, two Kir6.x isoforms, Kir6.1 (encoded by 
the KCNJ8 gene) and Kir6.2 (endcoded by the KCNJ11 gene), and two SUR 
isoforms, SUR1 (protein product of the ABCC8 gene) and SUR2 (protein 
products of the ABCC9 gene), have been identified in various tissues (reviewed 
by Aguilar-Bryan et al. 1998 & Wickenden et al, 2002). Alternative splicing of 
the last exon of ABCC9 gene gives rise to the isoforms SUR2A and SUR2B, 
which differ only in their carboxy-terminal 42 amino acid residues (reviewed by 
Aguilar-Bryan et al. 1998). Different combinations of Kir6.x and SUR.x 
isoforms/variants yield tissue-specific K At p  channel subtypes. Each subtype 
possesses different features and distinct functional properties. From functional 
expression studies, it is accepted that Kir6.1-SUR2B and Kir6.2-SUR2B 
channels are the two main types of KATp channels expressed in smooth muscle 
cells (reviewed in Teramoto, 2006).
Kir6.x subunits have two transmembrane domains, M1 and M2, cytoplasmic N- 
and C-termini and a pore-forming loop (Figure 7). SUR subunits possess large 
cytoplasmic domains containing two conserved nucleotide binding folds (NBFs), 
NBF1 and NBF2, with Walker A and B motifs (Figure 7). Both Kir and SUR 
subunits are needed for cell surface expression of these channels (reviewed by 
Teramoto, 2006).
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Figure 7) Schematic illustration of the predicted topologies of SUR.x and Kir6.x in KATp 
channels. TMD: transmembrane spanning domains of SUR.X, M: transmembrane segments of 
Kir6.x, NBF: nucleotide binding folds. Adapted from Teramato, 2006
1.3.2.3 Voltage gated K+ channels
The UBSM also expresses voltage sensitive K+ (Kv) channels, also known as 
delayed rectifier channels. These channels are not activated by intracellular 
Ca2+ (Davies et al, 2002). Instead they are activated by depolarisation in a 
voltage range near the resting membrane potential of detrusor smooth muscle. 
The UBSM is a rich source of Kv2.1 (Ohyo et al, 2000b; Gan et al, 2008). It is 
believed that these channels may be important in regulation of bladder SA (Gan 
et al, 2008).
The role of various K+ channels in mediating bladder smooth muscle 
spontaneous contractions will be discussed further in the Chapter 5.
2 4
1.4 Pathophysiology of the urinary bladder
The structure and function of the urinary bladder is known to be altered by a 
number of disease states and pathological conditions. Urodynamic 
investigations can identify bladder disorders and provide information that allows 
them to be classified. Bladder disorders can lead to failure to store or empty 
urine properly. Failure to store urine, which is one of the most common 
complications of urinary bladder dysfunction, is associated with urinary 
incontinence and DO.
1.4.1 Urinary incontinence
Urinary incontinence is ‘the involuntary leakage of urine’ and can be classified 
as stress, overflow or urge incontinence (Abrams et al, 2002).
Stress urinary incontinence is associated with an increase in intra-abdominal 
pressure due to activities such as sneezing, coughing and physical exertion 
and is caused by various factors such as lack of pelvic floor support and 
weakness in the urethral sphincter (Chappie et al, 2000).
Overflow incontinence is caused by situations where incomplete bladder 
emptying and overdistension of the bladder result in overflow and involuntary 
leakage of urine.
Urge incontinence is the complaint of involuntary leakage accompanied by or 
immediately preceded by urgency (Abrams et al, 2001; Wagg et al, 2007). 
Urgency is a common symptom associated with detrusor overactivity (DO) or 
overactive bladder syndrome (OABS), which is characterised by a strong desire 
to void that is hard to defer.
1.4.2 Detrusor overactivity
DO is urodynamically characterised by involuntary contractions of the detrusor 
during the filling phase, which may be spontaneous or provoked (Abrams et al,
2002). It is associated with the troublesome symptoms of urgency, with or 
without urge incontinence, with increased daytime frequency and nocturia 
(Milsom et al, 2001; Abrams et al, 2002; Hashim & Abrams, 2007). Urgency is
defined as a sudden compelling desire to pass urine that is difficult to defer
25
(Abrams et al, 2002), whilst nocturia is defined as waking up more than twice at 
night to urinate. Increased daytime frequency is the complaint by the patient 
who considers he/she voids too often by day (Abram et al, 2006b). This 
complex of symptoms is known as OABS, which is reported to have a 
prevalence of 12-17% in the adult population in Europe and the United States. 
The syndrome increases with age, with approximately 1 in 4 individuals older 
than 65 years experiencing OABS (Milsom et al, 2001; Andersson & Hedlund, 
2002; Andersson & Yoshida, 2003; Abrams & Andersson, 2007). Although 
OABS and DO do not always coexist, it has been reported that 83% of patients 
with DO had symptoms of OABs, and 64% of patients with OABS had DO 
(Abrams & Andersson, 2007). However, DO is an urodynamic observation and 
should not be confused with OABS.
1.4.3 The aetiology of detrusor overactivity
The precise causes of DO have not yet been defined. Possible explanations of 
how detrusor becomes overactive are provided by the neurogenic or nerve 
related, myogenic and autonomous theories (Abrams & Andresson, 2007).
1.4.3.1 The neurogenic theory of overactivity
The dependence of bladder functions on complex CNS signalling pathways 
renders these functions susceptible to disruption due to a variety of 
neurological disorders (De Groat, 1997) such as dementia, stroke, multiple 
sclerosis, Alzheimer, spinal stenosis, spinal cord injury and diabetes (Turner & 
Brading, 1997; Mostwin, 2002). The neurogenic theory of DO suggests that 
damage to or reduction in peripheral or central inhibitory pathways in the brain 
or spinal cord, or enhancement of transmission of excitatory input and 
sensitisation of peripheral afferent terminals in the bladder, secondary to a 
neurologic disease can unmask primitive voiding reflexes that trigger DO (de 
Groat, 1997). Interruption of descending spinal pathways results in 
reorganisation of afferent pathways with unmyelinated capsaicin-sensitive C- 
fibres assuming prominence in the micturition reflex arc, sensitisation of which 
increases bladder excitability. The common sources of afferent information are 
likely to be from the urothelium, lamina propria, ICs and afferents that originate 
in the bladder wall (Fowler, 2002; Dmochowski, 2006).
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1.4.3.2 The myogenic theory of overactivity
The myogenic or muscle related theory of DO suggests that changes in 
structure and function of the smooth muscle are necessary for the production of 
involuntary detrusor contractions, especially during the filling phase of the 
micturition cycle. The evidence for functional changes in smooth muscle 
properties come from experiments on strips of detrusor smooth muscle 
dissected from overactive bladders, which show abnormal spontaneous 
mechanical activity. The abnormal spontaneous activity contains elements of 
fused tetanic tension, which is never seen in normal bladders (Brading, 1997). 
One hypothesis is that changes in the properties of the detrusor in overactive 
bladder are caused by an overall reduction in the activity of the excitatory 
nerves to the smooth muscle. This triggers alterations in the smooth muscle, 
leading to increased excitability and electrical coupling between cells (Brading, 
1997; Hashim & Abrams, 2007). Thus, a local contraction in any part of the 
detrusor will spread throughout the bladder wall, resulting in coordinated 
myogenic contractions of the entire bladder.
Although it is believed that DO requires structural changes in the smooth 
muscle, the sequence of events leading to this varies with different aetiologies 
of overactivity such as bladder outlet obstruction and aging (Elbadawi et al, 
1993; Brading, 1997; Hashim & Abrams, 2007).
1.4.3.3 The autonomous theory of overactivity
The third theory, which is relatively new, is also myogenic in nature. In this 
theory, it is hypothesised that the bladder detrusor is modular i.e. it is made up 
of circumscribed areas of muscle which are supplied by an individual intramural 
bladder ganglia, or by a node of ICs (Drake et al, 2001; Hashim et al, 2007). It 
was suggested that a module can act as the smallest functional unit in the 
detrusor. Contraction of a module in isolation would generate localised activity, 
or micromotions. Synchronisation of activity between modules, which could 
propagate through the intramural nerve or IC networks, may result in 
macroscopic movements of the entire bladder (Drake et al, 2001). In the 
modular model, if the balance between excitation and inhibition is moved 
towards excitation, the module is predisposed to contraction. Therefore, 
exaggerated symptomatic expression of SA might result in DO (Drake et al,
27
2001; Gillespie, 2004). Furthermore, any factors that enhance communication 
between modules will predispose the bladder to DO.
It is possible that the true pathophysiology of DO may vary between individuals, 
and may involve one or more of the above mechanisms. A better 
understanding of the normal and pathophysiological function of the urinary 
bladder by use of different animal models may provide a better insight into the 
underlying mechanisms leading to DO.
1.4.4 Animal Models
Limited availability of human tissue due to ethical issues have led to the use of 
animal models for the study of bladder physiology and pathophysiology. Animal 
studies are useful for studying the underlying mechanisms of bladder function 
and can be used as models of human conditions. Use of animal models also 
allows for the comparison to normal age-matched controls, which is usually 
hard to achieve in human tissue (Turner & Brading, 1997). A wide variety of 
animal species have been utilised to investigate bladder function including non­
human primates, dogs, pigs, cats, rabbits, rats, guinea-pigs, mice and hamsters 
(reviewed by McMurray et al, 2006). The majority of these species share a 
number of common anatomical, pharmacological and neurophysiological 
features with humans. However, some of these species are also known to have 
specific differences in normal urinary tract structure and function compared to 
humans, which may be a problem when extrapolating animal findings to the 
human situation (reviewed in Andersson & Arner, 2004 & McMurray et al, 
2006). Several types of animal model have been used to study bladder 
dysfunction, and these include bladder outlet obstruction (BOO), neurogenic, 
and diabetic animal models.
1.4.4.1 Bladder outlet obstruction model
DO is commonly found secondary to conditions such as benign prostatic 
hyperplasia (BPH), bladder neck dysfunction and uncoordinated sphincter 
activity causing bladder outlet obstruction (BOO) (Mostwin, 2002). BOO causes 
many of the clinical, structural and neuropathic changes detected in DO. BPH
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represents the most common clinical example in males. 80% of cases suffering 
from BPH also suffer from symptoms of DO (Goldberg & Sand, 2002).
To mimic DO secondary to BOO, models of bladder obstruction have been 
created in various animal species by partial obstruction of the urethra using 
some form of ligature that either immediately occludes the urethra or that 
increasingly occludes the urethra as the animal grows (reviewed by Levin et al,
2000). For instance, outflow obstruction is produced in rats by placing a ligature 
around the urethra or by testosterone-induced enlargement of the prostate 
leading to DO and muscle hypertrophy (Lluel et al, 1998; Pandita et al, 1998). 
Such models show many of the structural and physiological changes seen in 
human obstructed bladder including increased spontaneous myogenic activity, 
altered responsiveness to stimuli, patchy denervation of the smooth muscle 
and bladder hypertrophy (Reviewed by Turner & Brading, 1997 & Brading, 
1997 & McMurry et al, 2006). However, induction of bladder outlet obstruction 
using surgical procedures is invasive to the animal and can vary in 
reproducibility.
1.4.4.2 The neurogenic overactive bladder model
Animal models of neurogenic DO are induced by cerebral infarction or chronic 
spinal cord injury (SCI) (reviewed by Turner & Brading, 1997 & McMurray et al,
2006). SCI is known to result in bladder dysfunction, including detrusor hyper- 
reflexia, in both humans and animal models (reviewed by Turner & Brading, 
1997). Apart from SCI a number of central nervous system disorders are known 
to be associated with DO such as Parkinson's disease, stroke and multiple 
sclerosis, all of which are associated with some form of central lesion (reviewed 
by McMurray et al, 2006). Therefore, animal models in which central lesions 
are induced experimentally exhibit an abnormal bladder phenotype such as 
reduced bladder capacity and DO (reviewed by McMurray et al, 2006).
1.4.4.3 Diabetic Mellitus (DM) and urinary bladder dysfunction
Diabetes mellitus and urological complications are very common health 
problems that markedly increase in prevalence and incidence with advancing 
age (reviewed by Brown et al, 2005). Over 50% of the male and female 
population with diabetes have bladder dysfunction (Kaplan et al, 1995; Brown
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et al, 2005). Current understanding of diabetic bladder dysfunction 
encompasses a broad spectrum of lower urinary tract symptoms including 
urinary urgency, frequency, nocturia, incontinence and an increased incidence 
of DO (Kaplan et al, 1995; Salinas Casado et al., 1999; Brown et al, 2005). 
Previously diabetic-induced bladder dysfunction, termed bladder cystopathy, 
was described with common symptoms of diminished bladder sensation, poor 
bladder contractility and increased postvoid residual urine (Frimodt-Moller, 
1978). However, bladder cystopathy most likely represents end-stage bladder 
failure, since symptoms of infrequent voiding, difficulty in initiation of voiding 
and postvoid fullness are relatively uncommon (Buck et al, 1973; Brown et al, 
2005). Diminished bladder contractility or sensation has also been found less 
often in diabetic patients and an acontractile bladder appears to be quite 
uncommon (Brown et al, 2005). Therefore, DO may be associated with earlier 
stages of diabetes.
The aetiology of DM-associated bladder complications is multifactorial. The 
different effects of DM on detrusor muscle function are demonstrated in Figure 
8. The underlying cause of the detrusor dysfunction may be altered physiology 
of the detrusor smooth muscle, altered innervation or dysfunction of the 
neuronal component or even urothelial dysfunction. Therefore it is important to 
know to what extent dysfunction of motor nerves and the detrusor itself 
contribute to bladder dysfunction in diabetes (reviewed by Turner & Brading, 
1997; Yoshimura et al, 2005; Brown et al, 2005).
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Streotozotocin (STZ)-induced diabetic rat model
A number of diabetic animals have been used to investigate bladder and 
urethral dysfunction. The diabetic rat is one of these models and has been 
shown to mimic structural and functional changes seen in diabetic human 
bladders, including polyuria, urinary retention, increased bladder mass and 
capacity (Steers, 1994; Pitre et al, 2002). The induction of experimental 
diabetes in the rat, using chemicals which selectively destroy pancreatic (3 cells 
is a common and simple method, with the most widely used chemicals being 
alloxan and streptozotocin (STZ) (Szkudelski, 2001).
STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyronose) is synthesised by 
Streptomycetes Achromogenes and is used to induce both insulin-dependent 
and non-insulin-dependent diabetes mellitus (IDDM and NIDDM, respectively). 
STZ impairs glucose oxidation and decreases insulin biosynthesis and 
secretion. It is believed that STZ is taken up by pancreatic (3 cells via the 
glucose transporter, GLUT2, where it alters the DNA of these cells either by 
fragmentation or alkylation (Morgan et al, 1994; Eisner et al, 2000). STZ is a 
nitric oxide (NO) donor and NO is liberated when STZ is metabolised inside the 
cells, and has been shown to be responsible for the destruction of pancreatic 
islet cells and DNA damage (Morgan et al, 1994). As well as releasing NO, STZ 
has been found to generate reactive oxygen species such as superoxide ions, 
which also contribute to DNA fragmentation and cell damage (Takasu et al, 
1991).
Frequently a single intravenous dose of STZ is used in adult rats to induce 
IDDM. Intraperitoneal administration of a 40-60mg/kg body weight dose (b.w) is 
also efficacious, although single doses below 40mg/kg b.w may be ineffective.
STZ action in the (3 cell is accompanied by characteristic alterations in blood 
insulin and glucose concentration. Two hours following injection, 
hyperglycaemia is detected in rats, with a simultaneous drop in blood insulin 
levels. Six hours after STZ administration, hypoglycaemia occurs with high 
levels of blood insulin. Finally hyperglycaemia returns with a decrease in blood 
insulin levels to below normal average values. Thus, within six hours of
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injection, STZ initiates pancreatic (3-cell damage which leads to the 
development of diabetic mellitus (West et al, 1996).
Smooth muscle dysfunction in the STZ-diabetic rat bladder
Diabetes mellitus has been shown to alter detrusor smooth muscle function in 
the STZ-diabetic rat model (Longhurst et al, 1986; Malmgren et al, 1989; 
Kubota et al, 2003; Beshay & Carrier, 2004; Liu & Daneshgari, 2005). Some 
studies have concluded that the major changes observed in bladder function in 
the STZ-diabetic rat model are a physiological adaptation of the organ to 
increased mass and workload due to the diuresis and polyuria that 
accompanies diabetes (Uvelius, 1986; Kudlacz et al, 1988; Kudlacz et al, 1989; 
Pitre et al, 2002). However, others have shown that there are true changes at 
the mygenic level leading to bladder dysfunction in this model (Beshay & 
Carrier, 2004; Stevens et al, 2006). Of the studies conducted, alterations in 
cholinergic, adrenergic and nitric oxide-related functional responsiveness, as 
well as changes in K+ channel function have been reported in UBSM cells from 
diabetic bladders (Longhurst & Belis, 1986; Malmgren et al, 1989; Steers et al, 
1990; Kamata et al, 1992; Tammela et al, 1994; Kubota et al, 2003; Nakahara 
et al, 2004; Stevens et al, 2006).
Pharmacological studies of muscarinic receptors in isolated bladder strips from 
the STZ-rat model have generated much uncertainty, with some studies 
reporting a supersensitivity and an increased contractile response of the 
diabetic detrusor to muscarinic agonists (Steers et al, 1990; Kamata et al, 1992; 
Kubota et al, 2003; Stevens et al, 2006) whilst others have reported a 
decreased (Longhurst & Belis, 1986; Malmgren et al, 1989; Liu & Daneshgari, 
2005) muscarinic component. An upregulation of M2- and M3-muscarinic 
receptors was also reported by Tong et al (1999, 2002) at the protein and 
mRNA level in the bladders from STZ-induced diabetic rats. This was 
associated with increased reactivity of detrusor strips to ACH and increased 
detrusor contractility. Recent research has also shown that muscarinic 
receptors are expressed on the urothelium and the suburothelium, and 
urothelial cells are capable of releasing ACH (Cheng et al, 2007; Tong et al, 
2006; Yoshida et al, 2006). Increased expression of urothelial M2- and MS- 
muscarinic receptors has been detected in STZ-rat bladder. This abnormal
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urothelial muscarinic receptor expression may be related to sensory 
disturbances of the bladder such as urgency, frequency and other symptoms of 
DO (Cheng et al, 2007; Tong et al, 2006).
Thus, changes in muscarinic receptor function of the STZ-diabetic rat bladder 
are still unclear and are further discussed in Chapter 3.
Alterations in ion channels have also been observed in detrusor smooth muscle 
from diabetic rats. The roles of BKca and SKca channels have been investigated 
and it is believed that the function of these channels is impaired in diabetic 
overactive detrusor and that this results in enhanced mechanical activity and 
spontaneous contractions (Nakahara et al, 2004). Changes in Ca2+ channel 
activity in STZ-diabetic rat detrusor have also been suggested to be associated 
with altered pharmacological responses of bladder smooth muscle strips from 
these animals (Belis et al, 1992). However the underlying mechanism of the 
signalling pathways of these channels requires further investigation.
Other changes, such as enhanced |31-adrenoreceptor relaxation (Kubota et al,
2003), increased responsiveness of isolated rat bladder strips to electrical field 
stimulation (Tammela et al, 1994), changes in nitric oxide synthase (NOS) and 
reactive nitrogen species formation during DM related bladder remodelling 
(Poladia & Bauer, 2003) and various other alterations have also been observed 
in bladders from diabetic animals (reviewed by Yoshimura et al, 2005). 
Mediators such as ATP, NO and prostanoids, which are released from the 
urothelial cells, may also influence afferent nerve activity and result in 
abnormalities detected in the diabetic bladder (Yoshimura et al, 2005; Pinna et 
al, 2000).
Since the biology of diabetic-associated bladder complications is multifactorial, 
alterations in the innervation or function of the neuronal component, i.e. diabetic 
neuropathy, may also play a role in UBSM dysfunction (reviewed by Yoshimura 
et al, 2005). The proposed mechanisms for neurogenic dysfunction in the 
diabetic bladder include altered metabolism of glucose, ischaemia and 
superoxide-induced free-radical formation as well as metabolic derangement of 
the Schwann cell and impairment of nerve conduction (Kudlacz et al, 1989; 
reviewed by Yoshimura, 2005). Defects in the sensory nerves of the bladder 
have also been implicated as a result of neuropathy in diabetes. A decrease in
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production of nerve growth factor (NGF), which is important in afferent 
signalling, was detected in 12-week STZ-diabetic rats, showing a relationship 
between bladder function and NGF levels (Sasaki et al, 2002).
Since there are no longitudinal studies conducted under similar experimental 
conditions, there is still much confusion over the time course, magnitude and 
mechanism of diabetic-related changes in detrusor smooth muscle function.
1.4.5 Pharmacological treatments of overactive bladder
Pharmacologic therapy remains the cornerstone of management for the majority 
of patients with overactive bladder. The principal pharmacological treatment 
used to improve the symptoms of OABS is based on muscarinic receptor 
antagonism (antimuscarinics). The antimuscarinic drugs available include 
oxybutynin, tolterodine and trospium chloride (reviewed by, Sellers and McKay,
2007). The mechanism of action of antimuscarinic drugs was traditionally 
considered to be at muscarinic receptors within the detrusor smooth muscle. 
This concept has now become increasingly controversial. At prescribed doses, 
antimuscarinic drugs do not inhibit the normal voiding phase of the micturition 
cycle, whilst they do alter bladder sensation during filling, as evidenced by an 
improvement in filling symptoms associated with OABS and bladder capacity. 
This has led to a recent hypothesis suggesting that antimuscarinic drugs may 
act via other mechanisms related to the afferent mechanosensory system rather 
than the efferent system (Chappie et al, 2005).
Although antimuscarinic drugs remain the main treatment for OABS, their usage 
is limited due to significant side effects such as dry mouth, blurred vision, 
constipation and urinary retention. Thus, there is a need for more effective drug 
treatments. Recent research has highlighted several potential targets for 
treatment of the overactive bladder, particularly within the mechanosensory 
pathways. Compounds currently under research include beta-adrenoceptor 
agonists, tachykinins, K+ channel openers, vanilloids and botulinum toxin 
(reviewed by Sellers & McKay, 2007).
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1.5 Aims and Objectives of the thesis
The STZ-diabetic rat is used commonly as a model of urinary bladder 
dysfunction and DO. However, there is much controversy regarding the 
underlying causes of urinary bladder dysfunction in this model. Thus, the aim of 
this thesis was to use this model along with normal control (non-diabetic) 
animals, in order to investigate the underlying physiology and pathophysiology 
of urinary bladder function, using a combination of in vitro pharmacology, 
molecular biology and immunology.
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Chapter 2: Validation 
and optimisation of 
the in vitro tissue bath 
technique for study of 
isolated bladder 
smooth muscle strips 
from the rat
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2.1 Introduction
In order to investigate the functional pharmacological properties of bladders 
from STZ-diabetic rats, an in vitro tissue bath technique was used throughout 
this thesis. The tissue bath is a traditional experimental set-up that has been 
used extensively to investigate the physiology and pharmacology of in vitro 
preparations. Typically, contractions of isolated tissues in response to particular 
concentrations of a pharmacological agent are measured and studied. 
However, in order to be able to compare the functional data obtained for 
animals where the bladder mass has increased, it is important to optimise and 
validate the experimental parameters and to ensure that all strips are at optimal 
condition for tension measurements.
2.2 Length-tension properties o f bladder sm ooth m uscle
Contraction of smooth muscle tissue involves interactions between the active 
elements, the contractile cells and passive structures, the connective tissue 
and extracellular matrix in which the cells are embedded (Meiss & Pidaparti, 
2005). More than 100 years ago it was demonstrated that the active tension of 
skeletal muscle was enhanced with increasing muscle length up to a certain 
point (Blix, 1891, 1893, 1894). Above this optimal length active tension starts to 
decrease, although passive tension increases exponentially with muscle length 
(Blix, 1891, 1893, 1894; Uvelius, 2001). When muscle is stretched beyond the 
length where maximum active tension is developed, the decrease in active 
tension is considered to be a result of decreasing overlap between the thick 
and thin filaments within the sarcomeres (Blix, 1891, 1893,1894). A decreased 
active tension is also seen at shorter length intervals, which is harder to explain 
and was suggested to be due to inefficient coupling between membrane 
activation and force output at shorter lengths (Rudel & Taylor, 1971).
Smooth muscle has a length-tension property that in principle appears the 
same as that of skeletal muscle. The active force developed by striated muscle 
fibres is directly proportional to the extent of over-lap between actin and myosin 
filaments. However, in contrast to this, the myofilaments of smooth muscle 
fibres do not form organised sarcomeres and the interactions between myosin
38
and actin filaments differ (Cooke & Fay, 1972). In smooth muscle, passive 
tension becomes considerable at short lengths which are below the optimal 
length for active tension development. Also smooth muscle seems to develop 
maximal active force over a much greater range of passive tension, which 
could be due to the different arrangement of the contractile filaments (Uvelius,
2001). There are no distinct layers of musculature in the urinary bladder and 
the structural units of the muscle are the bundles which are extremely variable 
in cross section, length and orientation. Thus, this may explain the 
extraordinary stretchability of the wall and development of active tension over a 
greater range of passive tension. These properties of the urinary bladder have 
a prime importance in its physiological role of accommodation and storage of 
urine (Longhurst et al, 1995; Uvelius, 2001). The presence of collagen fibres in 
the mucosa and serosa, as well as between muscle bundles and smooth 
muscle cells could also explain the stretchability of the bladder tissue.
When using in vitro tissue baths, it is common practice to set the isolated strips 
of bladder at the optimal length, Lo or optimal passive tension (loading tension), 
where a population of strips will, on average, generate their maximum active 
tension. In experimental animals, where bladder mass has increased, length 
tension experiments should especially be carried out to ensure that all strips 
are under optimal condition for active tension measurements. For example, 
Ekstrom & Uvelius (1981) demonstrated that length-tension properties of 
normal and denervated rat bladders differed and that denervated bladder strips 
had to be stretched to a considerably greater extent than those from normal 
bladders in order to reach optimum length for force tension development.
Changes in length-tension properties of bladders from diabetic animals have 
also been reported. Andersson et al (1988) demonstrated a rightward shift of 
length-passive and active tensions in bladders from 6-week diabetic female 
Sprague-Dawley rats. The same pattern was observed by Eika et al (1992) in 2 
months diabetic male Sprague-Dawley rats. It was hypothesised that changes 
in the relative concentration of connective tissue and contractile proteins and/or 
the orientation of smooth muscle fibres in the bladders, as well as biochemical 
changes that might have taken place and have had an impact on energy
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utilisation, are important in the functional changes observed in these animals 
(Longhurst et al, 1995).
2.3 Aim of the chapter
The aims of this chapter were to investigate the length-tension properties of 
detrusor strips from control (non-diabetic) and STZ-diabetic rats, in order to 
optimise the methodology for investigating the contractile function in 
subsequent tissue bath experiments and to measure the body weight and blood 
glucose levels of diabetic and control (non-diabetic) rats.
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2.4 Materials and Methods
2.4.1 Induction of diabetes
In this study, male Wistar rats (Harlan, UK) (approx 200-350g) received a single 
intraperitoneal injection of streptozotocin (STZ) (65mg/kg body weight) (Sigma, 
Dorset, UK), dissolved in 0.01 mM citrate buffer (pH=4) to induce diabetes. 
Solutions of STZ were prepared immediately before use due to the instability of 
this drug at room temperature.
Animals were used at 1, 4 and 8 weeks after injection. Non-diabetic rats were 
also used as controls. At termination blood glucose levels were measured using 
an ACCU-CHEK Advantage blood glucose monitoring system (Roche 
Diagnostics, Mannheim, Germany) and body weight was taken. Animals with 
glucose levels higher than 16mM were considered diabetic. Termination was via 
a schedule 1 method i.e. stunning followed by cervical dislocation. All 
procedures were carried out according to Home Office project licence 40/6774.
2.4.2 Tissue preparation
2.4.2.1 Dissection and removal of the bladder
The abdominal cavity of the rat was opened by a midline incision exposing the 
urinary bladder and urethra. The prostate was trimmed away using fine scissors 
taking care not to perforate the bladder wall. Figure 9 demonstrates the location 
of the urinary bladder from the ventral aspect. The bladder was removed and 
then placed in ice cold modified Krebs-bicarbonate solution (Krebs) (118.3mM 
NaCI, 11.7mM D-Glucose, 24.9mM NaHC03, 4.7mM KCI, 1.15mM MgS04, 
1.15mM KH2P04 and 1.9 mM CaCI2).
2.4.2.2 Bladder strip preparation
The urinary bladder was placed on a dissection tray containing Krebs and the 
loose serosal connective tissue, any remains of the prostate and fat were 
removed. A longitudinal incision was performed through the bladder from the
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base to the dome and the bladder was opened up to form a flat sheet. Using a 
razor blade, the base and the top of the dome were removed and 3-4 
longitudinal strips (depending on bladder size) measuring 2-4 x 6-12mm were 
then cut from the bladder body.
Figure 9) Location of the rat urinary bladder from the ventral aspect. Adapted form 
Longhurst and Uvelius, 2001.
The detrusor strips cut from the bladder body were subsequently attached at 
one end to tissue holders and at the other to Dynamometer UF1 force 
transducers (Pioden Controls Ltd, UK) using a surgical thread (Figure 10). The 
detrusor strips were then mounted in 15ml organ baths containing Krebs 
solution maintained at 37°C and gassed with 95% 0 2 and 5% C 02. A pH of 7.4 
was consistent under these conditions due to the buffering system established 
by the C 02 and NaHC03. Figure 10 illustrates the tissue bath set up.
Vas deferens
Bladder
Prostate
Seminal vesicle
2.4.3 In vitro tissue bath preparation
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Surgical Thread
<-----------  Force transducer
Tissue holder
Heated Water ou t< 37°C heated water in
Bladder strip
Physiological solution 
(Krebs inlet)Waste
solution outlet
95% 0 2, 5% C 0 2
Figure 10) Double-walled glass tissue bath setup (adapted from Longhurst and Uvelius,
2001)
The tension developed by the tissue was measured by the isometric force 
transducer connected to a Powerlab data acquisition system (ADInstruments, 
UK), which converted the analogue signal to digital, and used 'Chart 4.0' 
software (ADInstruments, UK), to enable analysis of the acquired data.
2.4.4 Investigation of length-tension relationship of detrusor 
strips from control (non-diabetic) and diabetic rats
After mounting the detrusor strips in the tissue baths, the initial passive tension 
was adjusted to 1g. Tissues were equilibrated for 60 minutes, with a wash every 
15 minutes with fresh Krebs buffer. Following equilibration the tissues were 
stimulated for 5 minutes with high (60mM) potassium (K+)-Krebs buffer 
(63.71mM NaCI, 11.7mM D-Glucose, 24.9mM NaHC03, 60mM KCI, 1.15mM 
MgS0 4 , 1.15mM KH2PO4 and 1.9 mM CaCl2 (obtained by exchanging NaCI with 
equimolar amounts of KCI)) to produce an active tension. Tissues were then 
allowed to relax for 10 minutes in calcium (Ca2+)-free Krebs buffer (118.3mM 
NaCI, 11.7mM D-Glucose, 24.9mM NaHC0 3 , 4.7mM KCI, 1.15mM MgS04,
43
1.15mM KH2P04). This sequence was repeated twice, allowing a stable 
contractile response to develop. The tissues were then shortened to a length at 
which there was no response to stimulation with high- K+ Krebs and then 
allowed to relax in Ca2+-free Krebs.
The length-tension curve was then constructed by increasing the length of the 
tissues by 1mm increments using a micrometer. At each length, tissues were 
stimulated for 5mins with high-K+ Krebs solution and then allowed to relax for 
10mins in calcium-free Krebs. Immediately after each switch to Ca2+-free Krebs, 
the length of the tissues was increased by 1mm (Figure 11). The strips were 
stretched in this stepwise manner until the responses to high-K+ Krebs started 
to decline. At the end of experiments tissues were weighed.
Ca -free Krebs
High-K+ Krebs
10mins AT
5mins
1mm
PTAT
Tension measured at Omm
High-K+ Krebs
Figure 11) An illustration of the length-tension protocol. Note that as the muscle is 
stretched, the baseline of the force record is raised due to passive tension (PT) in the muscle 
and contributes more to overall force than the active tension (AT)
2.4.5 Data analysis
Active tension (maximal tension in high-K+ Krebs minus passive tension) and 
passive tension (in Ca2+-free Krebs) tensions (g) were determined at each 
length (mm) (as shown in Figure 11) and were normalised for tissue weight 
(mg). The maximum passive tension was considered to have been reached
4 4
when a subsequent increase in the passive tension produced no significant 
difference in the active tension developed to high-K+ Krebs compared to the 
previous active response. Length-tension curves were constructed by plotting 
the increase in tissue length (mm) against the active and passive tensions (g/ 
mg tissue) developed by the detrusor strips at each length. Data was presented 
as mean±SEM.
Passive-active tension curves for control (non-diabetic) and diabetic tissues 
were also constructed by plotting the passive tension (g) at each length against 
the active tension (g/mg tissue) at the same length to determine the optimum 
passive tension (g) resulting in maximum active tension development.
2.4.6 Statistical analysis
Differences in maximum active contractions (absolute (g) and normalised per 
mg tissue) between control and diabetic tissues were compared using one way 
ANOVA followed by Dunnetts multiple comparison post hoc test. p<0.05 was 
considered significant.
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2.5 Results
2.5.1 STZ-diabetic rats
After 1-8 weeks of STZ-induced hyperglycaemia, significant differences in body 
weight were detected in the diabetic rats versus the control (non-diabetic) rats, 
such that at sacrifice STZ-diabetic rats had significantly decreased body 
weights compared to control (non diabetic) rats (Figure 12). In addition, the 
blood glucose concentrations of the STZ-diabetic rats were significantly higher 
than those of controls (Figure 12).
400n
1 -week D 4-week D 8-week D
C 1 -week D 4-week D 8-week D
Figure 12) Body weights and blood glucose levels of control (non-diabetic) (C) and 
diabetic (D) rats. C: N=5, 1-week D: N=6, 4-week D: N=5 and 8-week D: N=5. **p<0.01 vs. 
control (non-diabetic) animals. Data is presented as mean±SEM. N=number of animals.
4 6
STZ-diabetic rats also demonstrated an increase in the micturition frequency 
and volume compared to control (non-diabetic) rats (observational data only).
Non-urological complications, such as development of cataracts were also 
detected in these animals after 8-weeks of diabetes.
2.5.2 Investigation of length-tension relationship of detrusor 
strips from control (non-diabetic) and diabetic rats
Length-tension curves for bladder strips from control (non-diabetic), 1-week, 4- 
week and 8-week STZ diabetic rats are presented in Figure 13. Passive tension 
increased with tissue length in control (non-diabetic) and diabetic bladder strips 
(Figure 13). Active tension (in response to high-K+ Krebs) was increased up to 
a maximum in all groups before starting to decline as the tissue length 
continued to increase.
Detrusor strips from diabetic animals developed a significantly greater absolute 
active tension (g) than those from control (non-diabetic) rats (Table 1). 
However, when the active tension was expressed as tension g/mg tissue to 
normalise for differences in tissue weight, only the active tension (g/mg tissue) 
of 1-week diabetic tissues remained significantly greater than control (non­
diabetic) tissues.
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C (n=12)
1-week D 
(n=11)
4-week D 
(n=11)
8-week D 
(n=12)
Active tension (g) 1.68±0.26 3.32±0.43* 3.77±0.48** 3.84±0.39**
Active tension (g/mg tissue) 0.08±0.11 0.14±0.02** 0.09±0.01 0.09±0.01
Table 1) Maximum active tension developed in presence of high K+ Krebs in control 
(non-diabetic) (C) and diabetic (D) tissues. Data is expressed as mean grams or g/mg 
tissue ± SEM. n= number of detrusor strips. *p<0.05 & **p<0.01 vs. control (non-diabetic) 
tissues
To determine the effect of passive tension on the contractile response to high 
K+ Krebs, the active tension was plotted against the passive tension. The 
optimum passive tension, at which maximum active tension was generated, 
was determined using these graphs (Figure 14).
The active tension developed by detrusor strips from control (non-diabetic) 
rats reached a maximal level at 2.2g of passive tension. Bladder strips from 1 
week, 4 week and 8 week diabetic rats reached a maximum active tension at 
2 g, 2.3g and 2.1g of passive tension respectively (Figure 14).
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Figure 14) Passive tension-active tension curves for detrusor strips from control (non­
diabetic) (C) and diabetic (D) rats . Top panel: absolute values (g). Bottom Panel: g/mg 
tissue. C: n=12, 1-week D: n=11, 4-week D: n=11 and 8-week D:n=12. Data is presented as 
mean± SEM.
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2.6 Discussion
2.6.1 The STZ-diabetic rat
The chemical induction of diabetes using STZ, which specifically damages the 
P-cells in the pancreas, provides permanent diabetes that is suitable for long­
term studies. Chemically-induced type 1 diabetes is the most commonly used 
animal model of diabetes. Organ dysfunctions, such as those affecting the 
cardiac, renal, retinal and reproductive and digestive systems, seen in human 
patients are also detected in the STZ-diabetic rat (reviewed by Ozturk et al, 
1998 & McNeill, 1999). Although these complications were not the focus of this 
study, but cataracts, enlarged abdominal cavity and changes in the shape and 
size of the gastrointestinal tract were observed in these animals in the time of 
sacrifice. Also within one week following induction of diabetes, the STZ-diabetic 
rats demonstrated a loss in body weight and blood glucose concentrations 
increased significantly from normal levels of around 6mM to greater than 
20mM. A decrease in body weight and an increase in blood glucose levels in 
STZ- diabetic rats at different durations of diabetes have also been noted by 
several other investigators (Steers et al, 1990; Stevens et al, 2006; Liu & 
Daneshgari, 2006). Rats in this study also consumed a large amount of fluid 
and produced correspondingly high urine volumes, which is consistent with the 
observations of other studies (Reviewed by McNeill, 1999).
Significant alterations in urinary bladder morphology, physiology and 
pharmacology have been reported after the induction of diabetes mellitus. For 
example, a time-dependent increase in total bladder tissue mass and cross 
sectional lumen area was reported in 5-week STZ-diabetic rats by Pitre et al 
(2002). Rizk et al (2006) reported collagen accumulation, degenerated nerve 
fibres and myeline bodies between smooth muscle cells of 8-16-week STZ- 
diabetic rats. Other alterations in the pharmacological and physiological 
properties of the urinary bladder from STZ-diabetic rats are discussed further in 
the relevant chapters.
Since it has been suggested that an increase in bladder size affects length- 
tension properties of this organ (Ekstrom & Uvelius, 1981; Andersson et al, 
1988), it was necessary to perform length-tension experiments in order to
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determine what initial passive tension detrusor strips from control (non-diabetic) 
and diabetic animals should be placed under to achieve the optimum 
contractile responses during in vitro tissue bath experiments.
2.6.2 Length-tension properties of detrusor strips from 
control (non-diabetic) and diabetic rats
In the present study, the maximum active tension generated in response to 
high K+ Krebs was greater in all bladder strips from diabetic animals compared 
to those from control (Table 1). The reason for this is not clear, however, it 
could be the result of increased tissue mass in diabetic bladder due to polyuria. 
Indeed, after normalising data to account for tissue weight (g/mg tissue), there 
was no significant difference between the maximum active tensions of control, 
4-week and 8-week diabetic bladder strips. However detrusor strips from 1- 
week diabetic rats still showed a significantly greater active tension compared 
to control (non-diabetic) tissues. It is possible that there are compensatory 
changes to the bladder shortly after induction of diabetes, which stabilises with 
longer duration, indicative of time dependent changes in stimulus-contraction 
coupling.
The length-tension curves generated in this study indicate that in all groups, 
active tension increased with increasing the passive tension and reached a 
maximum around 2g of passive tension. However, from the length-tension 
curves for control (non-diabetic) and diabetic tissues, it is clear that a plateau 
can be observed where, over a range of passive tensions (1.5-3g), similar 
maximum active tensions can be generated. These results are similar to 
findings by Longhurst et al (1990) who demonstrated that comparison of 
contractile responses of bladders from control and 8-week diabetic rats should 
be performed at an optimal passive tension of £2 g to ensure that maximal 
active tension was generated. The range of passive tensions over which 
maximal active responses were observed can probably be related to the 
nonlinear arrangement of smooth muscle fibres and high collagen and elastin 
contents of the bladder wall, which form a three dimensional network. This can 
result in different groups of smooth muscle fibres being at optimal length at 
different degrees of passive tension (Andersson and Arner, 2004; Longhurst et
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al, 1990). Therefore, it appears that in these tissues the maximum active 
tension could be achieved over a range of passive tensions.
2.7 Summary
Overall, the results presented in this chapter illustrate that diabetic rats have 
significantly lower body weight and higher blood glucose levels compared to 
control (non-diabetic) rats. Also comparison of functional responses of urinary 
bladder strips between control and STZ-diabetic rat tissues should be 
performed at an optimal passive tension of >2g, to ensure that maximal active 
tension is generated. As such, in all subsequent experiments described, 
detrusor strips were mounted under 2g of passive tension.
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Chapter 3: Investigation 
of muscarinic- 
receptor- mediated 
contraction of 
detrusor strips from
the rat
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3.1 Introduction
Muscarinic receptors mediate the inhibitory and excitory effects of acetylcholine 
(ACH) in the urinary bladder smooth muscle. M2- and M3-muscarinic receptors 
predominate in the detrusor, with the population of M2-muscarinic receptor 
subtype being greater than the M3-receptor subtype so that the M2:M3 ratio is 
9:1 in the rat bladder and 3:1 in other species examined (reviewed by Eglen et 
al, 1994). In spite of this, it has been demonstrated that it is the minor 
population of M3-muscarinic receptors that mediate in vitro contraction of the 
detrusor in all species studied to date under normal physiological conditions 
(Wang et la, 1995; Choppin et al, 1998; Sellers et al, 2000; Chess-Williams, 
2002).
Alterations in muscarinic receptor function have been associated with detrusor 
overactivity (DO) and the widespread use of antimuscarinic agents for the 
treatment of DO over the past three decades highlights the key role of these 
receptors in the pathophysiology of this condition (Braverman et al, 1998; 
Pontari et al, 2004; Hedge, 2006).
3.1.1 The role of muscarinic receptors in detrusor overactivity 
(DO)
Alterations in muscarinic receptor-mediated pathways have been implicated in 
DO/pathological conditions of the bladder. An increased sensitivity and 
responsiveness of detrusor smooth muscle to muscarinic receptor agonists has 
been observed in various species and in different conditions leading to DO, 
including neurogenic overactive bladders (Saito et al, 1993; Stevens et al, 
2007), bladder outlet obstruction in humans (Harrison et al, 1987) and 
denervation, spinal cord-injury and diabetic-induced DO in rats (Gunasena et al, 
1995; Braverman et al, 1998b; Stevens et al, 2006). Possible mechanisms for 
the enhanced detrusor sensitivity to muscarinic agonists in these studies 
include an increase in muscarinic receptor density and/or alterations in the 
receptor response coupling.
Although some reports have not supported the idea of supersensitivity of 
bladder smooth muscle to muscarinic agonists (Nilverbrant et al, 1986), the
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balance of evidence supports the importance of these receptors in mediating 
the bladder function under pathological conditions.
Several studies have attempted to elucidate which muscarinic receptor 
subtypes may be involved in mediating detrusor contraction under these 
pathological conditions. It has been suggested that the M2-muscarinic receptor 
subtype may contribute to direct bladder smooth muscle contraction when the 
M3-muscarinic receptor subtype becomes pharmacologically inactivated or is 
dysfunctional. For example, it has been demonstrated that the pharmacological 
profile of the key muscarinic receptor antagonist inhibiting the detrusor 
contractions in neurogenic bladder dysfunction in humans is consistent with M2- 
muscarinic receptor mediated responses (Pontari et al, 2004; Braverman & 
Ruggieri, 2006). The same has been observed in detrusor strips from rat 
models of bladder outlet obstruction (Ruggieri & Braverman, 2006) and 
denervation (Braverman & Ruggieri, 2003; Braverman et al, 2006b). 
Immunoprecipitation studies in bladders from denervated and outlet obstructed 
rats demonstrated an increase in M2-muscarinic receptor protein density 
(Braverman & Ruggieri, 2003; Braverman & Ruggieri, 2006c) with a decrease 
(Braverman & Ruggieri, 2003) or no change (Ruggieri & Braverman, 2006c) in 
M3-muscarinic receptor density.
This concept of a role for the M2-muscarinic receptor in mediating bladder 
smooth muscle contraction in bladder dysfunction has been challenged by 
several studies. Stevens et al (2004a, 2004b, 2007) demonstrated that direct 
responses to muscarinic receptor stimulation of the detrusor muscle from 
patients with idiopathic and neurogenic overactive bladder are mediated via the 
M3-muscarinic receptor, with no change in the role of M2-muscarinic receptors. 
Krichevsky et al (1999) also demonstrated that in obstructed rat bladder, MS- 
muscarinic receptors have the predominant role in mediating detrusor 
contraction.
Thus, it is still unclear whether the M2-muscarinic receptor has a role in DO and 
bladder dysfunction.
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3.1.2 Muscarinic receptors in STZ-diabetic rat bladder
Pharmacological studies of muscarinic receptors in isolated detrusor strips from 
the sterptozotocin (STZ)-diabetic rat have generated contradictory results. 
Functionally, various studies have documented a supersensitivity and an 
increased contractile response of detrusor strips from STZ-diabetic rats to 
muscarinic agonists (Steers et al, 1990; Kamata et al, 1992; Kubota et al, 2003; 
Stevens et al, 2006) whilst others have reported a decrease (Longhurst & Belis, 
1986; Malmgren et al, 1989; Liu & Daneshgari, 2005) in the muscarinic 
mediated responses. An up-regulation of the M2- and M3-muscarinic receptors 
at the protein and mRNA levels has been reported by Tong et al (1999, 2002) in 
the bladders from STZ-diabetic rats. It was suggested that the up-regulation of 
M2-muscarinic receptors may upset detrusor stability by acting against the 
sympatho-inhibitory effect (mediated via |3-adrenoceptors and increase in 
urinary bladder smooth muscle (UBSM) cAMP levels) during the filling phase of 
the micturition cycle. Also up-regulation of M3-muscarinic receptors was 
suggested to account for the augmented response to acetylcholine (ACH) and 
the increased detrusor contractility found in the bladder strips from diabetic rats 
(Tong et al 1999, 2002). An increase in density of muscarinic receptors in the 
STZ-diabetic rat bladder has also been observed in radioligand binding studies 
by Stevens et al (2006). However, the increased sensitivity of detrusor strips 
from diabetic rats in this study was only partially related to the increased 
muscarinic receptor density. It was suggested that other mechanisms must also 
be operating at a cellular level to cause the tissue supersensitivity (Stevens et 
al, 2006).
The contradictory results on muscarinic-receptor mediated function of bladders 
from diabetic animal models may be due to the species of animal used, the 
duration of diabetes employed, as well as data normalisation procedures 
applied in each study (Waring & Wendt, 2000; Yoshimura et al, 2005). For 
example, in studies by Chang et al (2005) and Saito et al (2008) a general 
smooth muscle hypersensitivity and increased contractility to muscarinic 
receptor stimulation was reported in the bladder detrusor from alloxan-induced 
diabetic rabbit and type 2 Goto-kakizaki diabetic rats respectively, whilst in a 
study by Longhurst & Belis (1986), using STZ-diabetic rats, a decreased 
sensitivity of bladder smooth muscle to muscarinic agonists was observed
57
indicating species-dependent differences. Duration dependent differences have 
been hypothesised in the reports of Stevens et al (2006), who demonstrated an 
increase in sensitivity of detrusor to muscarinic stimulation from 1-week STZ- 
induced diabetic rats, whilst Longhurst & Belis (1986) demonstrated a decrease 
in sensitivity of detrusor to muscarinic stimulation in 2-months STZ-induced 
diabetic rats.
Due to these conflicting reports, further pharmacological and molecular 
experiments are needed to characterise and understand the role of the M2- and 
M3-muscarinic receptor-subtypes involved in mediating the detrusor 
contractions in this model of bladder dysfunction.
3.1.3 Pharmacological characterisation of muscarinic 
receptors in the smooth muscle
Classically, muscarinic receptors were defined on the basis of selective 
agonism by muscarine and antagonism by atropine. However, pharmacological 
characterisation of muscarinic receptors has long been hindered by a lack of 
selective agonists and highly selective antagonists for any single receptor 
subtype. In addition, cells frequently co-express more than one subtype of these 
receptors, adding further difficulty to assigning a functional response to a single 
receptor population (Caulfield & Birdsall, 1998; Scarpero & Dmochowski, 2001). 
The presently available muscarinic antagonists, although not completely 
selective, are the best current tools for discriminating muscarinic receptor 
subtypes in a given tissue. Obtaining affinity constants (pK) or affinity estimates 
(pA2) for the currently available muscarinic antagonists to generate an affinity 
profile of these drugs both at functional and cloned muscarinic receptors has 
been used extensively by pharmacologists, allowing for better characterisation 
of muscarinic receptors in a specific tissue (Caulfield & Birdsall, 1998; Scarpero 
& Dmochowski, 2003). Thus, a particular muscarinic receptor subtype is defined 
with affinity constants for a range of antagonists. Affinity constants of the key 
antagonists that can be used to achieve a pharmacological definition for M1-M3 
muscarinic subtypes are given in Table 2.
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Antagonist
Affinity constants(log dissociation constants of pKb values) for 
muscarinic receptors in mammalian smooth muscle
M1 M2 M3
Pirenzepine 7.8-8.5 6.3-6.7 6.7-7.1
AF-DX 116 6.4-6.7 7.1-7.2 5.9-6.6
Methoctramine 7.1-7.8 7.8-8.3 6.3-6.9
4-DAMP 8.6-9.2 7.8-8.4 8.9-9.3
p-FHHSiD 7.2-7.5 6.0-6.9 7.8-7.9
Himbacine 7.0-7.2 8.0-8.3 6.9-7.4
Table 2) Affinity ranges of key antagonists that can be used to achieve a pharmacological 
definition of M1-M3 muscarinic receptor subtypes. The values were estimated from studies 
on cloned receptors, radioligand- binding displacement studies as well as from functional 
studies of muscarinic receptors in various smooth muscle tissue in a variety of mammalian 
species. Collated from Caulfield, 1993; Eglen et al, 1994; Eglen et al, 1996; Caulfield & Birdsall, 
1998.
According to the antagonist affinities listed in Table 2, M1-muscarinic receptors 
can be defined as those with a relatively high affinity towards pirenzepine and 4- 
DAMP and a low affinity towards compounds such as AF-DX 116, compared to 
M2- and M3-muscarinic receptors. M2-muscarinic receptors exhibit a relatively 
high affinity towards methoctramine, AF-DX 116 and a low affinity for 
pirenzepine, 4-DAMP, and p-FHHSiD, compared to M1- and M3-muscarinic 
receptor subtypes. M3-muscarinic receptors have a relatively high affinity 
towards 4-DAMP, a moderate affinity for p-FHHSiD and a low affinity for 
pirenzepine, AF-DX 116 and methoctramine when compared with M1- and M2- 
muscarinic receptors.
There are also a number of relatively new muscarinic receptor antagonists such 
as darifenacin and solifenacin that demonstrate a higher affinity for M3-
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muscarinic receptors (Nilvebrandt et al, 1997; Gillberg et al, 1998; Wallis & 
Napier, 1999).
In order to obtain pKb and pA2 values for a specific muscarinic receptor 
antagonist in functional studies, cumulative concentration-response curves 
(CRCs) to a muscarinic receptor agonist in the absence and presence of the 
specific muscarinic receptor antagonist are obtained using a typical tissue bath 
set up. Postjunctional contractile responses of isolated smooth muscle tissue at 
each concentration of the muscarinic agonist are measured, up to a clearly 
defined sustained plateau. The correspondence between the concentration of 
the agonist and magnitude of the effect produced is an example of a 
concentration-response/dose-response relationship (Talarida & Jacob, 1979). 
The molar concentration of the agonist that produces 50% of the maximal 
possible effect is termed the EC5o value. The negative logarithm to base 10 of 
the EC5o value is termed pECso. The EC50 values of each CRC to the 
muscarinic receptor agonist in the absence and the presence of the antagonist 
are calculated. The presence of a competitive antagonist in a given 
concentration (B) produces a rightward displacement, or shift, of the agonist 
concentration-response curve. For a given concentration, the agonist dose-ratio 
or concentration-ratio (CR) can be determined. Affinity constants (pKb) can then 
be calculated using the formula:
pKb = log (CR-1) -  log [B]
In practice the calculation of pKb is made from not just one, but from several 
concentrations of the antagonist. By plotting the log (CR-1) values against log 
[B] values, a straight line with a slope of unity with an intercept with the abscissa 
is obtained. This method of plotting was used by Arunlakshana and Schild and 
is termed a Schild plot. The intercept of the straight line with the abscissa gives 
the p^ 2  value (affinity estimate) (Talarido & Jacob, 1979, Arunlakshana & 
Schild, 1959). The Schild plot is based on the assumption that agonist and 
antagonist combine with the receptor in a freely reversible but mutually 
exclusive manner, that equilibrium has been reached and that the law of mass 
action can be applied. Schild analysis is a fundamental measure of the 
antagonist affinity for the specified receptor and usually correlates with the 
affinity constants obtained from functional In vitro and radio-ligand binding 
studies (Arunlakshana & Schild, 1959; Neubig et al, 2003).
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If the slope of a Schild plot is similar to unity, this indicates that the responses of 
the tissue are mediated via a homogenous population of receptors. A slope 
different from unity implies a more complex interaction between the antagonist, 
the agonist and the receptor, including antagonism of the agonist action at more 
than one receptor, a stoichiometric difference from one antagonist molecule 
competing for the same receptor, a receptor with promiscuous contact with 
second messenger systems and others (Arunlakshana & Schild, 1959).
The functional analysis of muscarinic receptors in smooth muscle is not 
however, in itself, sufficient to fully assess their role in muscle function, since 
the approach does not yield any information on the receptor density or indeed 
the proportion of different muscarinic receptors expressed. Consequently, 
reverse transcription-polymerase chain reaction (RT-PCR), northern blot, 
western blot and other quantitative techniques should be used in concert with a 
functional approach to provide better characterisation (Eglen et al, 1996).
3.1.4 Molecular characterisation of muscarinic receptors in 
the smooth muscle
3.1.4.1 Real-time polymerase chain reaction (RT-PCR)
The fluorescence-based quantitative real-time reverse transcription-polymerase 
chain reaction (real time RT-PCR), first developed by Higuchi et al (1992), is a 
development of the established PCR technique and uses fluorescent labels to 
enable the continuous monitoring of amplicon formation throughout the reaction. 
Since many cellular processes concerning survival, growth, differentiation and 
function are reflected in altered patterns of gene expression, it has always been 
important in research to quantitate transcription levels of specific genes.
Real-time RT-PCR is now firmly established as a mainstream technology. Its 
high throughput, together with its use of novel chemistries, analysis of gene 
expression from very small amounts of sample, more reliable instrumentation 
and improved protocols have made it the method of choice for detection of 
mRNA. It allows quantification of relative differences in amounts of mRNA of the 
same gene between different samples e.g. control vs. treated.
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Real-time RT-PCR adheres to the same basic principles of PCR (denaturation, 
primer annealing and polymerisation), but the monitoring of the accumulation of 
the amplicon has been made possible by utilisating fluorescence dyes. The 
simplest method uses a fluorescent dye that binds specifically to double­
stranded DNA. SYBR-green is one of these fluorescent dyes and is used 
extensively. It binds to the minor groove of the PCR double stranded products 
as the reaction continues. This results in an increase in the fluorescence signal 
that is recorded during the annealing step, when double stranded products are 
formed. Fluorescence values are recorded during every cycle of a real-time 
PCR reaction and represent the amount of product amplified. The more 
template present at the beginning of the reaction, the fewer number of cycles it 
takes to reach a point in which the fluorescent signal is significantly above the 
background. This point is defined as the threshold cycle or the Ct value. Data 
obtained from a real-time PCR run yields a sigmoidal curve when fluorescence 
intensity is plotted against the cycle number (reviewed in Wong and Medrano, 
2005) (Figure 15). This curve can be broken down into four major phases: the 
linear ground phase, early exponential phase, log linear (exponential phase) 
and plateau phase. The Ct value is calculated at the early exponential phase. 
During the log linear phase, if the efficiency of the reaction is 100%, PCR 
reaches its optimal amplification period with amplified products doubling after 
every cycle. The plateau stage is reached when reaction components become 
limited and the PCR reaction is no longer useful for data calculation (reviewed 
in Wong and Medrano, 2005).
It must be noted that the DNA-binding fluorophore, SYBR green, may also bind 
to nonspecific products such as primer dimers. Primer-dimers can confuse 
interpretation of the results as false signals are generated. This problem can be 
solved using software capable of fluorescent melting curve analysis. Here the 
temperature at which the dsDNA amplicon is denatured is noted. The shorter 
primer-dimer can be discriminated by its reduced melting temperature 
compared with the full-length amplicon (Mackay et al, 2002).
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Figure 15) Phases of the PCR amplification curve. Adapted from Wong & Medrano, 2005.
3.1.4.2 Data analysis for real-time PCR
The Ct values obtained from a real-time RT-PCR reaction are then used in two 
types of calculations: absolute and relative quantitation.
Absolute quantitation of mRNA
In the absolute quantitation method, a standard curve is constructed from 
known standards and then is used to determine the concentration (copy 
number) of the starting templates according to their Ct values. This method 
assumes that all standards and samples have equal amplification efficiencies.
Relative quantitation
In relative quantitation, changes in sample gene expression are measured 
relative to an external standard or reference gene (house keeping gene). House 
keeping genes should have a stable expression in all cell types and their
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expression should not be affected by different experimental treatments. Using a 
house keeping gene compensates for introducing varying amounts of mRNA in 
the total RT reaction and thus producing different concentrations of the starting 
template between different samples.
There are two methods of relative quantitation: the delta-delta Ct method 
described by Livak & Schmittgen (2001) and the method described by Pfaffl 
(2001). In the delta-delta Ct method, it is assumed that the efficiency of the 
target and the reference genes are within a close range. The delta-delta Ct 
method is only applicable for a quick estimation of the relative expression ratio 
and follows the formula:
VCltio = 2 ^ ^  contro ~^ sample]
where ACt control is the difference between the Ct values of the target and the 
reference gene in the control (non diabetic) samples, and the ACt sample is the 
difference between the Ct values of the target and the reference gene in the 
diabetic samples.
However, for a more reliable and accurate result, it is important to calculate the 
amplification efficiency of the target and the reference genes. The equation 
described by Pfaffl (2001) is then used to calculate the relative 
increase/decrease in expression ratio of the target gene versus a housekeeping 
gene and also incorporates the amplification efficiencies of the target and the 
reference gene (Pfaffl, 2001).
- a  C  I  a f g  e t (  c o n t r o l  -  t r e a t e d  )
\  t a r g e t )ratio = -----------------—( , ..—
r e f  ( c o n t r o l  -  t r e a t e d )
\  r e f )
E =  efficiency of the target ( E target) or the housekeeping ( E ref) gene primers. ACt= 
the difference between the Ct values of the control (non-diabetic) sample and 
the treated (diabetic) sample.
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3.2 Aims of the chapter
The aim of this chapter was to characterise the muscarinic receptors mediating 
smooth muscle contraction in bladders from control (non-diabetic) and STZ- 
diabetic rats and to investigate of the expression of M2- and M3-muscarinic 
receptor subtypes in bladders from these animals.
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3.3 Material and Methods
3.3.1 Pharmacological characterisation of muscarinic 
receptors in the rat bladder smooth muscle
Diabetes was induced in male Wistar rats (weight range of 200-350g) by 
intraperitoneal injection of STZ as described in Chapter 2. Rats were sacrificed 
and the bladder was removed from control (non-diabetic), 1-week, 4-week, 8- 
week and 12-week diabetic animals. 3-4 longitudinal intact detrusor strips were 
cut from the bladder wall and were mounted in tissue baths as described in 
Chapter 2.
Following the equilibration period (60mins) in Krebs solution containing 5pM 
indomethacin (cyclooxygenase inhibitor) (Sigma, Dorset, UK), cumulative CRCs 
(1nM-10mM) to carbachol (CCH) a muscarinic receptor agonist, (Sigma, Dorset, 
UK) were obtained.
Tissues were washed with Krebs for 20 min until baseline tension returned and 
were then equilibrated for 30-45 min with Krebs solution containing a selective 
muscarinic receptor subtype selective antagonist (Figure 1).
Wash
Antagonist CCH
a
Continued presence 
of the antagonistAntagonist, 30-45 min incubation
CCH
Figure 16) Illustration of the experimental protocol employed for in vitro functional 
studies of muscarinic-receptors in isolated detrusor strips from the rat bladder.
The antagonists used were 4-DAMP (relatively selective M3-muscarinic 
receptor antagonist) (Tocris, Bristol, UK), methoctramine (relatively selective
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M2-muscarinic receptor antagonist) (Sigma, Dorset, UK) and pirenzepine 
(relatively selective M1-muscarinic receptor antagonist) (Sigma, Dorset, UK). 
Following incubation with the antagonist, a second concentration-response 
curve to CCH was constructed in the continued presence of the antagonist. 
Four consecutive concentration-response curves were obtained to CCH in each 
tissue, with washes between each; one control curve and three curves in the 
presence of increasing concentrations of pirenzepine (3-30 pM), 4-DAMP (3- 
30nM) or methoctramine (3-30 pM). Each tissue was subjected to only one 
antagonist throughout the experiment.
3.3.2 Data analysis
The changes in developed tension to CCH were plotted as a percentage of the 
maximum increase for each CRC or as absolute grams of tension. Individual 
E C 5o values (molar concentrations producing half maximal response) were 
determined by non-linear regression curve fitting of CRCs using GraphPad 
'Prism' (CA, San Diego, USA) software. Mean -log EC50 (-pEC50) values with 
SEM were calculated. CRCs were also plotted where the responses were 
normalised per mg of tissue, in order to calculate the maximum tension 
developed and to ensure that any changes observed in the responses of the 
bladder strips to CCH were not due to changes in the size of the bladder strips. 
In order to eliminate any time dependent changes in the tissues or any vehicle 
dependent effect, time control experiments were performed, where one detrusor 
strip was set up in parallel to experimental tissues and was treated with the 
vehicle only. These experiments were used to obtain correction factors which 
were then applied to the experimental data to eliminate any non-experimental 
changes. Correction factors were calculated for the changes in maximum 
contractions and pECsoS using the formula below:
2ndM ax stimulation response or pECso value
C F =  ----------------------------------------------------------------------------------
1st M ax stimulation response or pECS0 value
Affinity constants (pKB) for muscarinic antagonists were determined using the 
formula described in Section 3.1.3. pKB values are presented as mean ±SEM.
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Schild plots were also constructed and values determined from the 
intercept on the abscissa (Arunlakshana & Schild, 1959).
3.3.3 Statistical Analysis
Data are expressed as mean ±SEM. Differences in pEC5o values and mean 
maximum responses to CCH between control (non-diabetic) and diabetic 
tissues were compared using one way ANOVA followed by Dunnett’s multiple 
comparison post test. Differences between the mean maximum responses in 
the absence and the presence of the highest concentration of antagonist, was 
compared using Student’s f-test (two-tailed).
Departure from unity of the slopes of the Schild plots was determined using 
95% confidence intervals. Confidence intervals were calculated for the slopes of 
the Schild plots for each antagonist in control (non-diabetic) and diabetic 
tissues. If the confidence intervals overlapped with unity, then it was concluded 
that the slope is not significantly different from 1. If the range of confidence 
intervals did not span the number 1, then the slopes are significantly different 
from unity. If the confidence intervals of the Schild plots, for a specified 
antagonist, in diabetic tissues overlapped that of the control (non-diabetic) 
tissues, then it was concluded that the slopes are not significantly different from 
control (non-diabetic) tissues.
3.3.4 Molecular characterisation of muscarinic receptors in 
the rat bladder smooth muscle
3.3.4.1 RNA extraction
Freshly isolated whole bladders from control (non-diabetic) (n=5), 1-week (n=3), 
4-week (n=5), 8-week (n=6) and 12-week (n=8) diabetic rats were cut open and 
the urothelium was carefully dissected off the underlying tissue. The bladders 
were then snap frozen in liquid nitrogen and ground to powder using a pestle 
and mortar. The powdered tissue was transferred into 1ml of Tri-reagent
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(Ambion, Austin, TX, USA) and homogenised manually using a homogenisation 
vessel. The mixture of homogenised tissue in Tri-reagent was then transferred 
to a 1.5ml Eppendorf tube (Starlabs ltd, Milton Keynes, UK). Upon addition of 
200pl chloroform (Sigma, Dorset, UK) to the homogenised tissue and 
centrifugation (13000rpm for 10mins at 4°C), the mixture was separated into 
three phases: 1) an aqueous phase 2) an interphase containing DNA and 3) an 
organic protein phase. 400pl of the aqueous phase containing RNA was 
transferred into a new RNAse free Eppendorf tube. RNA was then isolated 
using a Ribo Pure™ kit (Ambion, Warrington, UK) according to the protocol 
provided by the manufacturer, which involved passing the RNA solution through 
a filter cartridge by centrifugation at 13000rpm for 1min. The RNA was 
subsequently bound to the resin of the cartridge and was then washed with high 
salt solutions provided in the kit. Finally the RNA was eluted using 50-1 OOpI of 
water. All RNA preparations were treated with RNAse free DNAsel to ensure 
that no genomic DNA was present in the reactions.The DNAsel was then 
inactivated by heating the mixture for 15mins at 65°C.
RNA integrity and concentration were analysed using an Experion automated 
electrophoresis system (Biorad laboratories, Hemel Hempstead, UK). In brief, 
1pl of RNA was loaded onto the microfluidic chips in the priming station. The 
samples were then automatically subjected to gel-based electrophoresis, 
staining, destaining, band detection and imaging. RNA integrity was evaluated 
by examination of the electropherogram and simulated gel view.
3.3.4.2 Complementary DNA (cDNA) synthesis
RNA samples were then used as templates for synthesis of first-strand cDNA by 
reverse transcription (RT). 100pl of RT reaction was prepared by mixing 65pl of 
RNA (final concentration in the reaction: 65-325ng/ul) with 8pl of oligo dTi8 
primers (final concentration in the reaction: 0.04mg/ml) and 5pl dNTPs (final 
concentration in the reaction: 0.5mM) in a 1.5ml Eppendorf tube and incubating 
the mixture at 65°C for 10min. The primed RNA was then incubated with 20pl 
reaction buffer (5x) (Invitrogen, UK) and 2pl superscript III enzyme (final 
concentration in the reaction: 4units/pl) (Invitrogen, UK) at 50°C for 60 minutes
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to initiate the cDNA synthesis reaction and then heated at 70°C for 10 min to 
inactivate the reaction.
3.3.4.3 Real time PCR and house-keeping gene validation
2pl of each RT reaction was diluted at 1:3 to 1:1000 in distilled RNAse/DNAse 
free water. These serial dilutions of cDNA were subsequently used in real-time 
PCR to determine the efficiency of the primers. A 20pl PCR reaction, consisting 
of the components described in Table 3, was prepared to the indicated end 
concentration.
Reagent Stock concentration Final concentration 
in the reaction
Volume added
SYBR Green iQ PCR 
mastermix (Biorad)
2x 1x 10|JI
Forward primer 5 |jM 0.25|jM 1 |jl
Reverse primer 5pM 0.25pM 1 pi
cDNA 1:3-1:1000
Table 3) The real-time PCR reaction components. Reagents used for amplification of serial 
dilutions of cDNA samples obtained from control (non-diabetic) and diabetic rat bladders with 
housekeeping gene and M2- and M3-muscarinic receptor primers.
Real-time PCR reactions were set up with either the housekeeping gene or the 
target gene (M2- or M3-muscarinic receptors) primers and were performed in 96 
well plates. The amplification primer pairs used for housekeeping genes and 
M2- and M3-muscarinic receptors are listed in Table 5. Primers were previously 
designed and validated for qPCR by Dr Neil McKay.
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Target gene Accession no Primer sequence P.S
GAPDH NM-008084 F: 5' ACCCAGAAGACTGTGGATGG 3' 
R: 5' CACATTGGGGGTAGGAACAC 3' 171 bp
Mouse p-actin NM_007393 F: 5' TGTTACCAACTGGGACGACA 3' 
R: 5' GGGGTGTTGAAGGTCTCAAA 3' 165bp
Collagen NM_053304 F: 5' CAACCTCAAGAAGTCCCTGC 3' 
R: 5' AGGTGAATCGACTGTTGCCT 3' 77bp
Albumin NM_134326. F: 5' CATCCTGAACCGTCTGTGTG 3' 
R: 5' TTTCCACCAAGGACCCACTA 3' 86bp
HPRT NM_012583 F: 5 ' GCGAAAGTGGAAAAGCCAAGT 3' 
R: 5' GCCAGACTGGAAAGCCAACTA 3' 155bp
UBC NM_017314 F :5'TCGTACCTTTCTCACCACAGTATCTAG 3' 
R :5'GAAAACTAAGACACCTCCCGATCA 3' 82bp
y w h a z
BC094305 F: 5' CAAGCATACCAAGAAGCAT T T GA 3' 
R: 5' GGGCCAGACCCAGTCTGA 3' 76bp
Table 4) House keeping genes primer sequences, gene accession numbers and product 
size. GAPDH=glyceraldehyde-3-phosphate dehydrogenase; HPRT=Hypoxanthine guanine 
phosphoribosyl transferase 1;UBC=ubiquitin; yWHAZ=tyrosine 3-monooxygenase/tryptophane 
5-monooxygenase activation protein, zeta polypeptide. bp= base pairs; P.S=product size, 
F=forward R=reverse.
Target gene Accession
no Primer sequence P.S
M2-muscarinic 
receptor subtype NM_031016
F: 5' TTAAAGTCAGCCGCCACCTT 3' 
R: 57 CAGGTCCCAAAGCCCAGTAG 3' 138bp
M3-muscarinic 
receptor subtype M62826
F: 5' AAGACCTGGCTGGCCTACAG 3' 
R: 5' TCCTGGATGATCGTTTCACG 3' 129bp
Table 5) Muscarinic M2- and M3-receptor gene primer sequences, gene accession 
numbers and product size. bp=base pairs. P.S= product size. F=forward R=reverse.
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Duplicate preparations of each dilution were used in the PCR reaction. Negative 
controls consisted of sterile distilled water instead of the cDNA template. Real­
time PCR was performed in a Bio-Rad iCycler and the data was collected 
automatically by the computer using iCycler software. The amplification cycle 
protocol was 3 min denaturation at 95 °C followed by 35 cycles at 95°C for 15s, 
60°C for 15s and 72°C for 30s, with a final step of 95°C for 30s (Figure 17).
Figure 17) Illustration of the real-time PCR thermal programme in the iCycler. a: data 
collection stage b: melt curve analysis.
Following the PCR reaction, the amplified products were subjected to a melt 
curve test.
3.3.4.4 Data analysis
Amplification efficiencies were calculated automatically by iCycler software by 
plotting the Ct values for each of the dilutions against the concentration. This 
resulted in a linear graph and the slope of the graph was subsequently used in 
the equation stated below to calculate the efficiency of the primers:
[^ -]
E  =  10 slope
Signals were considered to be indicative of correctly amplified products if the 
melt curve analysis exhibited only one sharp peak at high temperature and the 
negative control (no template) yielded no signal in real-time PCR.
Since it has been reported that the expression of some housekeeping genes 
can also vary in different experimental conditions it was important to validate the
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expression stability of a housekeeping gene for the specific requirements of our 
experiment prior to its use in normalisation (Dheda et al, 2004). In order to do 
this, seven housekeeping genes primers listed in Table 4 were used in a real 
time PCR reaction with cDNA obtained from control (non-diabetic) and diabetic 
rat bladder tissues. The most stable housekeeping gene was then determined 
using Excel based geNorm software
(http://medgen.ugent.be/~jvdesomp/genorm/).
Real-time PCR reactions were then set up as described to determine the 
expression ratios of M2 and M3 muscarinic receptors in diabetic bladder 
compared to control bladder.
Analysis was performed by calculating the relative expression ratio of the target 
gene (M2- or M3-muscarinic receptors) based on its efficiency (E) and the 
difference in Ct value (delta Ct) of the treated sample (diabetic) against that of a 
control (non-diabetic) sample and expressed in comparison to a reference gene 
according to the method describe by Pfaffl (2001).
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3.4 Results
3.4.1 Pharmacological characterisation of muscarinic
receptors in rat bladder smooth muscle
The muscarinic receptor agonist CCH produced concentration-dependent 
contraction of the bladder detrusor strips from control (non-diabetic) and 
diabetic animals (Figure 18).
The -pEC5o values for control and diabetic tissues were not significantly 
different from each other, demonstrating no change in sensitivity of diabetic 
tissues to CCH (Table 6).
C 1-week D 4-week D 8-week D 12-week D
-p EC50 5.72±0.04 5.80±0.03 5.63±0.05 5.52±0.05 5.83±0.03
Max(g) 2.90±0.20 4.69±0.22‘** 5.16±0.30*‘* 6.54±0.30‘“ 6.48±0.20***
Max(g/mg
tissue) 0.17±0.01 0.22±0.01* 0.14±0.01 0.19±0.02 0.15±0.01
n 30 31 24 20 20
Table 6) Responses of bladder strips from control (non-diabetic) (C) & diabetic (D) rats to 
CCH. pEC50 and maximum tension values are compared between control (non-diabetic) 
tissues versus diabetic tissues. ***p<0.001 & *p<0.05 vs. control (non-diabetic tissues) (C). 
n=number of detrusor strips.
Maximum responses to CCH in detrusor strips from control and diabetic rats 
are presented in Table 6. The maximum contractile responses (g) produced by 
CCH were significantly greater in bladder strips from diabetic rats compared to 
the controls (Table 6). However, since diabetic bladders showed an increased 
mass, the responses were normalised per mg tissue. Following normalisation of 
data to account for tissue weight, a significantly greater contractile response to 
CCH was observed only in bladder strips from 1-week diabetic rats compared 
to bladder strips from control rats (p=0.021). The normalised maximum 
responses of 4-week, 8-week and 12-week diabetic tissues did not differ 
significantly from the control (non-diabetic) tissues (Table 6) (Figure 18).
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4-DAMP, methoctramine and pirenzepine produced parallel, rightward 
displacements of the CRCs to CCH, without affecting maximum responses in 
bladder strips from control (non-diabetic) and diabetic rats (Figures 19-23; 
Tables 7-10). Mean affinity (pKB) values calculated for each antagonist are also 
shown in Tables 7-9 for bladder strips from control and diabetic rats. 4-DAMP 
antagonised CCH responses with high affinity whilst methoctramine and 
pirenzepine antagonised CCH responses with lower affinity. Mean affinity (pKB) 
constants for each antagonist were similar in control and diabetic tissues 
(Tables 7, 8 and 9).
Schild plots for each of the muscarinic receptor antagonists are demonstrated 
in Figures 19-23. The slope and pA2 values obtained from these plots for each 
antagonist in each group are demonstrated in Tables 7-9. Schild plots for the 
antagonism of responses by 4-DAMP and pirenzepine had slopes that did not 
differ significantly from unity confirming a competitive mode of action of the 
antagonists. However, the slopes of schild plots for methoctramine in 1-week, 
4-week and 8-week diabetic tissues were significantly less than 1 but not 
significantly different from control (non-diabetic) based on 95% confidence 
intervals (Table 11). The slope of Schild plots for methoctramine in 12-week 
diabetic tissues was not significantly different from 1 (based on 95% confidence 
intervals).
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4-DAMP Control 1-week D 4-week D 8-week D 12-week D
pKB 9.13±0.09 8.92±0.07 9.03±0.05 9.18±0.22 9.05±0.07
n 6 6 6 5 5
p a 2 9.07 8.78 8.87 8.98 8.89
slope 1.17±0.15 1.19±0.05 1.12±0.04 1.21±0.04 1.18±0.01
Table 7) Affinity estimates for 4-DAMP in control (non-diabetic) (C) & diabetic (D) 
detrusor strips. pA2 and slope values were derived from Schild plots. n=number of tissues. All 
data is expressed as mean±SEM
Meth Control 1-week D 4-week D 8-week D 12-week D
pKB 5.77±0.06 5.73±0.07 5.48±0.08 5.37±0.20 5.54±0.07
n 5 6 6 5 5
p a 2 5.92 5.87 5.73 5.44 5.58
slope 0.83±0.09 0.83±0.05 0.87±0.04 0.83±0.14 0.93±0.07
Table 8) Affinity estimates for methoctramine in control (non-diabetic) (C) & diabetic (D) 
detrusor strips. pA2 and slope values were derived from Schild plots. n=number of tissues. All 
data is expressed as mean±SEM.
Pirenz C 1-week D 4-week D 8-week D 12-week D
pKB 6.89±0.04 6.82±0.06 6.78±0.09 6.79±0.10 7.02±0.07
n 6 6 6 5 5
p a 2 6.92 7.01 6.77 6.80 7.01
slope 0.98±0.01 0.91±0.01 1.01±0.03 0.96±0.20 1.00±0.02
Table 9) Affinity estimates for pirenzepine in control (non-diabetic) (C) & diabetic (D) 
detrusor strips. pA2 and slope values were derived from Schild plots. n=number of tissues. All 
data is expressed as mean±SEM.
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Group
4-DAMP
(30nM)
Meth
(30pM)
Pirenz
(30pM)
C
1st curve (no antagonist) 2.94±0.5g 2.41±0.5g 3.78±0.3g
Max (g) (antagonist present) 3.74±0.5g 3.37±0.5g 5.00±0.4g
1-week D
1st curve (no antagonist) 5.06±0.5g 4.62± 0.5g 4.31±0.6g
Max (g) (antagonist present) 5.77±0.6g 4.79±0.5g 5.96±0.3g
4-week D
1st curve (no antagonist) 5.91±0.4g 4.66±0.6g 5.27±0.6g
Max (g) (antagonist present) 6.19±0.4g 5.69±0.5g 6.11±0.4g
8-week D
1st curve (no antagonist) 7.17±0.3g 6.51±0.3g 5.63±0.9g
Max (g) (antagonist present) 7.69±0.8g 7.45±0.4g 6.36±1.2g
12-week D
1st curve (no antagonist) 5.96±0.3g 5.95±0.4g 7.25±0.3g
Max (g) (antagonist present) 6.60±0.3g 6.07±0.5g 7.80±0.4g
Table 10) Effect of muscarinic antagonists on maximum responses to CCH in detrusor 
strips from control (non-diabetic) (C) & diabetic (D) rats . Maximum responses are 
expressed as absolute tension (g) (n=5-6). All data is expressed as mean±SEM.
Group Confidence intervals
C (n=5) 0.72-0.95
1-week D (n=6) 0.77-0.87
4-week D (n=6) 0.82-0.91
8-week D (n=5) 0.66-1.00
12-week D (n=5) 0.84-1.02
Table 11) Confidence intervals (95%) of slopes of Schild plots for methoctramine in 
control (non-diabetic) (C) and diabetic (D) tissues.
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3.4.2 Molecular characterisation of M2- and M3-muscarinic
receptor expression in rat bladder smooth muscle
3.4.2.1 Analysis of RNA integrity and quantity using Experion
The integrity of RNA samples from control (non-diabetic) and diabetic rat 
bladders were evaluated using Experion microfluidic electropherogram and 
subsequent simulated gel views. RNA integrity was confirmed by the presence 
of 28S and 18S rRNA peaks on the electropherogram and gel views produced 
by the Experion software. Figure 24 demonstrates an example of an 
electropherogram and stimulated gel view produced by the Experion software 
after the analysis of a control (non-diabetic) rat bladder sample. The presence 
of 28S and 18S ribosomal RNA bands confirms the high quality of this sample. 
Similar results were obtained for all diabetic rat bladder RNA samples 
(electropherogram not shown).
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Figure 24) Electropherogram and stimulated gel view obtained from Experion software, i)
Integrity of RNA was tested in a control (non-diabetic) sample by visualization of 18S and 28S 
rRNA peaks on the electropherogram. ii) Stimulated gel analysis: Lanes 1 and 2 represent RNA 
samples run in duplicate from a control (non-diabetic) bladder. No degradation can be seen in 
either lane.
84
3.4.2.2 Housekeeping gene validation
Primers designed for house keeping genes, listed in Table 4, were used in real­
time RT-PCR reactions with both control (non-diabetic), 1-week, 4-week, 8- 
week and 12-week diabetic bladder samples (n=6 for all groups) to determine 
the most stable housekeeping genes for the experimental conditions. The 
results of geNorm analysis are demonstrated in Figure 25. According to the 
results obtained from geNorm software, the most and the least stable 
housekeeping genes were HPRT and (3-actin respectively. Therefore, HPRT 
was used as the internal reference gene for calculation of expression ratios of 
M2- and M3-muscarinic receptors in the diabetic tissues compared to the 
control (non-diabetic) tissues.
Average expression stability values of housekeeping genes
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Figure 25) geNorm analysis demonstrating the most and the least stable housekeeping 
genes from control (non-diabetic) and diabetic samples.
85
3.4.2.3 Investigation of muscarinic receptor expression
In order to calculate the relative expression ratios of M2- and M3-muscarinic 
receptors in diabetic rat bladders vs. control (non-diabetic) rat bladders, 
amplification with house keeping and target gene primers was carried out in all 
dilutions (1:3, 1:10. 1:30, 1:100, 1:300, 1:1000) of each sample. The 
amplification curves for the serial dilutions of each sample (control (non­
diabetic) and diabetic) for each set of primers were analysed and the Ct values 
for each dilution were recorded. The efficiencies of each primer set for each 
sample were determined.
Figures 26 demonstrates examples of a real-time PCR amplification curve, an 
efficiency plot and a melt curve analysis for serial dilutions of a control (non­
diabetic) sample amplified with HPRT primers. The melt curve analysis 
demonstrates a clear sharp peak which is an indication of a specific amplified 
product. The Ct values of each dilution versus Iog10 concentration were plotted 
by iCycler, the result of which is a linear graph (Figure 26). The efficiency was 
then calculated by the software according to the formula described in section 
3.3.4.4. (Figure 26). Figures 27 and 28 also demonstrate the amplification 
curves, efficiency plots and melt curve analysis for M3- and M2-muscarinic 
receptor primers with cDNA samples obtained from control (non-diabetic) rat 
bladders. Identical analysis was also performed for samples from diabetic rat 
bladder tissues.
Since there was no significant difference in the efficiency values between any 
primer pair for any sample group, the mean efficiency value obtained for each 
was calculated and used in the equation described by Pfaffl (2001) to determine 
the relative expression ratios. The average efficiency values of each primer set 
(HPRT, M2 & M3) and the average Ct values of each sample group (control, 1, 
4, 8 and 12-week diabetic) for each primer set were subsequently used in the 
equation described by Pfaffl (2001) to obtain expression ratios.
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Figure 26) Real-time PCR amplification of HPRT primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1-1000), from left to right red & light green: 1:3, light blue and dark green: 1:10 , 
pink and dark blue: 1:30, purple and brown:1:100, yellow and dark purple: 1:300, red and 
green:1:1000 dilutions respectively, ii) Melt curve analysis demonstrates a clear sharp peak for 
all dilutions indicating the specifity of the PCR products produced iii) Efficiency graph generated 
by iCycler software by plotting the Ct values of each dilution against their concentration. The 
PCR efficiency is demonstrated as a percentage above the graph.
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Figure 27) Real-time PCR amplification of M3 primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1-1000), from left to right: light blue & dark green: 1:3, pink & blue: 1:10, dark blue 
& brown: 1:30, yellow & purple: 1:100, red and light green: 1:300, light blue & dark green: 
1:1000 dilutions, ii) Melt curve analysis demonstrates a clear sharp peak for all dilutions 
indicating the specifity of the PCR products produced iii) Efficiency graph generated by iCycler 
software by plotting the Ct values of each dilution against their concentration. The PCR 
efficiency is demonstrated as a percentage above the graph.
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Figure 28) Real-time PCR amplification of M2 primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1-1000), from left to right: Red & light green: 1:3 (duplicate), light blue and dark 
green: 1:10, dark blue: 1:30, purple and brown: 1:100, yellow and dark purple: 1:300, red and 
green: 1:1000 dilutions respectively, ii) Melt curve analysis demonstrates a clear sharp peak for 
all dilutions indicating the specifity of the PCR products produced iii) Efficiency graph generated 
by iCycler software by plotting the Ct values of each dilution against their concentration. The 
PCR efficiency is demonstrated as a percentage above the graph.
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The relative expression ratios of M2- and M3-muscarinic receptors for 1-week 
(n=3), 4-week (n=4), 8-week (n=6) and 12-week (n=8) diabetic denuded rat 
bladders compared to control (non-diabetic) tissues (n=5) (n=number of 
bladders) are shown in Table 12 .
Relative expression ratios 1 -week diabetics
4-week
diabetics
8-week
diabetics
12-week
diabetics
M2 2.20 1.14 1.19 1.01
M3 1.11 0.44 0.23 0.21
Table 12) Relative expression ratios of M2 and M3 muscarinic receptors in diabetic 
bladders compared to control (non-diabetic) bladders. Values <1 show a decrease in 
expression and values >1 demonstrate an increase in expression.
The relative expression ratio of the M2-muscarinic receptor was increased in 1- 
week, 4-week and 8-week diabetic tissues compared to control (non-diabetic) 
tissues, whilst it did not alter in 12-week diabetic rat bladders.
The relative expression ratio of the M3-muscarinic receptor was slightly 
increased in 1-week diabetic tissues, but was decreased in 4-week, 8-week and 
12-week diabetic tissues compared to control (non-diabetic) tissues.
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3.5 Discussion
Muscarinic antagonists are the mainstay of treatment for DO, yet little is known 
about the possible underlying changes in muscarinic-receptor-mediated 
pathways in this condition. Understanding the exact role of M2 and MS- 
muscarinic receptors in mediating the bladder detrusor contractions under 
normal and pathological conditions could help the development of better drug 
treatments in patients with voiding dysfunction and DO.
The sensitivity of the detrusor muscle to muscarinic agonists is altered in 
several disease states which lead to DO in humans, including denervation and 
bladder outflow obstruction (Harrison et al, 1987), with the animal models of 
these conditions demonstrating similar changes in detrusor function (Ruggieri & 
Braverman, 2006).
Diabetes has also been associated with DO (Salinas Casado et al. 1999) and in 
animal models of diabetes the detrusor can exhibit changes in the responses to 
cholinergic agonists similar to that observed in the human overactive detrusor 
(Mimata etal, 1995; Stevens etal, 2006).
On the basis of suggested altered biochemical and functional characteristics of 
muscarinic receptors in animal models of detrusor overactivity (DO) (Latifpour et 
al, 1989, Stevens et al, 2006), muscarinic-receptor-mediated function was 
investigated in the STZ-diabetic rat using muscarinic receptor agonists and 
receptor subtype selective antagonists
3.5.1 Responses of detrusor strips from control (non-diabetic)
and diabetic rats to CCH.
In the present study, although the absolute contractile responses (g) to CCH 
were larger in diabetic tissues compared to control (non-diabetic) tissues, after 
normalising the contractile responses to account for change in tissue weight, an 
increased maximum response to the muscarinic agonist, CCH, was only 
detected in detrusor strips from 1-week diabetic rats compared to control (non­
diabetic) tissues. The reason for this increased responsiveness of detrusor 
strips from 1-week diabetic animals is unknown but could be an initial 
compensatory response in 1-week diabetic tissues to diuresis and the metabolic
effects of diabetes, as suggested by Stevens et al (2006). Daneshgari et al 
(2006), who studied bladders from 3, 6, 9, 12 and 20-week STZ-diabetic rats, 
showed that diabetic bladders may undergo a contractile transition from a 
compensated to a decompensated state, with the decompensated state 
beginning 9-12 weeks after induction of diabetes. Liu & Daneshgari (2006), who 
also studied bladders from 4-day, 1-week, 2-week, 3-week and 9-week STZ- 
diabetic rats, showed that diabetic bladders undergo time dependent adaptive 
physical changes in the functional and structural components of the bladder 
wall. They believed that the significant increase in urine output in diabetic 
animals during the early stages of diabetes results in an increase in the bladder 
capacity and stimulation of hypertrophy and hyperplasia in the tissue. A major 
initial increase (from the normal levels) in the areas of the two main components 
of the bladder wall, the urothelium and smooth muscle, as a result of a vigorous 
growth response to polyuria, was detected in the bladders of 1-3-week diabetic 
rats. It was postulated that related alterations in bladder volume, rate of filling, 
and rate of stretch of the bladder results in changes in the shape of the smooth 
muscle cells and stimulation of DNA synthesis in these cells. This subsequently 
results in increased protein synthesis, cell mass and hyperplasia in the bladder 
which could account for the initial compensatory responses of the bladder 
smooth muscle in 1-3-week diabetic animals (Liu & Daneshgari, 2006). They 
suggested that the state of decompensation in the contractility of STZ-diabetic 
rat bladder at later stages of diabetes could be due to organ adaptation to the 
increased urine volume and increased bladder mass. Although Liu & 
Daneshgari (2006) concluded that the alterations detected in STZ-diabetic rat 
bladder are due to polyuria as the result of diabetes, Pitre et al (2002) noted 
that polyuria does not necessarily mimic the structural changes observed in 
bladders from STZ-diabetic animals. The results of the current study can not be 
associated with increase in tissue weight since the responses of detrusor strips 
from diabetic animals were normalised to the tissue weight.
An increased sensitivity to muscarinic agonists has been reported in the human 
overactive detrusor (Stevens et al, 2004a; 2004b). A similar increased 
sensitivity was also detected in the 1-week diabetic STZ-diabetic rat model of 
overactive bladder by Stevens et al (2006). However, conflicting results 
regarding the sensitivity of diabetic bladder detrusor to muscarinic agonists
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have been reported, with some groups demonstrating increased (Kolta et al, 
1985), decreased (Longhurst and Belis,1986) or no change in the contractile 
responses (Lincoln et al, 1984). In the present study, no change was seen in 
the sensitivity of diabetic tissues to muscarinic receptor stimulation compared to 
control (non-diabetic) tissues. Differences in the results obtained in this study 
compared to previous studies, such as Stevens et al (2006), could be due to 
differences in the experimental protocols. After conducting length-tension 
experiments (Chapter 2), the optimised initial load applied to the detrusor strips 
in the current study was 2g, whilst Stevens et al (2006) used an initial load of 1g 
during the equilibration period, which may have had an effect on the contractile 
responses. Differences in the time point at which diabetic animals have been 
used, or variations in the species of animals utilised in the experimental 
procedures, could also lead to discrepancies detected between various studies. 
For example, in the study by Malmgren et al (1989), who reported no change in 
muscarinic mediated contractions of detrusor strips, 6-week and 6-month 
female Sprague-Dawley diabetic rats were used (Malmgren et al, 1989), whilst 
in the study by Stevens et al (2006), an increase in sensitivity of CCH-induced 
contraction was detected in detrusor strips from 1-week diabetic male Wistar 
rats.
Although only 1-week diabetic tissues demonstrated a significant increase in 
their contractile responses to CCH, with no change in their sensitivity to this 
drug, changes in muscarinic-receptor subtype-mediated function could not be 
ruled out and were further investigated using muscarinic-receptor subtype 
selective antagonists.
3.5.2 Pharmacological characterisation of muscarinic 
receptors in the rat bladder smooth muscle
Muscarinic receptor subtype-mediated responses play a key role in bladder 
contractility and function. Thus, alterations in muscarinic receptor subtype 
mediated function may be important in the understanding of the disease state. 
Some groups (Braverman & Ruggieri, 2003) have suggested that muscarinic- 
receptor mediated detrusor contractions can alter from M3-mediated to M2-
93
mediated in pathological conditions such as bladder outlet obstruction and 
denervation in rats. Results of the present chapter demonstrated that the 
muscarinic-receptor mediating the direct contractile responses to CCH in 
bladder strips from control and diabetic rats displayed a high affinity for 4-DAMP 
(8.7-9.1), a low affinity for methoctramine (5.4-5.9) and an intermediate affinity 
for pirenzepine (6.8-7.0) and. In rat urinary bladder smooth muscle the affinity 
estimates of key antagonists pirenzepine (6.7-6.9) methoctramine (5.7-6.1) AF- 
DX 116 (6.2) and 4-DAMP (8.7-9.2) obtained from similar functional in vitro 
studies suggest the singular involvement of M3-muscarinic receptors in 
mediating the detrusor contraction (Longhurst et al, 1995b; Tong et al, 1997; 
Hedge et al, 1997).
The antagonist profile obtained in this chapter indicates that contractile 
responses of the detrusors from control (non-diabetic) and diabetic are 
mediated via M3-mucarinic receptor. In a recent similar study by Saito et al 
(2008), it was also demonstrated the detrusor contractions in young and old 
Type 2 Goto-Kakizaki diabetic rats are also mediated via the M3-muscarinic 
receptor only, with the role of M2-muscarinic receptor remaining unclear.
The antagonists used in this chapter had a competitive mode of action since the 
maximum contractions to CCH were unchanged in the presence of the highest 
concentration of the antagonists (30nM 4-DAMP, 30pM methoctramine and 
30pM pirenzepine). The slopes of the Schild plots for 4-DAMP and pirenzepine 
were not significantly different from unity in all tissues. However, the slope of 
the Schild plots for methoctramine were significantly less than unity, but not 
significantly different from control (based on 95% confidence intervals), in all 
groups except in 12-week diabetics in which Schild plots for methoctramine 
demonstrated a slope not significantly different form unity. The reason for the 
low slope of the Schild plots for methoctramine in 1-week, 4-week and 8-week 
diabetic tissues is not clear. One possible explanation might be the antagonism 
of a heterogeneous receptor population by methoctramine (Kenakin, 1993). In a 
study by Braverman et al (1998), involving pharmacological characterisation of 
muscarinic receptors in denervated rat bladder, the slope of Schild plots 
obtained for methoctramine were also significantly different from unity, but not 
significantly different from control values. Braverman et al (1998) suggested that
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a combination of M2- and M3-muscarinic receptors could be mediating the 
contractile responses in denervated rat bladder. However, methoctramine might 
have other non-specific effects. In the present chapter, involvement of M2- and 
M3-muscarinic receptors in mediating the STZ-diabetic rat bladder smooth 
muscle contraction can not be confirmed based on the profile of the muscarinic- 
receptor antagonist affinity values. However, the role of M2-muscarinic receptor 
in mediating the detrusor contraction in the STZ-diabetic rat bladder contraction 
can not be ruled out completely, especially since real-time PCR analysis 
demonstrated an increase in the expression levels of this muscarinic receptor- 
subtype.
3.5.3 Molecular characterisation of muscarinic receptors in 
the rat bladder smooth muscle.
Although no apparent change was detected in muscarinic receptor subtype- 
mediating direct contraction of detrusor in the present study, an increased 
expression of M2-muscarinic receptor mRNA was detected in 1-week, 4-week 
and 8-week diabetic bladders with no change in 12-week diabetic tissues. The 
expression of M3-muscarinic receptor was slightly increased in 1-week diabetic 
tissues, although 4-week, 8-week and 12-week diabetic bladders demonstrated 
a drastic decrease in the expression of M3-muscarinic receptor. The increase in 
expression of M2- and M3-muscarinic receptors in 1-week diabetic rat bladders 
may contribute to the significantly increased maximum responses to CCH seen 
in these tissues compared to control tissues. However, in 4-week and 8-week 
diabetic tissues, where M2-muscarinic receptor expression was increased and 
the M3-muscarinic receptor expression was decreased, the CCH mediated 
responses were unchanged compared to the controls (non-diabetics). Thus, it 
could be postulated that the M2-muscarinic receptor has a compensatory role in 
mediating the detrusor contraction in these tissues in the absence or reduced 
expression of M3-muscarinic receptors. However, this is not supported by the in 
vitro functional results described in section 3.5.2. since in 12-week diabetic rat 
bladders, the expression of M2-muscarinic receptor was unchanged, whilst 
there was a noticeable decrease in the expression of M3-muscarinic receptor. 
Functional data obtained for 12-week diabetic tissues, demonstrate no change
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in the CCH mediated responses, and thus it can be assumed that expression 
levels of muscarinic receptors at the mRNA level do not necessarily relate to 
functional results obtained in this chapter.
Previous studies have demonstrated an up-regulation of both muscarinic 
receptor subtypes at both the RNA and protein level in the detrusor and the 
urothelium of diabetic bladders (Tong et al, 2002; Tong & Cheng, 2002; Cheng 
et al, 2007). An increased expression of M2-muscarinic receptors was also 
detected in denervated rat bladders by Braverman et al (1998), with no change 
in the expression levels of muscarinic M3-muscarinic receptor. In another study 
by Braverman et al (2007) it was demonstrated that the sub-population of 
muscarinic receptors within the urothelium are different between bladders with 
normal and pathological contraction and that the M2-muscarinic receptor 
mediated contractions of human bladder from organ donors is associated with 
an increase in urothelial muscarinic receptors (Braverman et al, 2007). In the 
present study, urothelium/mucosa was removed from the detrusor and the 
bladders were then used for RNA extraction and real-time PCR analysis. Thus, 
an alteration in the urothelial muscarinic receptor expression can not be ruled 
out. It must be noted that changes in the muscarinic receptor subtype 
expression detected by various studies in diabetic and denervated bladders 
(Tong et al, 2002, Tong & Cheng, 2002; Cheng et al, 2007; Braverman et al, 
1998) could be due to changes in the expression levels of these receptors at 
the smooth muscle, nerve or urothelial levels. Thus, ideally, it would be 
informative to investigate the expression levels of muscarinic receptors in these 
cell populations before a conclusion can be made.
The change in the expression levels of M2- and M3-muscarinic receptors 
mRNA may also alter the M2:M3 ratio in the detrusors from diabetic rats. In this 
study, the M2:M3 ratio has increased in bladders from all diabetic rats 
compared to control (non-diabetic) tissues. However, it is important to consider 
that alterations in muscarinic receptor expression at the mRNA levels may not 
necessarily represent an upregulation or downregulation of functionally active 
muscarinic receptors, which may explain why in the present study no changes 
were observed in CCH-induced responses in 4-week, 8-week and 12-week 
diabetic tissues. Therefore, alterations in M2- and M3-muscarinic receptor
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expression at the protein level should be confirmed using radioligand binding 
experiments, Western blotting or other techniques.
3.6 Sum m ary
Muscarinic receptor-mediated contractions of control (non-diabetic) and diabetic 
rat bladder detrusor were analysed using classical pharmacological techniques.
In this study, the sensitivity of tissues from diabetic rats to CCH was not 
significantly different from control (non-diabetic) and only tissues from 1-week 
diabetic rats demonstrated a greater maximum response to CCH compared with 
controls.
The antagonism data demonstrated that the direct contractile response to CCH 
is mediated by the M3-muscarinic receptor in control (non-diabetic) rat bladder 
detrusor and no evidence could be found to indicate changes in the muscarinic 
receptor subtype mediating contraction of the diabetic overactive rat bladder 
detrusor.
Expression levels of the M2-muscarinic receptor subtype were increased in 1- 
week, 4-week, and 8-week diabetic detrusors, with no change in 12-week 
diabetic tissues. M3-muscarinic receptor expression was increased in 1-week 
diabetic rat bladder tissues compared to control (non-diabetic) tissues. 
However, in contrast the expression of the M3-muscarinic receptor was 
decreased in 4-week, 8-week and 12-week diabetic tissues compared to control 
(non-diabetic tissues. Changes in molecular expression of muscarinic receptors 
may not necessarily relate to changes seen at the functional receptor level.
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Chapter 4: Investigation 
of spontaneous 
activity in detrusor 
strips from rats
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4.1 Introduction
The myogenic theory of overactive detrusor suggests that as well as changes in 
structure and function of the smooth muscle, involuntary detrusor contractions, 
especially during the filling phase of the micturition cycle, are important in 
generation of the symptoms associated with urgency and frequency. In the 
STZ-diabetic rat bladder, increased involuntary detrusor contractions or SA 
have also been detected (Stevens et al, 2006) which may be associated with 
DO in these animals. However, in normal bladders, SA may also be important in 
mediating bladder tone and sensory afferent information from the detrusor.
4.1.1 The role of smooth muscle SA in normal urinary bladder 
function
Previously, the commonly accepted view of bladder function was that during the 
storage phase the bladder was not active and behaved as a compliant low 
pressure reservoir. It was thought that as the bladder filled, stretch receptors in 
the wall sent signals to the central nervous system (CNS) and at the “critical 
volume” the CNS coordinated a series of events which resulted in smooth 
muscle contraction and micturition. However, this view is now known to be 
simplistic. It is now believed that there are two distinct mechanisms generating 
contractile activity in the bladder: the autonomous or SA and the micturition 
contraction (Gillespie et al, 2003; Gillespie, 2003; Kanai et al, 2007).
Spontaneous contractions have been suggested to be myogenic in nature, 
since they occur in isolated in vitro bladder preparations (Liu et al, 1998; 
Hashitani & Brading, 2003). In the detrusor SA is associated with action 
potentials whose upstroke is carried by voltage dependent Ca2+ channel 
(VDCC) current and repolarised by large conductance Ca2+ activated K+ 
channels (BKca) channel activity. Transmembrane Ca2+ fluxes may result in 
Ca2+-induced Ca2+ release (CICR) from internal stores, which are replenished 
through feedback mechanisms employing BKCa and VDCCs (Hashitani et al, 
2004; Reviewed by Brading, 2006).
In many species spontaneous bladder contractions are believed to be important 
in generating periodic sensation and allowing the individual muscle bundles to 
adjust their length in response to filling, which allows the bladder to maintain its
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shape during this period (reviewed by Brading, 2006). At baseline, this activity is 
localised and can be multifocal, with separate areas of bladder wall contracting 
independently. In response to an increase in intravescical pressure or 
cholinergic stimulation by low concentrations of muscarinic agonists, 
propagating waves of contraction emerge (Drake et al, 2005). It is believed that 
these autonomous or spontaneous contractions have implications for the 
generation of additional afferent information from the bladder wall to the CNS 
and that without these contractions, the bladder would remain a floppy and 
relaxed organ (Drake et al, 2005).
Although the spontaneous contractions of the detrusor can occur in the absence 
of neural stimulation, they may be modulated by activation of various types of 
receptors (muscarinic, purinergic and adrenergic) (Ng et al, 2006). It has 
previously been shown that the amplitude and the frequency of spontaneous 
contractions can be augmented by addition of muscarinic receptor agonists 
such as CCH (Gillespie et al, 2003; Ng et al, 2006). The cells involved in 
mediating these spontaneous contractions must therefore express muscarinic 
receptors. It seems that at low concentrations (<300nM) of muscarinic agonists 
phasic contractions are activated, whilst at higher concentrations (>3pM), 
phasic activity and a tonic contracture are activated (Gillespie et al, 2003). The 
exact mechanisms of generation of spontaneous contractions in the bladder 
detrusor are still unclear, but may involve bladder smooth muscle cells, intra­
mural nerves, urothelial and suburothelial cells, as well as a network of ICs 
(which are described in chapter 6 ).
4.1.2 Implications of bladder smooth muscle spontaneous 
contractions in pathological conditions
In bladders from humans with DO and animal models of DO, spontaneous 
contractions have been shown to be increased (German et al, 1995; Mills et al, 
2000, Drake et al, 2006b) and these may underlie the abnormal rises in 
intravesical pressure which result in symptoms of urgency, frequency and urge 
incontinence (Brading, 2006). Intrinsic or spontaneous contractions have also 
been demonstrated to be more prominent in neonatal rats than adult rats (Ng et 
al, 2006). Whole rat bladders and isolated strips from neonatal rats exhibit high- 
amplitude, low frequency spontaneous contractions which may promote voiding
100
as neural control is still immature. Whilst every spontaneous contraction does 
not result in voiding, large-amplitude spontaneous contractions may enhance 
the likelihood of urine loss. The same high amplitude spontaneous contractions 
have also been demonstrated in the spinal cord transected rat, which is used as 
an animal model of DO (Drake et al, 2003b; Gevaert et al, 2006; Ikeda & Kanai, 
2008). Bladders from neonatal rats have also been used in numerous studies 
as a pathological model in an attempt to understand the underlying mechanisms 
of overactive detrusor spontaneous contractions (Ng et al, 2006; Kanai et al, 
2007).
As described in chapter 2, antimuscarinic agents are the preferred 
pharmacological treatment of DO and overactive bladder syndrome. Their 
mechanism of action, however, is not clear and it is believed that they may act 
during the filling phase when parasympathetic activity is low. These drugs are 
more effective in suppressing bladder activity in patients with DO than in normal 
subjects (reviewed by Yoshida & Andersson, 2003). It has been suggested that 
symptoms of DO may be caused by enhancement of spontaneous contractions 
due to leakage of small amounts of ACH from intramural nerves during bladder 
filling (Ng et al, 2006). The source of acetylcholine is still under debate, with 
some groups believing that urothelial cells are the main site of release (Yoshida 
et al, 2006), whilst others believe that intramural nerves are the main source 
(reviewed by Yoshida & Andersson, 2003). It has been demonstrated that both 
M2- and M3-muscarinic receptors are the targets of this ACH leakage and thus 
may be responsible for mediating bladder smooth muscle spontaneous 
contractions in pathological conditions. This may explain an effect of 
antimuscarinic agents in the filling phase of the micturition cycle (Ng et al, 2006; 
Mukerji et al, 2006). Many studies have tried to mimic these conditions by 
applying low concentrations of muscarinic agonists to bladder detrusor strips 
from normal and overactive bladders, in order to study the effect of muscarinic 
receptor stimulation on generation of spontaneous contractions (Gillespie et al, 
2003; Gillespie, 2003; Ng etal, 2006; Kanai etal, 2007; Finney etal, 2007).
SA in the UBSM of the STZ-diabetic rat model has only been investigated in a 
few previous studies (Tammela et al, 1994; Nakahara et al, 2004; Stevens et al, 
2006). Tammela et al (1994) demonstrated an increased SA in detrusor strips 
from STZ-diabetic rats, which was sensitive to the cyclooxygenase inhibitor,
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indomethacin, demonstrating the importance of prostaglandins in mediating this 
activity. These spontaneous contractions were insensitive to inhibition by the 
neurogenic blocker tetrodotoxin, confirming a myogenic basis. In the report by 
Nakahara et al (2004) enhanced SA in detrusor strips from STZ-diabetic rats 
was demonstrated after modulation of UBSM excitability by various ion channel 
openers and blockers. In addition the study by Stevens et al (2006) 
demonstrated an increase in basal SA of detrusor strips from 1-week diabetic 
rats. Apart from these few reports, studies on the properties of spontaneous 
contractions in the detrusor of the STZ-diabetic rat are very limited, with no 
reports on the cholinergic modulation of this SA. Further characterisation of SA 
in the modulation of UBSM contractility in STZ-diabetic rat may aid a better 
understanding of the underlying mechanisms that could lead to DO.
10 2
4.2 Aims of the chapter
The aim of the current chapter was to characterise the basal and cholinergic 
stimulated spontaneous contractions of detrusor strips from control (non­
diabetic) and STZ- diabetic rat bladders using in vitro pharmacology.
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4.3 Materials and Methods
4.3.1 Investigation of basal SA in bladder strips from control 
and diabetic rats
Longitudinal mucosa-intact strips (2-4 x 6-12mm) were isolated from the body 
of bladders from control (non-diabetic) (weight range 200-350g), 1-week, 4- 
week, 8 -week and 12-week diabetic Wistar rats (Harlan, UK), and suspended in 
15ml organ baths containing Krebs bicarbonate solution (containing 5pM 
indomethacin) as described in chapter 2. They were allowed to equilibrate for 
60mins and during the last 30mins of the equilibration period they were 
assessed for generation of basal SA. The frequency and the amplitude of basal 
SA were measured.
4.3.2 Induction of SA in bladder detrusor strips using low 
concentrations of carbachol (CCH)
In separate experiments, longitudinal mucosa-intact and denuded strips (2-4 x 
6-12mm) were isolated from the bladder body of 1-week, 4-week, 8 -week and 
12-week diabetic Wistar-Hans rats (Charles River, UK) and their age- matched 
controls. Mucosa was removed by sharp dissection under the dissecting 
microscope. Tissues were suspended in 15ml organ baths as described in 
chapter 2  and allowed to equilibrate for 60mins before being stimulated with low 
cumulative concentrations of CCH (0.05, 0.1 and 0.5pM). The tissues were 
incubated with each concentration of CCH for 5-10mins. The last 5-min period 
with each concentration was used to calculate the mean amplitude and the 
frequency of the spontaneous contractions.
4.3.3 Data analysis
To calculate the amplitude and the frequency of SA, a slightly modified method 
to that proposed by Imai et al (2 0 0 1 ) was used to define a single spontaneous 
contractile event. Firstly, maximum amplitude of contractile activity over a 5mins 
period was calculated in control (non-diabetic) tissues. Any contractions over 
and above the 30% of this mean were considered as single spontaneous 
contractions and counted for calculation of the frequency. The same 30% 
threshold line was also used for calculation of the frequency of SA in diabetic
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tissues (Figure 29). The amplitude of SA was expressed as absolute values (g) 
or normalised for tissue weight (g/mg). Data was expressed as mean±SEM.
Frequency in 5mins
Maximum
amplitude
30% of maximum
SA in age- matched control 
(non-diabetic) tissues
SA in relevant age-matched 
diabetic tissues
Figure 29) Calculation of the amplitude and the frequency of SA over a period of 5mins in 
control (non-diabetic) and diabetic tissues. Modified from Imai et al (2001).
4.3.4 Statistical analysis
Statistical analysis was performed using repeated measures ANOVA followed 
by Dunnett’s post hoc test for intra-tissue variations and unpaired Student’s t- 
test for inter-tissue variations. For multiple comparisons between different 
control (non-diabetic) and diabetic groups, one way ANOVA followed by 
Tukey’s post hoc test was performed.
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4.4 Results
4.4.1 Investigation of basal SA in detrusor strips from control
and diabetic rats
Basal spontaneous contractions were detected in detrusor strips from control 
(non-diabetic) and diabetic rats. However, of all the control and diabetic tissues 
tested, only 30% of control, 55% of 1-week, 54% of 4-week, 55% of 8 -week and 
5% of 12-week diabetic tissues developed basal spontaneous contractions. 
Typical chart recordings of these basal spontaneous contractions are shown in 
Figure 30.
The mean amplitude and frequency of basal SA in control (non-diabetic) (n=10) 
tissues were 0.021 ±0.001 g/mg tissue and 27.7±2.7 events in 5mins 
respectively. Detrusor strips (n=16) from 1-week diabetic rats demonstrated a 
basal SA with an amplitude of 0.045±0.007 g/mg tissue and a frequency of 
23.5±1.3 events in 5mins. The basal SA in detrusor strips (n=13) from 4-week 
diabetic rats had a mean amplitude of 0.025±0.004 g/mg tissue and a frequency 
of 27.3±2.62 events in 5mins. The mean amplitude of basal SA in detrusor 
strips from 8 -week diabetic rats was 0.027±0.005 g/mg tissue, whilst the 
frequency was 16.5±1.7 events in 5mins. Only one detrusor strip from 12-week 
diabetic rats demonstrated basal SA, with an amplitude of 0.007g/mg tissue and 
a frequency of 9 events in 5mins. No further statistical analysis was performed 
on 1 2 -week diabetic tissues.
When the amplitude of basal SA of each diabetic group was compared to 
control (non-diabetic) tissues, detrusor strips from 1 -week diabetic rats 
demonstrated a significantly (p<0 .0 1 ) greater amplitude of basal spontaneous 
contractions compared to control tissues. There was no significant difference in 
the amplitude of SA between control (non-diabetic) vs. 4-week and 8 -week 
diabetic tissues
The frequency of basal SA in detrusor strips from 1-week and 4-week diabetic 
rats was not significantly different compared to control (non-diabetic) tissues. 
However, the frequency of basal SA in 8 -week diabetic tissues was significantly 
(p<0.01) lower than control (non-diabetic) tissues (Figure 31).
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Figure 30) Typical chart recordings of basal spontaneous contractions in detrusor strips 
from control (non-diabetic) (C) and diabetic (D) rats.
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Figure 31) Comparison of the amplitude and the frequency of basal spontaneous 
contractions between control (non-diabetic) (C) & diabetic (D) tissues. C: n=10, 1-week D: 
n=16, 4-week D: n=13 & 8-week D: n=11. Data is presented as mean±SEM. **p<0.01 vs. 
control (non-diabetic) tissues.
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4.4.2 Induction of spontaneous activity by CCH in bladder 
strips from control (non-diabetic) and diabetic rats.
The non-selective muscarinic agonist CCH induced spontaneous bladder 
contractions in a concentration-dependent manner in control (non-diabetic) and 
diabetic rat bladder strips (Figure 32). At low concentrations (0.05pM), CCH 
increased spontaneous contractions without causing a tonic contraction, 
whereas 0.1 pM CCH caused a transient tonic contraction. 0.5pM CCH caused 
an even larger increase in tonic contraction, with the spontaneous contractions 
being superimposed on the top of this large slow tonic wave (Figure 32).
4.4.2.1 Effect of CCH on the SA in bladder detrusor from 1-week 
diabetic rats
CCH induced SA in a concentration-dependent manner in 1-week diabetic 
tissues and their age-matched controls (non-diabetic) with detrusor strips from 
STZ-diabetic rats showing a greater response to CCH. Figure 33 demonstrates 
the effect of CCH on the amplitude and frequency of SA in 1-week diabetic 
detrusor strips versus age-matched controls (non-diabetic). There was a 
significant difference in the amplitude of CCH-stimulated SA between detrusor 
strips from 1 -week diabetic vs. their age matched control (non-diabetic) rats at 
both 0.1 pM CCH and 0.5pM CCH (Figure 33).
The frequency of CCH-stimulated SA was significantly less in 1-week diabetic 
tissues compared to controls at 0.1 pM and 0.5pM CCH (Figure 33).
4.4.2.2 Effect of CCH on the SA in detrusor strips from 4-week 
diabetics
CCH induced SA in a concentration-dependent manner in 4-week diabetic 
tissues and their age matched controls (non-diabetic). However, there was no 
significant difference in the amplitude of CCH-stimulated SA between control 
(non-diabetic) and diabetic tissues at all concentrations of CCH tested (Figure
34). There was also no significant difference in the frequency of CCH-stimulated
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SA between both groups upon stimulation with increasing concentrations of 
CCH (Figure 34).
Tension
9)
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0.05|jM CCH 0.1 mM CCH
0.5mM CCH
0.5|jM CCH
0.1 mM CCH
0.05mM CCH
1-week D
5mins
10
0.5(jM CCH8
0.05pM CCH 0.1 |JM CCH6
g)
2
5mins 8-week D
10
0.5(jM CCH8
0.05|jM CCH
2
5mins 12-week D
Figure 32) Typical chart traces showing the effect of increasing concentrations of CCH 
on spontaneous contractions in detrusor strips from a representative control (non­
diabetic) (C) & diabetic (D) rats.
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Figure 33) Comparison of the amplitude and the frequency of CCH-stimulated SA in 
control (C) (age-matched non-diabetic) and 1-week diabetic (D) tissues at increasing 
concentrations of CCH (0.05-0.5pM). C: n=24 & 1-week D: n=31. *p<0.05 & ***p<0.001 
indicate a significant difference between control (non-diabetic) and diabetic tissues. Data is 
presented as mean±SEM
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Figure 34) Comparison of the amplitude and the frequency of CCH-stimulated SA in 
control (C) (age-matched non-diabetic) and 4-week diabetic (D) tissues at increasing 
concentrations of CCH (0.05-0.5pM). C: n=19 & 4-week D: n=12. Data is presented as 
mean±SEM
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4.4.2.3 Effect of CCH on the SA in detrusor strips from 8-week diabetic 
rats
CCH induced SA in a concentration-dependent manner in 8 -week diabetic 
tissues and their age matched controls (non-diabetic). The only significant 
difference detected was between the amplitude of stimulated SA in 8 -week 
diabetic tissues vs. age matched controls (non-diabetic) at 0.1 pM CCH (Figure
35).
There was no significant difference in the frequency of stimulated SA between 
control and 8 -week diabetics (Figure 35).
4.4.2.4 Effect of CCH on the SA in detrusor strips from 12-week 
diabetic rats
CCH also induced SA in a concentration dependent manner in 12-week diabetic 
tissues and their age matched controls. However, the amplitude of SA in 12- 
week diabetic tissues was significantly less than that of 1 2 -week age matched 
control (non-diabetic) tissues upon stimulation with all concentrations of CCH 
(0.05-0.5pM) (Figure 36).
The frequency of SA in 12-week diabetic tissues was also significantly less than 
12-week control (non-diabetic) tissues upon stimulation with 0.05 and 0.1 pM 
CCH (Figure 36).
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Figure 35) Comparison of the amplitude and the frequency of CCH-stimulated SA in 
control (C) (age-matched non-diabetic) and 8-week diabetic (D) tissues at increasing 
concentrations of CCH (0.05-0.5pM). C: n=12 & 8-week D: n=12. *p<0.05 indicates a 
significant difference between control (non-diabetic) and diabetic tissues. Data is presented as 
mean±SEM
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Figure 36) Comparison of the amplitude and the frequency of CCH-stimulated SA in 
control (C) (age-matched non-diabetic) and 12-week diabetic (D) tissues at increasing 
concentrations of CCH (0.05-0.5pM). C: n=13 & 12-week D: n=12. *p<0.05, **p<0.01 & 
***p<0.001 indicate a significant difference between control (non-diabetic) and diabetic tissues. 
Data is presented as mean±SEM.
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4.4.2.5 Comparison of the effect of 0.5pM CCH on SA in bladder strips 
from control (non-diabetic) and diabetic rats
Control (non-diabetic) rats
Since stimulation of control (non-diabetic) and diabetic tissues with 0.5|jM CCH 
produced the largest spontaneous contractions, the changes in the amplitude 
and frequency of these contractions at this concentration of CCH was compared 
between different age-matched control groups. As demonstrated in Figure 37, 
the amplitude of CCH-induced SA did not change with time in control (non­
diabetic) tissues and the frequency of CCH-stimulated SA was only significantly 
different between 1-week and 12-week control (non-diabetic) tissues (Figure 
37).
Diabetic rats
In diabetic tissues, detrusor strips from 1-week diabetic rats demonstrated 
significantly greater amplitude of SA upon stimulation with 0.5pM CCH 
compared to all other diabetic groups. The frequency of CCH-stimulated SA 
was significantly higher in 8 -week diabetic tissues compared to 1 -week and 1 2 - 
week diabetic tissues (Figure 37).
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4.4.3 Effect of removal of the mucosa on CCH-induced SA
Earlier data presented in this chapter showed that, differences in the CCH- 
induced SA were mainly detected in detrusor strips from 1-week and 1 2 -week 
diabetic rats. Thus, to examine whether the mucosa plays a role in mediating 
these differences, the effect of increasing low concentrations of CCH on the SA 
was examined in detrusor strips denuded of mucosa from control (non-diabetic), 
1 -week and 1 2 -week diabetic rats.
4.4.3.1 Effect of removal of the mucosa in control (non-diabetic) 
detrusor strips
The amplitude and the frequency of CCH-stimulated SA in control (non-diabetic) 
intact and denuded detrusor strips at each concentration of CCH were 
compared (Figure 38). CCH induced SA in a concentration-dependent manner 
in intact and denuded detrusor strips. Removal of the mucosa had no significant 
effect on the amplitude and the frequency of CCH-stimulated SA (Figure 38).
4.4.3.2 Effect of removal of the mucosa in 1-week diabetic detrusor 
strips
CCH induced SA in a concentration dependent manner in intact and denuded 
detrusor strips from 1-week diabetic rats. Removal of the mucosa had no effect 
on the amplitude and the frequency of CCH-induced SA (Figure 39).
4.4.3.3 Effect of removal of the mucosa in 12-week diabetic detrusor 
strips
CCH induced SA in a concentration dependent manner in intact and denuded 
detrusor strips from 12-week diabetic rats. The amplitude of SA in denuded 
detrusor strips from 1 2 -week diabetic rats was significantly greater than intact 
detrusor strips from these animals at all concentrations of CCH tested (Figure 
40). The frequency of SA in the denuded tissues was significantly higher than 
the intact tissues at 0.05 and 0.1 pM concentrations of CCH (Figure 40).
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Figure 38) Comparison of the amplitude and the frequency of CCH-stimulated 
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Figure 40) Comparison of the amplitude and the frequency of CCH-stimulated 
spontaneous contractions in 12-week diabetic (D) intact and denuded tissues at 
increasing concentrations of CCH. 12-week D (intact): n=12 & 12-week D (denuded): n=8. 
*p<0.05, **p<0.01 & ***p<0.001 indicate a significant difference between intact and denuded 
detrusor strips. Data is presented as mean±SEM
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4.5 Discussion
4.5.1 Investigation of basal spontaneous activity in bladder
detrusor strips from control (non-diabetic) and diabetic rats
Increased basal spontaneous contractions are associated with DO and OAB 
(Brading, 1997). In the present chapter, basal spontaneous contractions were 
detected in detrusor strips from control (non-diabetic), 1-week, 4-week and 8- 
week diabetic rats but not in 12-week diabetic rats. The detrusor strips from 1- 
week diabetic rats demonstrated a profound increase in amplitude of basal 
spontaneous contractions compared to control (non-diabetic) tissues. This 
significant increase in the amplitude of basal SA was not detected in the 
detrusor strips from 4-week and 8-week diabetic rats and 12-week diabetic 
tissues did not demonstrate any basal SA. The frequency of SA in detrusor 
strips from 1-week, 4-week and 8-week diabetic rats was not significantly 
different from controls.
An increased basal SA in detrusor strips from 1-week STZ-diabetic rats has 
also previously been reported by Stevens et al (2006) and can be associated 
with urodynamic changes (such as increased diuresis) detected by Malmgren et 
al (1989) in bladders of these animals at early stages of diabetes. The decrease 
in basal SA in detrusor strips from 12-week diabetic rats may also be 
associated with functional changes such as atonic detrusor and urinary 
retention detected in bladders of these animals at the later durations of diabetes 
as reported by Lincoln et al (1984) and Daneshgari et al (2006). Therefore, the 
initial increase in basal SA in 1-week diabetic tissues and the decrease in 12- 
week diabetic tissues may be related to time-dependent compensatory and 
decompensatory changes in function and structure of the STZ-diabetic urinary 
bladder, as previously suggested in Chapter 3. One possible compensatory 
mechanism could be altered expression of connexin proteins, which are 
important for maintenance of gap junctions in virtually all cell types. It has been 
reported that the expression levels of connexin proteins increases significantly 
within three days of diabetes, and later (after 2-weeks) returns to normal levels 
(Poladia et al, 2005). These findings may well be related to the enhanced SA 
detected in 1-week diabetic versus 12-week diabetic tissues, since increased 
number of gap-junctions could result in augmented intercellular communication
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and increased propagation of action potentials within the muscle bundles and 
subsequent rise in SA.
The amplitude of SA may be dependent on changes in cellular Ca2+ levels via 
either VDCCs or Ca2+ released via the ryanodine receptors of the SR, whereas 
the frequency of SA reflects mechanisms that regulate UBSM action potential 
firing such as opening of BKCa channels (Buckner et al, 2 0 0 2 ). High amplitude 
basal SA could therefore be associated with Ca2+ handling mechanisms in 
UBSM cells in detrusor strips from 1-week diabetic rats. Since high amplitude 
basal SA has been associated with DO, it could be speculated that these 
spontaneous contractions may also result in DO in 1-week diabetic rats, by 
enhancing afferent nerve firing in vivo and promoting efferent nerve stimulation 
and un-controlled urine loss as suggested by Kanai et al, 2007 in their study on 
neonatal rat bladders, although this requires confirmation by urodynamic 
studies.
For the initial studies on SA, bladders from male Wistar rats, supplied by Harlan 
were used. Due to a change in the animal supplier from Harlan to Charles 
River, subsequent experiments were carried out on bladder tissue from male 
Wistar-Hans rats. However, it became apparent throughout the course of our 
investigations that no basal SA developed in the bladder tissues from these 
animals. Ideally, further experiments would have been performed to investigate 
the underlying mechanisms of basal SA and the effect of the mucosa in 
modulation of this activity. In spite of this, it was possible to investigate 
cholinergic induction and modulation of SA in the bladders of these animals.
4.5.2 Induction of SA by CCH in detrusor strips from control 
(non-diabetic) and diabetic rats
As described previously, recent interest in cholinergic modulation of 
spontaneous contractions was stimulated by the hypothesis that symptoms of 
DO may be due to the enhancement of spontaneous contractions by leakage of 
small amounts of acetylcholine from intramural nerves (Andersson & Yoshida, 
2003). Various studies have demonstrated increased SA in bladder strips from 
various species upon cholinergic stimulation (Gillespie et al, 2003; Drake et al,
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2003; Ng et al, 2006; Gevaert et al, 2008). However, no investigations have 
looked at the cholinergic modulation of SA in STZ-diabetic rat bladder. In the 
present chapter, SA was induced in detrusor strips from control (non-diabetic), 
1-week, 4-week, 8 -week and 12-week diabetic rats using low concentrations 
(0.05-0.5pM) of the non-selective muscarinic agonist, CCH. The amplitude and 
the frequency of CCH-induced SA in detrusor strips from diabetic animals and 
their age-matched controls (non-diabetic) were measured and compared at 
each concentration of CCH. The main differences observed in the amplitude of 
SA between control (non-diabetic) and diabetic tissues were detected in 1-week 
and 1 2 -week diabetic rats. i.e. detrusor strips from 1 -week diabetic tissues 
demonstrated a significantly higher amplitude of SA compared to their age- 
matched controls (non-diabetics) whilst 1 2 -week diabetic tissues demonstrated 
a significantly lower amplitude of SA compared to their age-matched controls 
(non-diabetics). When the amplitude of SA at 0.5pM CCH was compared 
between all diabetic tissues, detrusor strips from 1 -week and 1 2 -week diabetic 
rats demonstrated the highest and the lowest amplitude of SA compared to all 
other diabetic tissues respectively. Since the age-matched control (non­
diabetic) tissues demonstrated no change in the amplitude of SA with duration, 
it can be concluded that the changes seen in 1 -week diabetic tissue versus all 
other diabetic groups are indeed true differences due to secondary responses 
of the UBSM to diabetes.
The reason for the increased amplitude of SA in 1-week diabetic tissues is 
unknown but changes in intracellular Ca2+ levels due to alterations in the activity 
of VDCCs or Ca2+ release mechanisms from internal stores may be important 
underlying factors. Also in parallel with excitation-contraction coupling, the 
sensitivity of contractile proteins to Ca2+ may have altered in the diabetic 
tissues, resulting in the current observations. The increased and decreased 
amplitude of SA in detrusor strips from 1-week and 12-week diabetic animals 
may also be due to a contractile transition from a compensated to a 
decompensated state at later durations of diabetes or an organ adaptation to 
diuresis and the metabolic effects of diabetes, some of which were described 
earlier in Chapter 3.
The frequency of stimulated SA was also measured and compared between 
different control and diabetic rat bladder tissues. Detrusor strips from 1-week
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and 12-week diabetic rats demonstrated a significantly lower frequency of SA 
compared to their aged matched controls. In 1-week diabetic tissues, the 
decreased frequency of SA compared to the age-matched control (non-diabetic) 
tissues could be due to more organised pattern of Ca2+ and voltage activity in 
the detrusor resulting in greater magnitude and lower frequency of spontaneous 
contractions as suggested to occur in the detrusors from spinal transected rats 
by Ikeda & Kanai (2008). Also since the amplitude of SA is significantly greater 
in 1 -week diabetic tissues compared to their age-matched control (non-diabetic) 
tissues, in the length of time taken for one contractile event to subside in 
detrusor strips from 1 -week diabetic rats, during the same amount of time, 
control (non-diabetic) tissues will contract several times resulting in subsequent 
increase in the frequency of SA.
The decrease in frequency of stimulated SA in detrusor strips from 12-week 
diabetic rats compared to their age-matched control (non-diabetic) tissues could 
be due to the general decrease in the SA in 12-week diabetic tissues. Since the 
frequency of SA is dependent upon mechanisms that regulate smooth muscle 
action potential firing (such as opening of K+ channels), it could be speculated 
that alterations in K+ channels function in the diabetic tissues may result in the 
altered frequency of CCH-induced SA.
When the frequency of SA at 0.5pM CCH was compared between different 
diabetic tissues, a noticeable increase in the frequency of stimulated SA was 
detected in detrusor strips from 8 -week diabetic rats compared to 1 -week and 
12-week diabetic tissues. In age-matched control (non-diabetic) tissues, there 
was a significant difference in the frequency of CCH-stimulated SA between 1- 
week and 12-week tissues only. Thus, it can be assumed that the differences 
seen in amongst the diabetic tissues are true differences as a result of diabetes 
and are not due to time dependent changes as a result of age in these animals. 
However, the reason behind the increased frequency of SA in 8 -week diabetic 
tissues is not clear. This could also be due to contractile transition from a 
compensated to a decompensated state which manifests itself as more frequent 
SA in 8 -week diabetic tissues.
It is assumed that the frequency of SA is not as important as the amplitude of 
these contractions in generation of DO, since reports from neonatal rat bladders
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(used as a model for overactive bladder) have demonstrated that in vitro SA 
changes from high amplitude, low frequency contractions in neonatal rats to a 
low-amplitude high frequency phasic contractions during postnatal 
development. This is in line with more controlled micturition in these postnatal 
animals (Ng et a/; 2006, 2007).
4.5.3 Effect of removal of the mucosa on CCH-induced SA
It has been postulated that intrinsic mechanisms in the bladder wall are 
responsible for modulation of SA in detrusor smooth muscle. Potential 
structures within the bladder wall that could regulate this SA include the 
urothelial layer, lamina propria and ICs (Ikeda & Kanai, 2008).
The effect of the mucosa on spontaneous contractions has been studied 
previously (Levin et al, 1995; Meng et al, 2008; Ikeda & Kanai, 2008). As 
described in chapter 1 , urothelial cells have neuronal like properties and release 
factors such as ATP, ACH, prostaglandins and NO (Birder et al, 2001; Beckel et 
al, 2004; Beckel et al 2006; Birder, 2005; Beckel et al, 2006; De Groat, 2006), 
which could also be important in mediation of SA in the detrusor muscle. In the 
study by Ikeda & Kanai (2008) removal of the urothelium resulted in reduced 
muscarinic-stimulated spontaneous contractions in spinal cord transected rat 
bladder tissues. They suggested that the SA of bladder smooth muscle may be 
controlled by muscarinic receptors expressed on the urothelium. These results, 
contradict other studies suggesting an inhibitory effect of the urothelium on 
detrusor contractile activity (Levin et al, 1995; Meng et al, 2008). The release of 
a UDIF from the urothelium has been reported to inhibit bladder contractions 
(Hawthorn et al, 2000). UDIF is released under the control of two mediators, 
namely, ATP, through purinergic receptors and acetylcholine (ACH) via 
muscarinic receptors. Stimulation of tissues with CCH may enhance the release 
of UDIF which could influence spontaneous contractions. Therefore, removal of 
this barrier may enhance the spontaneous bladder contractions
In the present study, removal of the mucosa did not significantly affect the CCH- 
induced SA in detrusor strips from control (non-diabetic) and 1-week diabetic 
rats. However, removal of the mucosa had a significant effect on the CCH-
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induced SA in detrusor strips from 12-week diabetic rats i.e. 12-week diabetic 
denuded tissues demonstrated a significantly higher amplitude and frequency of 
CCH-induced SA compared to 12-week diabetic intact tissues. Thus, it appears 
that there is an inhibitory effect of the mucosa on the spontaneous contractions 
of the bladder detrusor in 1 2 -week diabetic rats, but not in control (non-diabetic) 
and 1-week diabetic tissues. This may suggest that stimulation of muscarinic 
receptors expressed on the urothelial cells does not normally play a role in 
mediating the spontaneous contractions in rat bladder, but they may be 
important in mediating the release of UDIF from the urothelial cells at later 
durations of diabetes.
However, it must be noted that there is a possibility that preparation of denuded 
muscle strips may damage the bladder tissue and the underlying structures of 
the urothelium such as the myofibroblasts and the ICs. This could result in the 
release of factors such as ACH from the various cell types present in the 
bladder, leading to enhanced spontaneous contractions detected in the 1 2 - 
week diabetic denuded tissues.
Changes in the SA of the detrusor from STZ-diabetic rats is likely to have a 
number of causes that originate from defects to the cellular, multicellular and 
nervous mechanisms that determine normal function. In this chapter some of 
the possible causes leading to altered SA in detrusor strips from these animals 
were discussed. However, whether these altered responses result in whole 
bladder defects remains to be answered.
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4.6 Summary
Muscarinic-receptor mediated mechanisms that modulate SA are of 
considerable interest, since antimuscarinics are used clinically to treat the 
symptoms of DO. In the present study, basal spontaneous contractions were 
significantly greater in detrusor strips from 1-week diabetic rats and were 
significantly decreased in 12-week diabetic tissues
CCH induced spontaneous contractions in control (non-diabetic) and diabetic 
tissues. Detrusor strips from 1-week diabetic rats demonstrated a greater 
increase in amplitude of spontaneous contractions, which may be important in 
generation of DO in these animals, whilst 12-week diabetic tissues 
demonstrated a significantly decreased SA, which may be associated with 
detrusor under-activity and atonic bladders in these animals.
The bladder urothelium did not play a role in modulation of SA in detrusor strips 
from control (non-diabetic) and 1-week diabetic rats, but was important in 
mediation of SA in 12-week diabetic tissues.
It must also be considered that bladder spontaneous contractions can be 
modulated by various mechanisms such as increased cell excitability and 
changes in the properties of other cell types that may be involved in generation 
of this activity. Thus, in the subsequent chapters the aim was to unravel the 
possible mechanisms that contribute to modulation of SA in control and diabetic 
rat bladders.
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Chapter 5: An 
investigation of the 
role of potassium 
channels in the 
modulation of 
spontaneous 
contractions of rat 
bladder detrusor
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5.1 Introduction
As described in Chapter 4, urinary bladder smooth muscle (UBSM) exhibits 
spontaneous action potentials that are associated with the spontaneous 
contractions in this tissue (Heppner et al, 1997; Brading, 2006). Ca2+ entry 
through voltage dependent Ca2+ channels (VDCCs) is responsible for the 
upstroke of the action potentials whilst the repolarisation phase is mediated by 
the activity of large conductance Ca2+ activated K+ (BKCa) (Heppner et al, 1997) 
and perhaps voltage dependent K+ (Kv) channels (Thorneloe & Nelson, 2003). 
SKca channels are also known to be important determinants of UBSM 
excitability and contractility. The activation of small conductance Ca2+ activated 
(SKca) channels generates a long-lasting hyperpolarisation termed the slow 
afterhyperpolarisation (sAHP) (Fujii et al, 1990). The resting membrane 
potential of UBSM is also controlled by BKca, ATP sensitive K+ ( K At p )  and 
probably Kv channels (Heppner et al, 1997; Petkov et al, 2001; Thorneloe & 
Nelson, 2003).
Since bladder detrusor spontaneous activity (SA) is dependent upon the 
electrical properties of smooth muscle cells, changes in K+ channel function and 
expression have been suggested as possible underlying mechanisms of 
increased SA and subsequent detrusor overactivity (DO) (Christ et al, 2001; Fey 
et al, 2003; Meredith et al, 2004; Darblade et al, 2006; Werner et al, 2007; 
Brown et al, 2008). Opening of K+ channels may also be an attractive way of 
treating overactive detrusor by eliminating undesired bladder contractions and 
increasing the UBSM stability (Gopalakrishnan & Shieh, 2004). Numerous 
studies have explored the role of BKCa, SKCa and K At p  channel modulators in 
mediation of the SA of the bladder detrusor of various species (Herrera et al, 
2000; Petkov et al, 2001; Gopalakrishnan et al, 2002; Herrera et al, 2003; Fey 
et al, 2003; Malysz et al, 2004; Ng et al, 2006), thus highlighting the 
fundamental role of these channels in mediating UBSM tone and contractility.
5.1.1 BKca channels in bladder smooth muscle
The role of BKca channels in stabilising membrane potential and regulating the 
excitability and contractility of UBSM cells was discussed briefly in chapter 1. 
BKca channel activity in UBSM depends primarily on depolarisation of the
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membrane and Ca2+ influx through VDCCs, as well as so called "Ca2+ sparks" 
caused by localised Ca2+ release from ryanodine receptors (RyRs) (Herrera et 
al, 2 0 0 1 ; Meredith et al, 2004). Moreover, it is known that BKCa channels can 
also be regulated by phosphorylation and G-protein-coupled receptor 
interactions. For example, in a study by Nakamura et al (2002), it was 
demonstrated that muscarinic receptor stimulation initially activates and then 
inhibits BKCa channels. It was suggested that the inhibition of BKCa channels is 
mediated through the M2-muscarinic receptor signal transduction pathway. 
However, the exact mechanism by which the M2-muscarinic receptor achieves 
this inhibition is unknown. An indirect modulation of BKca channels by 13- 
adrenoceptors has also been reported by Petkov & Nelson (2005) and Brown et 
al (2008). They demonstrated that stimulation of (3-adrenoceptors leads to 
activation of protein kinase A (PKA), which has been shown to increase Ca2+ 
spark activity in UBSM and result in subsequent activation of BKCa channels 
(Petkov & Nelson, 2005; Brown et al, 2008).
Since the BKca channel is one of the most physiologically relevant modulators 
of UBSM excitability, alterations in this channel’s expression or activity should 
lead to dramatic functional effects and increased SA. There are several lines of 
evidence that confirm the important role of BKCa channels in abnormal detrusor 
contractions. Firstly Heppner et al (1997) demonstrated that inhibition of BKCa 
channels with the specific BKCa channel blocker iberiotoxin (IBTX) enhances the 
action potential frequency and detrusor contractility in guinea-pig UBSM. An 
analogous increase in the UBSM action potential frequency also has been 
reported in animal models of DO with bladder outlet obstruction (Li et al, 2007). 
Secondly Genetic deletion or inhibition of expression (via gene knock out (KO) 
studies) of the BKCa channel pore-forming a-subunit in mice, leads to complete 
absence of BKCa currents in UBSM (Meredith et al, 2004), and deletion of the 
regulatory (31-subunit leads to reduced BKCa channels activity (Petkov et al, 
2001), resulting in DO. It was observed that the absence of functional BKCa 
currents significantly enhances basal and nerve-mediated UBSM contractility. 
Thirdly consistent with this, overexpression of the BKCa channel a-subunit, using 
naked DNA gene transfer techniques, eliminated DO induced by partial outlet 
obstruction in rat (Christ et al, 2001).
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In the STZ-diabetic rat bladder, an elevated expression of BKca channel 
regulatory a- and (3-subunits was suggested to be associated with enhanced SA 
detected in the bladders of these animals (Nakahara et al, 2004). Although 
Nakahara et al (2004) failed to demonstrate this at the mRNA level, it was 
hypothesised that diabetes might increase the expression of BKca channels 
through post-transcriptional mechanisms. Currently, there are very few studies 
on the role of these channels in modulation of STZ-diabetic rat bladder 
contractility. Since an increased SA has been reported previously in detrusor 
strips from STZ-diabetic rats (Stevens et al, 2006), and confirmed in the 
previous chapter, it is possible that changes in BKca channel activity and 
expression may have a role in modulating this SA.
5.1.2 Pharmacology of BKca channels
Currently, there are several specific BKca channel modulators available, which 
are used extensively for functional in vitro characterisation of these channels in 
pharmacological studies.
5.1.2.1 BKCa channel openers
Agents that cause BKca channel activation are termed BKCa channel openers. 
Activation of BKCa channels by openers stabilises cell excitability by membrane 
hyperpolarisation and subsequent relaxation or inhibition of action potential 
generation. Thus, opening of these channels could have a profound effect on 
reduction of SA in DO. BKCa channels are particularly more appealing as 
therapeutic targets than other K + channel, such as K a t p  channels, because they 
are not expressed in cardiac tissue (reviewed by Ghatta et al, 2006), and thus 
fewer possible adverse effects.
There are many diverse compounds that lead to BKCa channels opening. 
Among these, a large series of synthetic benzimidazolone derivatives, such as 
NS1619 and NS004, the biarylureas like NS1609, and biaryl amines such as 
mefenamic and flufenamic acids, are the best characterised BKCa channel 
openers. These compounds can affect the channel either by modulating the 
Ca2+ binding site at the C-terminus end of the a-subunit or by strengthening the 
interaction of a and (3 subunits (reviewed by Ghatta et al, 2006).
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The effect of several BKca channel openers on modulation of detrusor 
contraction and SA, under normal and pathological conditions, has been 
investigated in numerous species (Imai et al, 2001; Malycz et al, 2004; Mora & 
Suarez-Kurtz, 2005; Darblade et al, 2006; Ng et al, 2006). Contradictory results 
have been obtained from these studies, with some groups reporting no change 
in the myogenic activity of detrusor strips after exposure to increasing 
concentrations of BKca channel agents (Mora & Suarez-Kurtz, 2005), whilst 
other groups have demonstrated an inhibition of myogenic contractions with 
these drugs (Sheldon et al, 1997; Imai et al, 2001). For example in a study by 
Mora & Suarez-Kurtz (2005) the effect of NS1608 on the myogenic SA of 
detrusor strips from guinea pig urinary bladder was examined. It was 
demonstrated that this BKca channel opener does not have a significant 
inhibitory effect on the spontaneous contractions of normal guinea-pig urinary 
bladder. In contrast, Imai et al (2001) demonstrated that NS1619 (30pM) 
significantly reduced the SA of detrusor strips from normal guinea-pig urinary 
bladder. Therefore, the effect of BKca channel openers in mediating bladder 
detrusor contractions is still not fully clear.
5.1.2.2 BKca blockers
The first potent peptide blockers of the BKCa channel were purified from Leiurus 
quinquestriatus (charybdotoxin; CHTX), Buthus famulus (iberiotoxin; IBTX) and 
Centruroides limbatus (limbatotoxin; LBTX). IBTX is a potent BKca channel 
blocker and acts by blocking the K+ current flow (IC50= 5-1 OnM) by binding to a 
site in the external vestibule of the pore and thus occluding the channel 
(reviewed by Kaczoroworski & Garcia, 1999 & Ghatta etal, 2006).
Other chemicals, such as quaternary ammonium compounds like 
tetraethylammonium (TEA) and tetrabutylammonium (TBA) (although are not 
specific) and alkaloids such as paxilline, penitrem A and verruculogen, are also 
classified as BKCa channel blockers (Reviewed by Ghatta et al, 2006).
A number of studies have demonstrated that BKCa channel blockers can 
increase SA in UBSM under normal and pathological conditions in several 
species (Defarias et al, 1996; Imai et al, 2001; Nakahara et al, 2004; Darblade 
et al, 2006; Shieh et al, 2007), emphasising the importance of these channels in 
modulating the UBSM tone and excitability.
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5.1.3 SKCa channels in the bladder smooth muscle
As well as BKca channels, SKca channels have an important contributory role in 
UBSM excitability and contractility. Of the SKCa channel family (SK1-3), mRNA 
for the SK2 and- SK3 subunits has been reported in mouse and rat UBSM 
(Herrera et al, 2003; Thorneloe et al, 2008; Hougaard et al, 2009).
SKca channels are activated by an increase in intracellular Ca2+ concentrations 
and they underlie the sAHP phase of the action potential in UBSM (Herrera et 
al, 2003). The sAHP limits the firing frequency of repeated action potentials and 
subsequently limits the basal level of UBMS excitability and subsequent 
contractility (Herrera & Nelson, 2002).
The role of SKca channels has been studied in the bladders of transgenic mice 
overexpressing SK3 channels (Herrera et al, 2003). It was demonstrated that 
suppression of SKCa channel expression by dietary doxycycline (DOX) is 
associated with an increase in the frequency of SA in UBSM in vitro and DO in 
vivo (Herrera et al, 2003).
Currently, there is only one study investigating the role of the SKca channel in 
modulation of urinary bladder SA in STZ-diabetic rats (Nakahara et al, 2004). In 
this study, blockade of SKca channels by the selective SKca channel blocker, 
apamin, significantly increased the SA of detrusor strips from STZ-diabetic rats 
compared to control (non-diabetic) rats (Nakahara et al, 2004).
5.1.4 Pharmacology of SKCa channels
5.1.4.1 SKca channel openers
There are as yet few studies of the effect of SKca channel openers on inhibition 
of detrusor contractility. Various compounds have been classified as SKca 
channel openers such as DCEBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H- 
benzimidazol-2-one) and NS309 (3-oxime-6,7-dichloro-1H-indole-2,3-dione), 
which have been shown to inhibit VDCC activity in mouse bladder myocytes 
(Morimura et al, 2006). However, their specifity remains unclear. In vivo studies 
have shown that NS309 increases bladder capacity and micturition volume 
(Pandita et al, 2006). Recently the role of NS4591 (4,5-dichloro-1,3-diethyl-1,3- 
dihydro-benzoimidazol-2 -one), a new modulator of SKca channels, was
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investigated in the mediation of SA in detrusor rings from normal rats. It was 
demonstrated that NS4591 significantly inhibits CCH-induced spontaneous 
contractions in bladder detrusor rings, although the specifity of this drug is 
under question, since it also affects IKca channels (Hougaard et al, 2009).
5.1.4.2 SKCa channel blocker
Apamin is a bee venom peptide toxin that specifically blocks all types of SKCa 
channels (Vergara et al, 1998). Application of apamin increased the amplitude 
and decreased the frequency of spontaneous contractions in the guinea-pig 
urinary bladder (Imai et al, 2001; Herrera et al, 2000). Buckner et al (2002) also 
demonstrated that apamin increases both the amplitude and frequency of SA in 
pig urinary bladder. Electrophysiological studies show that apamin reduces 
UBSM action potential afterhyperpolarisation, which results in conversion of 
individual action potentials into bursts of action potentials in the UBSM cells. 
The results obtained from studies with apamin suggest that SKca channels play 
an important role in the regulation of bladder function and provide rationale as a 
target for treatment of DO (Gopalakrishnan & Shieh, 2004).
5.1.5 Katp channels in the bladder smooth muscle
Katp channels in the bladder smooth muscle play a critical role in controlling 
myogenic tone and excitability. An increase in K a t p  channel activity can have a 
large effect on cell membrane potential and smooth muscle tone (Petkov et al, 
2 0 0 1 ). Openers of K At p  channels decrease smooth muscle 
excitability/hyperexcitabilty by hyperpolarising the cell membrane by increasing 
the permeability of the cell to K+ ions (Quayle et al, 1997). Small increases in 
K a t p  channel activity are likely to move the resting membrane potential away 
from the threshold of action potential activation and thus have significant 
inhibitory effects on related spontaneous contractions (Petkov et al, 2001). Due 
to their important role in regulation of membrane excitability, K At p  channels 
have been extensively explored as possible therapeutic targets for treatment of 
overactive detrusor, with openers identified from diverse structural classes 
(Pinna et al, 2005; Elzayat et al, 2006; Shieh et al, 2007b; Kamiyama et al, 
2008). However, studies on the role of these channels on modulation of 
detrusor contractility in diabetic bladder are scarce.
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5.1.6 Pharmacology of KAtp channel
5.1.6.1 Katp Channel openers
First generation K a t p  channel openers such as cromakalim were shown to 
reduce SA in vitro, when tested on normal and overactive detrusor smooth 
muscle strips from different species (Foster et al, 1989; Martin et al, 1997; 
Milicic et al, 2006). However, these drugs were unsuccessful in clinical 
applications due to their lack of bladder selectivity compared with vascular 
tissue (Nurse et al, 1991). This lead to development of ‘uroselective’ second- 
generation compounds such as ZD-6169 and its derivative, ZD226600. These 
drugs have been shown to greatly reduce DO in different animal models 
(Wojdan et al, 1999). The recently identified K a t p  opener, WAY-133537, has 
been reported to be effective in vitro in relaxing detrusor strips from a paraplegic 
rat model of neurogenic DO (Elzayat et al, 2006). Other K At p  channel openers 
such as YM934 (Fey et al, 2003) and novel cyanoguanidine compounds (Perez- 
Medarno et al, 2007) have also been developed which have inhibitory effects on 
smooth muscle contractions in normal and overactive detrusor.
5.1.6.2 Katp channel blockers
The mechanism of action of K a t p  channel openers has been established 
primarily through the finding that sulphonylureas such as glibenclamide, a 
potent and selective K At p  channel blocker, are able to reduce the functional and 
electrophysiological actions of the K a t p  channel in vascular and non-vascular 
smooth muscle. Apart from sulphonylureas, a number of other compounds such 
as imidazolines (e.g. alinidine) and chemically related compounds including 
phentolamine, have also been shown to inhibit the relaxant actions of K At p  
channel in smooth muscle cells (Mcpherson et al, 1999).
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5.2 Aim of the chapter
The aim of this chapter was to investigate the role of K+ channels in modulation 
of basal and muscarinic-receptor stimulated SA in detrusor strips from control 
(non-diabetic) and diabetic rats.
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5.3 Materials and Methods
5.3.1 Functional investigation of the role of BKCa> KAtp and 
SKCa channels in mediating the SA of detrusor strips from control 
(non-diabetic) and diabetic rats
5.3.1.1 Modulation of BKCa channels
Longitudinal strips of smooth muscle (2-4 x 6-12mm) were isolated from the 
bladder body of 1-week, 4-week, 8 -week and 12-week diabetic rats and their 
age-matched controls (non-diabetic), and suspended in 15ml organ baths as 
described in chapter 2 .
Following equilibration for 60mins, tissues were stimulated with 0.5pM 
concentration of carbachol (CCH) to induce spontaneous contractions.
In the continuous presence of 0.5pM CCH, increasing cumulative 
concentrations of NS1619 (1-30pM) (Sigma, Dorset, UK) were added to the 
tissues and the effects of this drug on the SA was assessed. Tissues were 
incubated with each concentration of NS1619 for a period of 15mins. During the 
last 5mins of each incubation period, the mean amplitude and the frequency of 
SA were calculated and analysed.
The effect of the vehicle, dimethyl sulfoxide (DMSO), (Sigma, Dorset, UK) on 
SA was also examined in parallel experiments to account for any time- or 
vehicle-dependent changes in the SA.
After assessing the effect of NS1619, detrusor strips from control (non diabetic); 
1-week, 4-week, 8 -week and 12-week diabetic rats and only rats were washed 
for 30mins with fresh Krebs bicarbonate solution. Following return to basal 
tension, tissues were exposed to increasing concentrations of IBTX (0.01- 
0.1 pM) (Alomone labs, Jerusalem, Israel). Tissues were incubated with each 
concentration of IBTX for a period of 10-15mins. The last 5mins period with 
each concentration of IBTX was used to calculate the mean amplitude and the 
frequency of the spontaneous contractions.
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5.3.1.2 Modulation of KAtp channels
Longitudinal strips of smooth muscle (2-4 x 6-12mm) were isolated from the 
bladder body of 1 -week control (non-diabetic) and diabetic rats, and suspended 
in 15ml organ baths as described previously.
Following equilibration for 60mins, tissues were stimulated with 0.5pM 
concentrations of CCH to induce SA.
In the continuous presence of 0.5pM CCH, increasing cumulative 
concentrations of cromakalim (0.1-10pM) (Sigma, Dorset, UK) were added to 
the tissues. Detrusor strips were incubated with each concentration of 
cromakalim for a period of 15mins. The mean amplitude and the frequency of 
SA in the last 5min of each incubation period were calculated and analysed.
The effect of the vehicle, DMSO, was also examined on the SA in parallel 
experiments to account for any time- or vehicle-dependent changes in the SA.
The effect of increasing concentrations of K a t p  channel blocker, glibenclamide 
(1-1 OpM), on basal SA of detrusor strips from control (non-diabetic) and diabetic 
rats was also investigated as described for IBTX in section 5.3.1.1.
5.3.1.3 Modulation of SKca channels
The effect of increasing concentrations of the SKca channel blocker, apamin 
(0.01-0.1pM), on basal spontaneous contractions of bladder strips from control 
(non-diabetic) and diabetic rats was also investigated as described for IBTX in 
section 5.3.1.1. Tissues were incubated with each concentration of apamin was 
for a period of 10-15mins. The last 5mins period with each concentration was 
used to calculate the mean amplitude and the frequency of the spontaneous 
contractions.
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5.3.2 Data Analysis
To calculate the amplitude and the frequency of SA, a slightly modified method 
to that proposed by Imai et al (2001) was used to define a single spontaneous 
contractile event, as described previously in section 4.3.3. SA was expressed 
as the mean contraction amplitude/mg tissue and frequency ± SEM during the 
last 5mins period within a 10-15mins interval. Percentage change in the 
amplitude and the frequency of SA was also calculated in the presence of K+ 
channel openers relative to that in the absence of the opener i.e. 0.5pM CCH 
only.
5.3.3 Statistical analysis
Statistical analysis was performed using repeated measures ANOVA followed 
by Dunnett’s post hoc test for intra-tissue variations and unpaired Student’s t- 
test for inter-tissue variations. For multiple comparisons between different 
control (non-diabetic) and diabetic groups, one way ANOVA followed by 
Tukey’s post hoc test was performed.
5.3.4 Investigation of K+ channel expression in the rat bladder 
using real-time PCR.
cDNA samples, which were prepared previously in chapter 3 from bladders of 
control (non-diabetic), 1-week, 4-week, 8 -week and 12-week diabetic rats were 
used in this set of experiments.
Real-time RT-PCR was carried out as described in chapter 3 to determine the 
expression ratios of BKCa channel subunits (Slo1 and Slo(31) and K At p  channel 
subunits (Kir6.1 and SUR2B) relative to the housekeeping gene HPRT in 
diabetic tissues vs. control (non-diabetic) tissues using previously designed and 
optimised primers (Table 13).
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K+ Channel Subunits(genes)
Accession
no Primer sequence PS
BKca
Slo-1
(KCNMA1) NM-031828
F: 5'GCATCAGGCAGAAGATCAGG 3' 
R: 5 ' GGGGATGGTGGTTGTTATGG 3'
180
bp
Slop-1
(KCNMAB1) NM-019273
F: 5'GGGAAGAAGCTGGTGATGGC 3' 
R: 5'TTCCTGGTCCTTGATGTTGG 3'
244
bp
Katp
Kir 6.1 
(KCNJ8) AB-043636
F: 5'TGGGTGACCTGAGGAAAAGC 3' 
R: 5'TATCGTACAGGGGGCTACGC 3'
204
bp
SUR2B
(ABCC9) AB-045281
F: 5'ACAGATGGCTGGAGGTCAGG 3' 
R: 5'TCGTGAGGGCATACAGAAGG 3'
126
bp
Table 13) B K Ca channel subunits (Slo-1 & Slop-1) and KAtp channel subunits (Kir6.1 & 
SUR2B) gene primer sequences, gene accession numbers and product size. bp= base 
pairs; P.S=product size, F=forward R=reverse.
Data analysis was performed as described in chapter 2. Briefly, by calculating 
the relative expression ratio of the target gene (K+ channels subunit) based on 
its efficiency (E) and the difference in Ct value (delta Ct) of the treated sample 
(diabetic) against that of a control (non-diabetic) and expressed in comparison 
to a reference gene (HPRT) as described by Pfaffl (2001):
n  \  AC, 1 ^ 8  e l( control-treated  ) 
ta rget )
x AC r e f  {control-treated  )
\  r e f )
E =  efficiency of the target ( E target) or the housekeeping ( E ref) gene primers. ACt= 
the difference between the Ct values of the control (non-diabetic) sample and 
the treated (diabetic) sample.
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5.4 Results
5.4.1 Effects of the BKCa channel opener, NS1619, on 
stimulated SA in control (non-diabetic) and diabetic intact tissues
Typical chart recordings showing the effect of the BKCa channel opener, 
NS1619, on CCH-induced SA detrusor strips from control (non-diabetic), 1- 
week, 4-week, 8 -week and 12-week diabetic tissues are shown in Figure 41.
5.4.1.1 The effect of NS1619 on CCH-stimulated SA in detrusor strips 
from 1-week diabetic rats
In 1-week diabetic tissues and their age-matched control (non-diabetic) group 
NS1619 had a limited effect and elicited a significant inhibition of the amplitude 
of CCH-induced SA only at the highest concentration (30pM) (Figure 42).
NS1619 did not affect the frequency of SA at any of the concentrations 
examined (Figure 42)
When the percentage change in the amplitude of the SA in the presence of 
30pM NS1619 was calculated relative to spontaneous contractions in the 
absence of the opener (i.e. in the presence of 0.5pM CCH only), there was no 
significant difference between age-matched control (28.76±4.16%) and diabetic 
(24.35± 4.2%) tissues. The same results were observed for the frequency of SA 
(control: -5.45±9.77% versus diabetic: 16.83±4.16%)
The vehicle, DMSO, did not produce any significant effects on the amplitude 
and the frequency of SA in either control (non-diabetic) or diabetic tissues. 
(Figure 41).
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Tension
g)
0.5mM CCH
T 1pM NS1619 3|jM NS1619 10mW NS1619I I I I 30(jM NS1619
.......................................................
10mins
UICCH 1uM NS1619 3uM NS1619 10uM NS1G19 30uM NS1S19
g)
10mins 1-week D
0.5uM CCH 1u¥  NS1619
i,
3uM NS1619
iOmins
10uM NS1619 30mM NS1619
4-week D
1|jM NS1619 3jjM NS1619
10[jM NS1619 30|jM NS1619
g)
g)
8-week D
IOmins
1pM NS1619 10uM NS16193uM NS1619 30uM.NS16190.5uM CCH
IOmins
g)
DMSO
IOmins
DMSO DMSO DMSO
12-week D
DMSO
Vehicle control
Figure 41) Typical chart recordings of the effect of increasing concentrations of NS1619 
and DMSO on CCH induced SA in detrusor strips from representative control (non­
diabetic) (C) & diabetic (D) rats.
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frequency of SA induced by 0.5pM CCH in control (non diabetic) (C) and 1-week diabetic 
(D) tissues. C: n=5 (top panel) & 1-week D: n=10 (lower panel). **p<0.01 versus paired OpM 
NS1619 response. Data is presented as mean±SEM.
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5.4.1.2 The effect of NS1619 on CCH-stimulated SA in detrusor strips 
from 4-week diabetic rats
NS1619 did not affect the amplitude or the frequency of SA in 4-week age- 
matched control (non diabetic) tissues (Figure 43). In 4-week diabetic tissues 
only 30pM NS1619 significantly inhibited the amplitude of SA but had no effect 
on the frequency of SA (Figure 43).
When the amplitude and the frequency of SA in the presence of 30pM NS1619 
were calculated as percentage change relative to spontaneous contractions in 
the absence of NS1619 (i.e. in presence of 0.5pM CCH only), there was no 
significant difference between age-matched control (non-diabetic) tissues 
(amplitude: 4.32±11.28% & frequency: -0.68±9.94) versus diabetic (amplitude: 
29.95± 8.09% & frequency: 7.16±3.44%) tissues.
5.4.1.3 The effect of NS1619 on CCH-stimulated SA in detrusor strips 
from 8-week diabetic rats
NS1619 decreased the amplitude of SA in 8 -week age-matched (non-diabetic) 
and 8 -week diabetic tissues only at 30pM (Figure 44). This concentration of 
NS1619 also significantly decreased the frequency of SA in control (non­
diabetic) tissues, but it did not affect the frequency of SA in 8 -week diabetic 
tissues (Figure 44).
The percentage change of both the amplitude and the frequency of stimulated 
SA, at 30pM NS1619 relative to that of SA in the absence of NS1619 (i.e. 
0.5pM CCH only) were calculated for control (non-diabetic) and diabetic tissues 
and compared. There was no significant difference in the percentage change of 
the amplitude: (28.37± 11.00% in controls (non-diabetic) vs. 16.07± 7.39% in 
diabetics) and the frequency (30.87± 16.24% in controls (non-diabetic) vs. 
4.75± 4.60% in diabetics) of stimulated SA at 30pM NS1619 between both 
groups.
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5.4.1.4 The effect of NS1619 on CCH-stimulated SA in detrusor strips 
from 12-week diabetic rats
In 12-week age-matched control (non-diabetic) tissues, the amplitude of SA was 
significantly decreased at 10pM and 30pM NS1619. However, the amplitude of 
SA in 12-week diabetic tissues was significantly decreased only at 30pM 
NS1619 (Figure 45). NS1619 did not affect the frequency of SA in either tissue 
group at the concentrations tested (Figure 45).
There was no significant difference in the %change of the amplitude of SA in 
the presence of 30pM NS1619 between control (non-diabetic) (31.01±6.52%) 
and 12-week diabetic (30.60±3.55%) tissues. The same results were observed 
for the frequency of SA for controls (non-diabetic) (28.97±19.66%) versus 12- 
week diabetic (7.98±10.05%) tissues.
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Figure 43) Effect of increasing concentrations of NS1619 on the amplitude and frequency 
of SA induced by 0.5pM CCH in 4-week control (non diabetic) (C) and 4-week diabetic (D) 
tissues. C: n=8 (top panel) & 4-week D: n=9 (lower panel). **p<0.01 versus paired OpM 
NS1619 response. Data is presented as mean±SEM.
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The percentage change in the amplitude and the frequency of spontaneous 
contractions in the presence of highest concentration of NS1619 (30 pM) 
relative to the absence of NS1619 i.e. in the presence of 0.5pM CCH was 
compared between control (non-diabetic) and diabetic tissues and plotted 
against the duration of diabetes (Figure 46). There was no significant difference 
in the percentage change of the amplitude and the frequency of CCH-stimulated 
SA between different age-matched control (non-diabetic) groups at 30pM 
NS1619. There was also no significant difference in the percentage change of 
the amplitude and the frequency of stimulated SA at 30pM NS1619 between 
different diabetic groups with duration (Figure 46).
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Figure 46) Percentage changes in the amplitude and the frequency of CCH-stimulated SA 
in the presence of 30pM NS1619. Data is plotted against the duration of diabetes (weeks) in 
detrusor strips from control (non-diabetic) and diabetic rats. n=5-10. Data is presented as 
meantSEM.
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5.4.2 Effects of the BKCa channel blocker IBTX on basal SA in 
control (non-diabetic) and diabetic tissues
The hypothesis that blocking BKca channels can induce basal SA in UBSM cells 
was examined by incubating the detrusor strips from control (non-diabetic) 
(n=5), 1-week (n=8 ), 4-week (n=5), 8 -week (n=3) and 12-week (n=4) diabetic 
rats with increasing concentrations (0.01, 0.03 and 0.1 pM) of IBTX was 
investigated on basal contractile activity in tissues.
Typical chart recordings from control (non-diabetic) and diabetic tissues in the 
presence of increasing concentrations of IBTX are demonstrated in Figure 47. 
Before treatment with IBTX, little or no spontaneous contractions could be 
detected in detrusor strips from control (non-diabetic) and diabetic rats. 
However, after treatment of the detrusor strips with the highest concentration of 
IBTX (0.1 pM), SA developed in all tissues, with the exception of detrusor strips 
from 1 2 -week diabetic rats.
The amplitude and the frequency of basal SA increased upon addition of IBTX 
in detrusor strips from 1 -week diabetic rats and their age-matched control (non­
diabetic) group. However, only at 0.1 pM was this significant. 0.01 pM and 
0.03pM IBTX did not have a significant effect on the amplitude or the frequency 
of SA in either group (Figure 48).
Although the effect of 0.1 pM IBTX on amplitude of basal SA was greater in 1- 
week diabetic detrusor strips (0.041 g/mg tissue) than in the control (non­
diabetic) tissues (0.014g/mg tissue), this difference was not significant (p=0.07). 
There was also no significant difference in the effect of 0.1 pM IBTX on the 
frequency of basal SA between 1-week diabetic and control (non-diabetic) 
tissues.
In 4-week diabetic tissues, 0.01 and 0.03pM IBTX did not have a significant 
effect on the amplitude and the frequency of SA, whilst 0.1 pM IBTX significantly 
increased the amplitude and the frequency of basal SA (Figure 49).
A similar effect was seen in 8 -week diabetic tissues i.e. only 0.1 pM IBTX 
produced a significant increase in amplitude of SA. However, in this group the
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frequency of SA in the diabetic tissues was also significantly increased upon 
application of both 0.03pM and 0.1 pM IBTX (Figure 49).
IBTX increased the amplitude or the frequency of basal SA only slightly in 12- 
week diabetic tissues and this increase was not significant (Figure 49).
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i
g)
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C
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I
1-week D
5mins
4
0.01mM IBTX 0.03mM IBTX 0.1 mM IBTXg)3
2
4-week D0
5mins
g) 0.01mM IBTX 0.03mM IBTX
0.1 mM IBTX
I I I
5mins
g)
0.01mM IBTX 0.03mM IBTX
I .
0.1 mM IBTX
I
5mins
8-week D
12-week D
Figure 47) Typical chart recordings of basal SA in the presence of increasing 
concentrations of IBTX in control (non-diabetic) (C) & diabetic tissues.
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^
In order to compare the effects of IBTX between different diabetic groups, the 
amplitude and the frequency of SA at 0.1 pM IBTX were plotted against the 
duration of diabetes (Figure 50). Although 1-week diabetic tissues 
demonstrated a greater increase in the amplitude of SA upon stimulation with 
0.1 pM IBTX compared to all other diabetic groups, this increase was only 
significantly greater than the 12-week diabetic tissues. There was no significant 
difference in the increase of the amplitude of basal SA between all other groups 
(Figure 50).
The frequency of SA in the presence of 0.1 pM IBTX increased with duration of
diabetes up to 8 -weeks post STZ-injection and then decreased in detrusor strips
from 12-week diabetic rats. The frequency of SA was significantly higher in 8 -
week diabetic tissues at 0.1 pM IBTX compared to 1-week and 12-week diabetic
%
tissues (Figure 50).
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5.4.3 Effect of the K At p  channel opener cromakalim on CCH-
stimulated SA in control (non-diabetic) and diabetic tissues
Typical chart recordings of the effect of the K At p  channel opener cromakalim on 
CCH-induced SA in detrusor strips from 1-week diabetic rats and their age- 
matched controls (non-diabetics) are demonstrated in Figure 51. The effect of 
cromakalim on inhibition of CCH-induced SA was only investigated at this 
duration of diabetes.
Tension
9)
8
6
3jjM Crom4
2
0
g)
6 -
4 -
0.5(iM CCH
0.3|jM Crom
1|jM Crom
3jjM Crom
10|jM Crom
30mins 1 -week D
Figure 51) Typical chart recordings of the effect of increasing concentrations of 
cromakalim on CCH-induced SA in detrusor strips from 1-week and diabetic (D) rats and 
their age-matched controls (non-diabetics) (C).
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Cromakalim did not have a significant effect on the amplitude of CCH-induced 
SA in either control (non-diabetic) (n=11) or diabetic (n=14) tissues (Figure 52). 
However, cromakalim did significantly decrease the frequency of SA in control 
(non-diabetic) tissues at 1pM, 3pM and 10pM and in the diabetic tissues at 3pM 
and 10pM.
The percentage change in the amplitude and the frequency of CCH-stimulated 
spontaneous contractions in the presence of 3pM and 10pM cromakalim 
relative to that in the absence of cromakalim (i.e. in presence of 0.5pM CCH 
only), was calculated and compared between control (non-diabetic) and diabetic 
tissues. There was no significant difference in the percentage inhibition of the 
amplitude of SA between the control (non-diabetic) (3pM: 2.46±8.94%, 10pM: 
23.35±9.34%) and the diabetic (3pM:5.42±6.37%, 10pM:8.05±7.15%) tissues at 
both concentrations of cromakalim. However, percentage inhibition of the 
frequency of SA at 3pM and 10pM cromakalim was significantly greater 
(p<0.05) in control (non-diabetic) tissues (3pM: 34.70±10.41%,
10pM:41.34±10.08%) than the diabetic tissues (3pM:11.69±6.13%, 10pM: 
18.60±5.70%).
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Figure 52) Effect of increasing concentrations of cromakalim on the amplitude and the 
frequency of SA induced by 0.5pM CCH in control (non-diabetic) (C) and diabetic (D) 
tissues. C: n=11 & 1-week D: n=14. *p<0.05 & **p<0.01 versus paired 0.5pM CCH response. 
Data is presented as mean±SEM.
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5.4.4 Effects of the KATP channel blocker glibenclamide on the 
basal SA in control (non-diabetic) and diabetic tissues
The effect of the K Atp  channel blocker glibenclamide on basal SA was 
investigated in detrusor strips from 1-week diabetic rats and their age-matched 
controls. Typical chart recordings of the effect of glibenclamide on basal SA in 
control and diabetic rat bladder detrusor strips are demonstrated in Figure 53.
Tension
1pM Glibenclamide
I
3pM Glibenclamide
I
10(jM Glibenclamide
I
5m ins
C
1jjM Glibenclamide
I
3|jM Glibenclamide
I
10|jM Glibenclamide
I
5mins 1-week D
Figure 53) Typical chart recordings of the basal SA in the presence of increasing 
concentrations of glibenclamide in control (non-diabetic) (C) and 1-week diabetic (D) 
tissues.
Glibenclamide failed to induce basal SA in detrusor strips from control (non­
diabetic) and diabetic rats.
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5.4.5 Effects of the SKCa channel blocker apamin on basal SA 
in control (non-diabetic) and diabetic tissues
The effect of the SKCa channel blocker apamin on basal SA was investigated in 
control (non-diabetic) and 1-week diabetic rat bladder tissues. Typical chart 
recordings of the effect of apamin on basal SA in control (non-diabetic) and 
diabetic rat bladder detrusor strips are demonstrated in Figure 54.
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4 -[
0.01mM Apamin
0.03pM Apamin 0.1 pM Apamin
I I I
1 - .
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I
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Figure 54) Typical chart recordings of the effect of increasing concentrations of apamin 
on basal SA in 1-week control (non-diabetic) and diabetic tissues.
Apamin failed to induce SA in detrusor strips from controls (non-diabetic) and 
diabetic rats.
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5.4.6 Investigation of K+ channel subunit expression in
diabetic rat bladder using real-time PCR
5.4.6.1 Relative expression ratios of BKca channel subunits in diabetic 
versus control (non-diabetic) rat bladders
Amplification with house-keeping (HPRT) and target gene primers (Slo1 and 
Slopi) was carried out in each control (non-diabetic) and diabetic sample. In 
order to calculate the relative expression ratio of BKca channel subunits, Slo1 
and Slo(31, in diabetic versus control (non-diabetic) rat bladders, the efficiencies 
of each primer set (Slo|31, Slo1 and HPRT) for each sample were determined. 
The amplification curves for serial dilutions of each bladder sample, control 
(non-diabetic) and diabetic for each set of primers (Slo(31, Slo1 and HPRT) 
were analysed and the Ct values for each dilution were recorded.
Figure 55 shows an example of a real-time PCR amplification curve for serial 
dilutions of a control (non-diabetic) bladder sample amplified with Slo1 primers. 
The melt curve analysis demonstrates a clear sharp peak which is an indication 
of a specific amplified product. The Ct value of each dilution versus the 
concentration was graphed by iCycler software (Figure 55). The efficiency of the 
primer set was then calculated by the software according to the equation 
described in chapter 3 (section 3.3.4.4) (Figure 55). Figure 56 also 
demonstrates the amplification and melt curve analysis plus the efficiency plot 
for Slo(31 primers with cDNA samples obtained from control (non-diabetic) rat 
bladder. The same analysis was performed for samples from diabetic rat 
bladder tissues.
There was no significant difference in the efficiency values between any primer 
pair for any sample group. Therefore, the mean efficiency values for each 
primer set (Slo1, Slo(31 and HPRT) were calculated and used for determining 
the expression ratios using the method described by Pfaffl (2001). For each 
sample group, control (non-diabetic), 1-week, 4-week, 8 -week and 12-week 
diabetic, mean Ct values for the 1:10 dilution of each sample for each primer 
pair were calculated and subsequently used in the equation described by Pfaffl
(2 0 0 1 ) to calculate the expression ratios.
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Figure 55) Real-time PCR amplification of Slo1 primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1:1000), from left to right: Red & light green:1:3, light blue and dark green: 1:10, 
pink and dark blue: 1:30, purple and brown:1:100, yellow and dark purple: 1:300, red and 
green: 1:1000 dilutions respectively, ii) Melt curve analysis demonstrates a clear sharp peak for 
all dilutions indicating the specifity of the PCR products produced, iii) Efficiency graph generated 
by iCycler software by plotting the Ct values of each dilution against their concentration. The 
PCR efficiency is demonstrated as a percentage above the graph.
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Figure 56) Real-time PCR amplification of Slopi primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1:1000), from left to right Red & light green:1:3, light blue and dark green: 1:10 , 
pink and dark blue: 1:30, purple and brown:1:100,yellow and dark purple: 1:300, red and 
green:1:1000 dilutions respectively, ii) Melt curve analysis demonstrates a clear sharp peak for 
all dilutions indicating the specifity of the PCR products produced, iii) Efficiency graph generated 
by iCycler software by plotting the Ct values of each dilution against their concentration. The 
PCR efficiency is demonstrated as a percentage above the graph.
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The relative expression ratios of BKCa channel subunits, Slo1 and Slopi, for 1- 
week (n=3), 4-week (n=4), 8-week (n=5) and 12-week (n=6) diabetic rat 
bladders compared to control (non-diabetic) tissues (n=5) (n=number of 
bladders) are shown in Table 14.
Relative expression ratios 
compared to the control (non­
diabetic) bladders
1 -week 
diabetics
4-week
diabetics
8 -week
diabetics
1 2 -week 
diabetics
Slo1 0.60 0.25 0.15 0.17
Slopi 0.92 0.73 0.29 0.32
Table 14) Relative expression ratios of Slopi and Slo1 muscarinic receptors in diabetic 
bladders compared to control (non-diabetic) bladders. Values <1 show a decrease in 
expression and values >1 demonstrate an increase in expression.
The ratios demonstrated a decrease in the expression of BKCa channel subunits 
in all diabetic groups relative to control (non-diabetic) tissues, with bladders 
from 8 and 12-week animals demonstrating the greatest reduction in the 
expression of both subunits. The decrease in the Slo1 gene expression was 
more profound than the Slopi gene in all groups.
166
5 . 4 . 6.2  Relative expression ratios of the K a t p  channel subunits in
diabetic rat bladders versus control (non-diabetic) rat bladders
Amplification with house keeping (HPRT) and target gene (Kir6.1 & SUR2B) 
primers was carried out in each control (non-diabetic) and diabetic bladder 
sample. In order to calculate the relative expression ratio of K At p  channel 
subunits Kir6.1 and SUR2B in 1-week diabetic versus control (non-diabetic) rat 
bladders, the efficiencies of each primer set (Kir6.1, SUR2B & HPRT) for each 
sample were determined. The amplification curves for serial dilutions of each 
control (non-diabetic) and diabetic sample for each set of primers were 
analysed and the Ct values for each dilution were recorded.
Figure 57 demonstrates an example of a real-time PCR amplification curve for 
serial dilutions of a control (non-diabetic) sample amplified with Kir6.1 primers. 
The melt curve analysis demonstrates a clear sharp peak which is an indication 
of a specific amplified product. The Ct value of each dilution versus the 
concentration was plotted and graphed by iCycler software (Figure 57). The 
efficiency of the primer set was then calculated by the software according to the 
equation described in chapter 3 (section 3.3.2.2) (Figure 57). Figure 58 also 
demonstrates an example of an amplification and melt curve analysis plus the 
efficiency plot for SUR2B primers with cDNA sample obtained from a control 
(non-diabetic) rat bladder. The same analysis was also performed for samples 
from diabetic rat bladder tissues.
There was no significant difference in the efficiency values between any primer 
pair for any sample group. Therefore, the mean efficiency values for each 
primer set (Kir6.1, SUR2B & HPRT) were calculated and used for determining 
the expression ratios using the method described by Pfaffl (2001). For each 
sample group (control (non-diabetic) and 1-week diabetic) mean Ct values for 
the 1 : 1 0  dilution of each sample for each primer pair were calculated and 
subsequently used in the equation described by Pfaffl (2001) to obtain 
expression ratios.
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Figure 57) Real-time PCR amplification of Kir6.1 primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1:1000), from left to right: Red & light green:1:3 (duplicate), light blue and dark 
green: 1:10, pink and dark blue: 1:30, purple and brown:1:100,yellow and dark purple: 1:300, 
red and green:1:1000 dilutions respectively, ii) melt curve analysis demonstrates a clear sharp 
peak for all dilutions indicating the specifity of the PCR products produced, iii): Efficiency graph 
generated by iCycler software by plotting the Ct values of each dilution against their 
concentration. The PCR efficiency is demonstrated as a percentage above the graph.
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Figure 58) Real-time PCR amplification of SUR2B primers with serial dilutions of cDNA 
prepared from control (non diabetic) rat bladder tissue, i) Amplification curve for serial 
dilutions (1:3-1:1000), from left to right: light blue & dark green: 1:3, pink & blue: 1:10, dark blue 
& brown : 1:30 low & purple: 1:100, red and light green:1:300, light blue & dark green :1:1000 
dilutions. Middle panel: Melt curve analysis demonstrates a clear sharp peak for all dilutions 
indicating the specifity of the PCR products produced. Lower panel: Efficiency graph generated 
by iCycler software by plotting the Ct values of each dilution against their concentration. The 
PCR efficiency is demonstrated as a percentage above the graph.
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The relative expression ratio of K a t p  channel subunits Kir6.1 and SUR2B were 
calculated in 1-week (n=3) diabetic compared to control (non-diabetic) tissues 
(n=5) (n=number of bladders) using the Pfaffl method as described in chapter 2 
(Pfaffl, 2001). HPRT was used as the reference gene in the Pfaffl equation.
Table 15 demonstrates the relative expression ratios of Kir6.1 and SUR2B 
genes in 1 -week diabetic rat bladders compared to control (non-diabetic) 
tissues
Relative expression ratios compared to 
the control (non-diabetic) group
Kir6.1 0.65
SUR2B 0.45
Table 15) Relative expression ratios of Kir6.1 and SUR2B in the 1-week diabetic rat 
bladders compared to control (non-diabetic) tissues. Values <1 show a decrease in 
expression and values >1 demonstrate an increase in expression.
The ratios demonstrated a decrease in the expression of K A t p  channel subunits 
in 1 -week diabetic group relative to control (non-diabetic) tissues.
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5.5 Discussion
DO is associated with increased spontaneous bladder contractions, which often 
result in symptoms of urgency and incontinence and as described previously, 
the cause of DO may lie within the UBSM (Brading, 1997). Current treatments 
for DO have unwanted side effects, and thus a greater understanding of the 
underlying mechanisms involved in regulating UBSM contractility and 
excitability is crucial for developing new therapeutic agents. In recent years 
much effort has been focused on increasing our understanding of the function of 
K+ channels, such as BKca, K A t p  and SKca channels, in regulating UBSM 
excitability and contractility. It is believed that activation of these channels may 
prove useful in the treatment of overactive detrusor by causing a 
hyperpolarisation the membrane potential in UBSM cells and a reduction in the 
opening of VDCCs which leads to reduced Ca2+ entry and a subsequent 
relaxation of the detrusor muscle.
There are very few studies investigating the role of K+ channels in mediating the 
SA of the detrusor from the STZ-diabetic rat model. Here, a combination of 
molecular and pharmacological approaches were used to characterise the role 
of BKCa, S K c a  and K a t p  channels in modulating UBSM SA in control (non­
diabetic) and STZ-diabetic rat bladder tissues.
5.5.1 The role of BKCa channels in modulation of CCH-
stimulated SA in control (non-diabetic) and diabetic tissues
Understanding the role of BKCa channels in the modulation of cholinergic 
stimulated bladder SA was one of the questions explored in this chapter, since it 
is was hypothesised that abnormal enhancement of smooth muscle excitability 
could be due to alterations in BKCa channel activity.
5.5.1.1 The effect of BKca channel opener NS1619 on CCH-stimulated 
SA in control (non-diabetic) and diabetic rat bladder
Effect of NS1619 on the amplitude and the frequency of CCH-stimulated SA
The effect of NS1619 in modulation of bladder SA was first demonstrated by 
Sheldon et al (1997) in normal guinea-pig urinary bladder. It was shown that 
NS1619 can inhibit detrusor spontaneous contractions in a concentration
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dependent manner. Imai et al (2 0 0 1 ) also demonstrated a significant reduction 
in the amplitude and the frequency of basal SA in guinea-pig detrusor strips 
after exposure to 30pM NS1619. The effect of NS1619 on inhibition of CCH- 
induced SA in neonatal rat bladders was investigated by Ng et al (2006). They 
demonstrated a significant reduction in both the amplitude and the frequency of 
CCH-induced SA in whole urinary bladders of neonatal rats at 30pM NS1619. In 
the present study, the role of NS1619, in modulation of CCH-induced SA was 
examined in control (non-diabetic) and diabetic tissues. The results 
demonstrated that NS1619 had a significant effect on the amplitude of SA only 
at the highest concentration (30pM) tested, with no effect on the frequency of 
SA in all groups at any of the concentrations tested. There was no significant 
difference in the functional responses of control (non-diabetic) and diabetic 
tissues to NS1619.
The amplitude of a spontaneous contraction depends on the increase in 
intracellular Ca2+ levels as result of Ca2+ entry caused by membrane 
depolarisation, as well as CICR via RyRs in the SR (Herrera et al, 2000). Since 
NS1619 only decreased only the amplitude of SA in detrusor strips from control 
(non-diabetic) and diabetic rats in the current study, this may demonstrate that 
this drug is interfering with Ca2+ entry and release mechanisms in the UBSM. 
This hypothesis is supported by the study of Sheldon et al (1997), who 
investigated the effect of NS1619 on detrusor contractility of guinea-pig urinary 
bladder, and demonstrated that NS1619 acts by increasing the open probability 
of BKCa channels. Opening of the BKca channels results in a decrease in the 
inward Ca2+ current and a subsequent decrease in the amplitude of UBSM SA. 
Thus, it was concluded that NS1619 effectively inhibits guinea-pig detrusor 
smooth muscle by involving both activation of BKca channels and inhibition of 
Ca2+ channels (Sheldon etal, 1997).
The frequency of phasic contractions should reflect mechanisms that result in 
action potential firing. Since the initiation of action potentials depend on Ca2+ 
entry, accumulated inactivation of VDCC by membrane hyperpolarisation will 
lead to a cessation of action potentials and subsequently determine the onset 
and length of the interval between contractions (Herrera et al, 2000). The 
underlying reason for the lack of effect of NS1619 in inhibiting the frequency of 
SA in detrusor strips from control (non-diabetic) and diabetic rats in the current
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study is not clear, since the opening of the BKca channels is important in 
restoring the membrane potential and mediating the action potential frequency. 
Further experiments using electrophysiology to investigate the electrical 
properties of the bladder including single smooth muscle cells could enhance 
our understanding of the effect of NS1619 on the frequency of action potential 
firing. Also it must be noted that modulation of channels in in vitro functional 
experiments may not necessary translate to a measurable physiological 
response.
The limited inhibitory effect of NS1619 on CCH-stimulated SA
Although various studies have demonstrated that low micromolar 
concentrations of BKca channel openers can cause a significant stimulation of 
these channels in isolated UBSM cells (Siemer et al, 2000; Sheldon et al, 
1997), the present study demonstrated a relative lack of functional response in 
both control (non-diabetic) and diabetic tissues to NS1619. The reason for this 
is unknown. The lack of sensitivity could be due to diffusion barriers in detrusor 
strip preparations, which may affect the concentrations reaching the drug’s 
postulated site of action. This hypothesis was proposed by Mora & Suarez- 
Kurtez (2005) after demonstrating that NS1608 had no effect on the myogenic 
contractile activity of detrusor strips from guinea-pig urinary bladder.
Another possibility may be that the membrane depolarisation and the 
subsequent elevation of intracellular Ca2+ concentration during the action 
potential in UBSM cells was sufficient to cause activation of BKCa currents. 
Thus, additional stimulation induced by NS1619 may be insufficient to affect the 
excitation-coupling process in functional experiments when other depolarising 
K+ currents are operative.
Counter to the above possibility, another possible reason for insensitivity of 
diabetic and control (non-diabetic) tissues to NS1619 could be muscarinic 
inhibition of BKca channels in the UBSM cells. Previous studies (Kume & 
Koltikoff, 1991; Nakamura et al, 2002) have demonstrated that Ca2+-activated 
K+ (Kca) currents are inhibited by muscarinic agonists in bladder smooth muscle. 
It is believed that muscarinic stimulation of the smooth muscle cells results in a 
marked rise in intracellular Ca2+ and a graded depolarisation, which is 
enhanced by Kca channel inhibition and lowering K+ conductance (Kume &
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Koltikoff, 1991). Nakamura et al (2002) also demonstrated a muscarinic 
receptor-mediated inhibition of BKca channels in rat bladder smooth muscle 
following cholinergic stimulation. Nakamura et al (2002) believed that this 
inhibition was mediated via the M2 muscarinic receptor signalling pathway. In 
the experiments conducted in this chapter, control (non-diabetic) and diabetic 
tissues were stimulated with low concentrations of CCH to enhance 
spontaneous contractions. Thus, it could be hypothesised that CCH-induced 
muscarinic receptor activation may also inhibit BKca channels in the UBSM of 
rat and thus render the tissue relatively insensitive to the actions of BKca 
channel openers.
The relative lack of inhibition of SA in control (non-diabetic) and diabetic tissues 
by NS1619 does not necessarily indicate that the same underlying mechanisms 
are acting in the UBSM cells of both groups of animals. As seen in Table 14, the 
expression of the BKca channel subunits is decreased in diabetic bladder. A 
similar finding was shown by Li et al (2008), who demonstrated a reduced BKca 
channel expression in the bladders of partially outlet obstructed rats. Studies 
have demonstrated the importance of the presence of both of the BKca channel 
subunits in the smooth muscle for regulation of contractility. In a study by 
Petkov et al (2001b), which used gene knockout mice lacking the pi-subunit of 
the BKca channel, a reduced activity of these channels was observed. Petkov et 
al (2001b) also reported that detrusor strips from these mice had elevated SA, 
with high amplitude, low frequency contractions. In UBSM cells lacking the 13- 
subunit, BKca channels also had a much lower open probability. In the current 
chapter, a decrease in expression of the Slop-1 gene, which encodes the (3- 
subunit, along with a decrease in Slo-1 gene, which encodes the pore-forming 
a-subunit of BKca channels, was detected in the diabetic bladders. This 
decrease in the mRNA expression of BKca channel a- and p-subunits in the 
diabetic bladders, if reflected at the functional protein level, could potentially 
explain the reduced activity and the insensitivity of these tissues to openers 
such as NS1619 respectively. In other words, there are simply not enough 
channels to have a significant effect on the UBSM’s membrane potential and 
detrusor contractility. However, since the same pattern of insensitivity to 
NS1619 was also detected in detrusor strips from control (non-diabetic) rats, the 
decreased expression levels of BKca channels’ subunits in the diabetic bladder
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can not serve as a solid argument for the lack of sensitivity of the diabetic 
tissues to NS1619.
5.5.1.2 The effect of BKca channel blocker IBTX on basal SA in control
(non-diabetic) and diabetic rat bladder
The effect of inhibition of BKca channels on the spontaneous contractions of 
normal bladders in various species has been studied extensively. BKca channel 
blockade in UBSM results is increased SA in these tissues (Imai et al, 2001; 
Buckner et al, 2002; Darblade et al, 2006). In terms of the effect of IBTX on 
bladders from diabetic animals, only one study by Nakahara et al (2004) has 
looked at the effect of BKca channel modulation by IBTX in bladders from 8 - 1 0  
week diabetic rats, it was demonstrated that diabetic tissues react much more 
strongly after exposure to IBTX than control (non-diabetic) tissues. In the 
present chapter, the effect of the BKca channel blocker IBTX on basal SA of 
detrusor strips from control (non-diabetic) and diabetic rats was also 
investigated. IBTX, at the highest concentration (0.1 pM) produced changes in 
SA similar to those induced by CCH including a rise in amplitude and frequency 
of basal spontaneous contractions in control (non-diabetic) and all diabetic 
tissues except in detrusor strips from 1 2 -week diabetic rats, which 
demonstrated a relative lack of functional response to IBTX. The SA induced by 
0.1 pM IBTX had greater amplitude in 1-week diabetic tissues compared to their 
aged matched control (non-diabetic) tissues, but this was not significant. The 
frequency of the SA was not different between control (non-diabetic) and 1- 
week diabetic tissues in the presence of 0.1 pM IBTX. The lack of significance 
between control (non-diabetic) and diabetic animals may be due to the limited 
number of tissues used in these experiments and further experiments may 
highlight a significant difference
Clear differences were detected in responses of detrusor strips from 1-week 
and 12-week diabetic rats to IBTX. 1-week diabetic tissues demonstrated 
significantly higher amplitude of SA upon stimulation with 0.1 pM IBTX 
compared to 12-week diabetic tissues. Thus, differences between functional 
responses of 1 -week and 1 2 -week diabetic tissues are consistent with the 
results obtained from previous chapters, demonstrating an increased and 
decreased contractility in 1 -week and 1 2 -week diabetic tissues respectively.
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These differences could be due to different underlying mechanisms controlling 
the membrane potential of UBSM cells or altered levels of baseline UBSM 
activity and excitability in these rats. Altered expression of BKca channels may 
be another possible reason for the observed differences between responses of 
1-week and 12-week diabetic tissues. For example, in a study by Ng et al 
(2007), who investigated the effect of IBTX on spontaneous contractions of 
UBSM from neonatal and postnatal rats, it was demonstrated that detrusor 
strips from neonatal rats (used as a model of DO) demonstrate high amplitude, 
low frequency spontaneous contractions upon exposure to IBTX, whilst detrusor 
strips from postnatal rats demonstrate low amplitude high frequency SA. This 
pattern of activity correlated with the expression levels of BKca channel a- 
subunit in these animals, i.e. the expression levels of BKCa channels a-subunit 
increased during postnatal maturation of the bladders. Thus, it was concluded 
that changes in expression levels of BKca channels in bladder smooth muscle 
might be involved in the downregulation of SA during postnatal maturation (Ng 
et al, 2007). The authors suggested that the lack of feedback pathway of BKca 
channels in UBSM cells in neonatal rat bladders, as seen in studies using BKca 
knock out mice (Meredith et al, 2004; Thorneloe et al, 2005), excitability of 
UBSM remains unchecked, leading to detrusor muscle instability which is a 
primary cause of DO. In the current chapter, a decreased expression of BKca 
channel subunits mRNA was also detected in bladders form diabetic rats. 
However, in contrast to the study by Ng et al (2007), the expression levels of 
BKca channel subunits in the diabetic bladders decreased with duration of 
diabetes, which does not correlate with the functional data obtained for these 
tissues i.e. if a decrease in the expression of BKca channel subunits is 
associated with an increase in the SA, then 12-week diabetic tissues should 
have demonstrated the highest amplitude and frequency of IBTX-induced SA 
compared to all other groups, whilst they were insensitive to modulation with 
IBTX. One possible explanation for these contradictory results could be that in 
12-week diabetic tissues, the expression levels of BKca channels have declined 
to such low levels that blockade of these channels does not have any further 
effect on the membrane potential and other compensatory mechanisms or 
channels may be playing a role in the modulation of UBSM membrane potential. 
In addition, it has been shown that residues on the extracellular loop of the (31 
subunit of BKCa channels are very important in creating high affinity IBTX
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binding sites (reviewed by Ghatta et al, 2006). Thus, the observed reduction in 
pi subunit expression may affect IBTX binding to BKca channels and result in 
insensitivity of 12-week diabetic tissues to IBTX In 1-week, 4-week and 8 -week 
diabetic tissues, the reduction in BKCa (31 subunit expression, may not have 
such a dramatic effect on IBTX binding affinity. Also modulating the channel’s 
activity in in vitro tissue bath experiments may not necessarily have a 
measurable functional response. In order to make definitive conclusions, further 
investigations on the expression of these channels at-the protein level, as well 
as studying the channel’s activity at single cell level are needed.
The role of other cell types in mediating detrusor contractions upon modulation 
of BKCa channels must also be considered, since ICs found in the bladder are 
believed to demonstrate calcium activated and voltage dependent currents 
(McCloskey, 2005). Therefore, further investigations on the role of these cells in 
mediating spontaneous contractions and their density in bladder tissues at the 
different stages of diabetes, may provide a better understanding of the 
underlying mechanisms that lead to the current results.
5.5.2 The role of K A t p  channel in modulation of CCH- 
stimulated SA in control (non-diabetic) and diabetic rat bladder
The effect of K a t p  channel modulation by cromakalim on the SA of detrusor 
muscle has been investigated previously in the guinea-pig bladder (Foster et al, 
1989; Imai et al, 2001). In these studies, cromakalim had a significant inhibitory 
effect on both the amplitude and the frequency of SA. The results of other 
experiments demonstrated that activation of < 1 %  of K a t p  channels was enough 
to significantly inhibit the action potentials and the related SA (Petkov et al, 
2001) Therefore, it was hypothesised that UBSM may be very sensitive to K a t p  
channel openers, since small changes in KATP-channel activity are likely to 
move the resting membrane potential away from the threshold of action 
potential activation (Petkov et al, 2001). In the present chapter, the role of K a t p  
channel opener cromakalim was investigated in detrusor strips from control 
(non-diabetic) and diabetic rats. In comparison to the effect of BKca channel 
opening, which only had an effect on the amplitude of S A ,  activation of K a t p  
channels had a significant effect only on the frequency of SA. This suggests
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that opening of these channels may have a profound effect on action potential 
activation and firing in UBSM of the rat.
K a t p  channel openers such as cromakalim, YM934, ZD6169, A-278637 and 
WAY-133537 have been shown to reduce the amplitude and the frequency of 
spontaneous contractions evoked by acetylcholine (Martin et al, 1997; Wojdan 
et al, 1999; Gopalakrishnan et al, 2002). However, it has also been shown that 
muscarinic receptor activation could suppress 40-70% of K A t p  currents in UBSM 
(Bonev and Nelson, 1993b), oesophageal muscularis mucosae (Hatakeyama et 
al, 1995) and trachea (Nuttle and Farley, 1997) through protein kinase C- 
mediated pathways. In the present study, the reason for the lack of effect of 
cromakalim on the amplitude of muscarinic stimulated SA in control (non­
diabetic) and diabetic rat bladder tissues is not clear. One possible explanation 
again could be the untranslated electrical activity of channels to functional 
responses in rat urinary bladder.
SA in diabetic tissues was less responsive to the activation of K A t p  channels by 
cromakalim compared to controls (non-diabetic). The reason for this is not clear. 
In a similar study by Jarajapu et al (2006) it was demonstrated that the 
responses of bladder tissues from 2 -months diabetic rats to pinacidil were also 
significantly less than in control (non-diabetic) tissues. In the present study, 
Kir6.1 and SUR2B expression levels were decreased in diabetic rat bladders, 
which could explain the reduced functional effect to cromakalim. It maybe that 
there are not enough K A t p  channels expressed in the diabetic tissues to 
demonstrate a functional response to cromakalim. Also, the general belief, from 
reconstitution studies on KATp channels, is that their K+ selectivity, inward 
rectification and unitary conductance are determined by Kir6 .x subunits, whilst 
their pharmacology and sensitivity to drugs and nucleotides depends on their 
SUR subunits (Babenko et al, 1998). Thus, the reduction in expression of the 
SUR2B subunit could explain the reduced sensitivity of the diabetic tissues to 
cromakalim. However, changes in the expression levels of K A t p  channels 
subunits at the mRNA level do not necessarily correlate with the number of 
functional channels at the protein level, thus any conclusion based on the 
expression levels of these channels at the molecular level must be interpreted 
with care.
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The K a t p  channel blocker glibenclamide failed to have a significant effect in 
inducing basal SA in both control (non-diabetic) and diabetic rat bladder tissues 
in this study. The same has been observed in human (Darblade et al, 2006), pig 
(Buckner et al, 2002) and guinea-pig (Imai et al, 2001) UBSM. The lack of 
functional responses to glibenclamide in control (non-diabetic) and diabetic 
bladder tissues may indicate that in rat UBSM cells that Katp channels are 
closed and thus do not participate in the regulation of phasic contractions under 
basal conditions.
5.5.3 The role of SKCa channel in modulation of SA in control 
(non-diabetic) and diabetic rat bladder
The role of SKca channels in modulating the SA has been investigated by 
various studies in mouse and rat urinary bladder (Herrera et al, 2003; Hougard 
et al, 2009). These studies have demonstrated that the modulation of SKca is 
important in mediating SA of the bladder under pathological conditions leading 
to DO in these species.
In the current study, detrusor strips from control (non-diabetic) and diabetic rats 
were insensitive to modulation by apamin. This suggests that SKca channels 
may not be important in mediating UBSM membrane potential or spontaneous 
bladder contractions in this species under the current experimental setup.
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5.6 Summary
The effect of various K+ channel modulators on basal and CCH-stimulated 
spontaneous contractions in control (non-diabetic) and diabetic rat bladders was 
investigated. Overall, it was demonstrated that only at 30pM could NS1619 
reduce the amplitude of SA in both control (non-diabetic) and diabetic tissues 
with no effect on the frequency of the SA. However, closure of BKca channels 
had a significant effect on both the amplitude and the frequency of SA in control 
(non-diabetic) and diabetic tissues (with the exception of 1 2 -week diabetic 
tissues). IBTX had a greater effect in increasing the amplitude of the SA in 
detrusor strips from 1-week diabetic tissues compared to all other groups. A 
decrease in expression of BKca channels subunits was detected in all diabetic 
tissues.
Opening of K A t p  channels by cromakalim had a significant inhibitory effect on 
the frequency of CCH-induced SA in both control (non-diabetic) and diabetic rat 
bladder tissues. Diabetic tissues seemed to be less sensitive to this modulation 
compared to the control (non-diabetic) tissues, suggesting a possible down 
regulation of K a t p  channel activity in the diabetic tissues which was confirmed at 
the mRNA level for the SUR2B and Kir6.1 subunits by real-time PCR.
SKca channels do not appear to play a role in the modulation of SA in these 
tissues.
A better understanding of the K+ channel defects in the urinary bladder smooth 
muscle could be achieved by electrophysiological techniques that allow the 
study of ion channels function at a single cell level.
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Chapter 6: Identification 
and characterisation 
of c-kit positive cells 
in rat urinary bladder
181
6.1 Introduction
It is believed that the urothelial and the sub-urothelial cells of the bladder play a 
significant role in the generation and modulation of bladder sensation (Gillespie 
et al, 2005). Recently a specialised type of cell, similar to Interstitial cells of 
Cajal (ICCs) in the gut, have been found in various parts of the urinary tract of 
human, guinea pig, pig and mouse, where they are believed to play a role in 
processing sensory information, pacemaking and modulating contractile 
function (Klemm et al, 1999; Lang et al, 2001; Pezzone et al, 2003; Drake et al, 
2006; Metzger et al, 2008). Various terms have been used to describe these 
cells, including myofibroblasts, interstitial cells (ICs), interstitial cells of Cajal-like 
cells and pacemaking cells. In practice, the precise distinction between these 
cells is unclear due to their phenotypic plasticity. However a consistent 
terminology is needed for these cells to clarify their physiological role in the 
bladder. In this chapter they will be referred to as interstitial cells (ICs).
6.1.1 Characterisation of interstitial cells (ICs) and c-kit
signalling pathways
ICs were first discovered in the gut by Ramon Cajal (Cajal, 1983). He described 
a network of ICs, which he believed were a type of premature neuron, and 
suggested that these cells were influenced by various neurotransmitters and 
exerted a direct regulatory effect on smooth muscle cells (reviewed by Brading 
& McCloskey, 2005). It has been established that there are different subsets of 
ICs present throughout the alimentary tract, each with different regulatory roles 
(Faussone-Pellegrini & Thuneberg, 1999). A pacemaker function has been 
demonstrated in cells lying close to the myenteric plexus (IC-MY) and the 
colonic ICs associated with the submuscular plexus (IC-SMP). Other subsets of 
these cells are found intramuscularly, in circular muscle layers in the small 
intestine, in the deep muscular plexus and the submucous plexus and are 
believed to be involved in mediation and modulation of inhibitory and excitatory 
innervation and mechanoreception of the muscle (reviewed by Faussone- 
Pellegrini & Thuneberg, 1999 & Brading & McCloskey, 2005).
ICs were first detected by standard histological techniques that had been 
developed for identification of neurons, such as silver staining and methylene
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blue. With the advent of electron microscopy it was possible to observe the 
morphological features of these cells in the gut, which allowed a clear distinction 
from smooth muscle cells and fibroblasts (reviewed by Faussone-Pellegrini & 
Thuneberg, 1999; Sanders & Ward, 2006). However, it is worth mentioning that 
there remains a group of cells which have ultrastructural characteristics of both 
smooth muscle cells and fibroblasts and therefore it is convenient to have a set 
of characteristics that defines what could be called an IC “prototype”. IC 
prototypes in the gut have an elongated cell body and several slender 
processes, branching to give numerous secondary and tertiary processes. They 
can be distinguished from fibroblasts by their narrow rounded or slightly 
flattened processes which in fibroblasts are very thin and broad (reviewed by 
Faussone-Pellegrini & Thuneberg, 1999).
ICs have a close relation with smooth muscle cells and nerves. Contact with 
smooth muscle cells occurs through areas of close opposition, interdigitation, 
intermediate junctions or gap junctions, depending on the location and the 
species studied. A heavy innervation is a common feature of ICs, with close 
opposition with transmitter-containing varicosities. This characteristic of ICs 
suggests a role in neurotransmission and pacemaker activity (reviewed by 
Faussone-Pellegrini & Thuneberg, 1999; Sanders & Ward, 2006)
Although electron microscopy allows vigorous examination of cell to cell 
interactions, this method is limited in obtaining a widespread image of cellular 
distribution and function and is also a very labour intensive technique (Sanders 
& Ward, 2006). Therefore, various markers for identification of ICs in 
histochemical and immunochemical studies have been used such as different 
enzymes such as diaphorases (Xue et al, 1993), nitric oxide synthase (Xue et 
al, 1994), maganese superoxide dismutase (Fang & Christensen, 1995), heme 
oxygenase 2 (Miller et al, 1998), intermediate filaments such as vimentin 
(Torihashi et al, 1994), receptor proteins such as c-kit (Maeda et al, 1992), 
tachykinin receptors (Grady et al, 1996), as well as other antigenic proteins like 
cyclic GMP (Ward et al, 1998) and CD34 (Hirota et al, 1998).
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6.1.2 c-kit structure and function
Labelling of the c-kit receptor as an immuno-marker for ICs is one of the most 
widely used methods for identification of these cells, since genuine or 
identifiable fibroblasts and smooth muscle cells are c-kit negative.
c-kit is a receptor tyrosine kinase which is encoded by the proto-oncogene c-kit 
and signalling via this receptor is essential for development of IC phenotype and 
electrical rhythmicity (Maeda et al, 1992; Torihashi et al, 1995). The proto­
oncogene c-kit is the normal cellular homolog of the oncogene v-kit of the HZ4- 
feline sarcoma virus (McCulloch & Minden, 1993). c-kit maps to the long arm of 
human chromosome 4 and to mouse chromosome 5 and is allelic to the murine 
White spotting locus (W) (Lev et al, 1994; Viagoftis et al, 1997).
c-kit is a type III receptor kinase and is structurally similar to platelet-derived 
growth factor receptors (PDGFRs) (Viagoftis et al, 1997). These receptors have 
unique features, such as an extracellular (EC) domain made up of five 
immunoglobulin-like repeats and a tyrosine kinase (TK) domain that is split into 
two domains (TK1 and TK2) by an insert sequence of variable length (Kitamura 
& Hirota, 2004; Webseter et al, 2006). A schematic diagram of the kit receptor is 
demonstrated in Figure 59.
Figure 59) Schematic diagram of the receptor tyrosine kinase, c-kit. Adapted from Kitamura 
& Hirota, 2004; Webster et al, 2006.
Tyrosine kinase I 
Hydrophilic inter-kinas 
Tyrosine kinase I
J  Transmembrane domain 
y  Juxtamembrane domain
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K Kinase domain
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binding domain
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Immunohistochemistry using c-kit labelling has improved our understanding of 
the structure and distribution of IC networks and has enhanced our perception 
of the anatomic relationship between ICs and enteric neurons, smooth muscle 
cells and other cells such as macrophages (reviewed by Ward & Sanders,
2001). Also identification of c-kit, lead a team of Japanese scientists to develop 
a neutralising antibody, ACK2, to block c-kit signalling in order to determine the 
consequences of reduced c-kit function (Nishikawa et al, 1991; Sanders & 
Ward, 2006). Administration of c-kit-neutralising antibodies and blocking the c- 
kit pathway greatly reduced the population of ICs in the Gl tract by inducing 
apoptosis in these cells. This had a negative impact on neural responses and 
generation of electrical slow waves, which are the basic electrical rhythm of the 
Gl tract and are essential for the normal motility patterns of the gut. This 
supported the idea that signalling via c-kit is essential for the development and 
maintenance of the IC phenotype (Torihashi et al, 1995). Animal models with 
mutations in the gene encoding c-kit, surgical treatment, infections and animals 
treated with chemicals have also been used to gain a better understanding of 
the function of IC cells (Ward et al, 1994; Huizinga et al, 1995; Sanders, 2006). 
IC networks do not develop in animals in which the function of the c-kit protein 
is genetically impaired i.e. by inducing loss-of-function mutations in the c-kit 
gene or the gene for the ligand for c-kit, stem cell factor gene (Sanders, 2006).
The signalling pathways associated with c-kit activation are numerous. Binding 
of the c-kit ligand, stem cell factor, to the receptor results in dimerisation and 
autophosphorylation on key tyrosine residues within the receptor. These 
phosphorylated tyrosine residues associate with substrates of various kinds 
(Kitamura & Hirota, 2004; Ronnstrand, 2004). The phosphatidylinositol-3-kinase 
(PI3K)/Akt system is one of the major pathways which is dependent on 
interaction with c-kit. Activation of PI3K via c-kit produces phosphatidylinositol- 
3,4-biphosphate, which, in turns activates Akt, a serine-theorine kinase. The 
activated Akt is involved in the inhibition of apoptosis of cells, whose survival 
depends on c-kit signalling (Kitamura & Hirota, 2004).
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6.1.3 c-kit inhibition by Glivec (imatinib mesylate)
Recently, selective tyrosine kinase inhibitors have been developed which have 
been used for functional analysis of ICs in different tissues. Glivec (imatinib 
mesylate) is one of these tyrosine kinase inhibitors, and has been used in the 
treatment of Philadelphia chromosome positive chronic myeloid leukaemia and 
c-kit positive gastrointestinal stromal tumours (Kubota et al, 2004). The active 
substance of this drug is the mesylate salt of Glivec which is known to 
specifically inhibit the tyrosine kinase activity of c-kit and platelet-derived growth 
factor receptor (PDGFR) (Heinrich et al, 2000; Kraus & Van Etten 2005). Glivec 
can block autophosphorylation of c-kit, as well as Akt, which can result in 
induction of apotosis in c-kit signalling-dependent cells. This drug has been 
used extensively for studying the role of ICs in generation of spontaneous 
electrical activity, which is present in various smooth muscle organs such as the 
uterus, intestine, myometrium and bladder (Biers et al, 2006; Hutchings et al, 
2006; Kubota et al, 2006; Popescue et al, 2006). In a recent study by Hashitani 
et al (2008) it was demonstrated that Glivec can significantly downregulate the 
spontaneous contractions of guinea-pig stomach by inhibiting the increase in 
intracellular Ca2+ in smooth muscle cells rather than by specifically inhibiting the 
activity of c-kit signalling. However, the effects of Glivec on isolated ICs needs 
to be investigated directly.
6.1.4 Electrical properties of ICs
Microelectrode recordings from ICs dissociated from the myentric plexus of the 
gut show regular large depolarisations (slow waves), which then depolarise 
neighbouring smooth muscle cells (Ward et al, 1994). This can lead to opening 
of VDCCs in smooth muscle cells, resulting in action potential generation (Ward 
et al, 1994). Ca2+ entering through these channels, elicits Ca2+ induced Ca2+ 
release (CICR) from smooth muscle sarcoplasmic reticulum (SR) via ryanodine 
receptors (RYRs) and subsequent activation of the contractile machinery. 
These contractions, which occur coincidently with the slow waves of 
depolarization in ICs, are ideal for gut motility and peristalic movements 
(Brading & McCloskey, 2005). It is believed that ICs are responsible for 
generation of spontaneous electrical activity, as they show spontaneous
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changes in membrane potential, which may influence the SA detected in 
different smooth muscle organs (Koh et al, 1998; Sergeant et al, 2000).
6.1.5 ICs in the bladder
The SA of the bladder (discussed in chapter 4) is similar to peristaltic movement 
of the Gl tract. Since the co-ordinated contractions in the Gl tract are modulated 
by ICs, it was postulated that a similar type of cell may be present in the 
bladder. Many investigations have been carried out in different species in order 
to identify and characterise these cells using various bio-markers and 
methodologies.
6.1.5.1 Immunological markers for identification of ICs in the urinary
bladder
ICs were first described in the guinea-pig and human bladder as target cells for 
nitric oxide (NO), and responded to this stimulus with an increase in immuno- 
reactivity for cGMP (Smet et al, 1996). ICs in human and guinea-pig bladders 
also showed immunoreactivity for vimentin (Van der AA, 2004; Davidson & 
McCloskey, 2005).
ICs in human bladder also express the vanilloid receptor, VR1/TRPV1, and the 
vanilloid receptor-like protein, VRL1/TRPV2, indicating a possible role in 
noxious stimuli transduction (Ost et al, 2002; Van der AA et al, 2004).
Sui et al (2002) also reported a network of ICs in human urinary bladders, which 
demonstrated immunoreactivity to connexin 43. They believed that this network 
is well-placed beneath the urothelium to act as an integrating network for 
signals to and from afferent and motor nerves respectively. However, it was 
found that this suburothelial cell layer stained poorly for the c-kit receptor. Sui et 
al (2 0 0 2 ) also demonstrated that c-kit and a coincidental staining for desmin 
were apparent in the basal layer and even in the intermediate regions of the 
urothelial layer rather than in the connexion 43/vimentin positive cell layer in the 
suburothelial space and thus concluded that c-kit staining cannot be used as a 
marker to distinguish suburothelial interstitial cells (Sui et al, 2002).
ICs have also been identified in the guinea-pig bladder by McCloskey and 
Gurney (2002), using antibodies to the c-kit receptor. ICs with immunoreactivity
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to c-kit, and similar morphology to that described by McCloskey and Gurney
(2002), were also reported by Hashitani et al (2004) in guinea pig urinary 
bladder.
While a wide range of c-kit antibodies are available commercially, many fail to 
detect ICs in positive control tissue, c-kit antibodies have failed to detect ICs in 
murine bladders, thus immunoreactivity for cGMP after exposure to a NO donor, 
has been used as a marker for identification of these cells in the bladder of this 
species (Smet et al 1996; Lagou et al, 2006b).
6.1.5.2 Location of ICs in the urinary bladders
There have been numerous reports on the location of ICs in the bladder. Smet 
el al (1996) reported that ICs were more numerous in the guinea-pig bladder 
body than in the urethra. ICs were present in large numbers throughout the 
muscle bundles and within the interstitium of the bladder, but were concentrated 
more in the outer fibromuscular coat where the processes formed a dense 
interconnected network (Smet et al, 1996). Multiple labelling studies in guinea- 
pig urinary bladders using confocal microscopy revealed that ICs were located 
on the boundary of smooth muscle bundles, running axial with smooth muscle 
cells and were positioned in close proximity to intramural nerves, particularly to 
nNOS-containing neurons (McCloskey & Gurney, 2002). Hashitani et al (2004) 
reported three subpopulations of these cells in the guinea-pig urinary bladder. In 
their study, ICs were found adjacent to the boundary of muscle bundles, some 
ICs were found scattered among smooth muscle cells within muscle bundles 
and in addition to these, ICs were also found in connective tissues between 
smooth muscle bundles (Hashitani et al, 2004). Gillespie et al (2004, 2005) also 
reported cGMP positive cells in guinea-pig urinary bladder, which were present 
immediately beneath the urothelium and on the outer muscle layers.
In comparison with the study by Smet et al (1996), Van Der Aa et al (2004) 
found that in humans, ICs seem to be smaller in number in the bladder body 
than in the bladder neck. Co-localisation of c-kit immunostaining and connexin 
43 immunostaining demonstrated that a network of ICs localised beneath the 
urothelium and between smooth muscle cells of the bladder (Van der AA, 
2004). Sui et al (2002) reported a population of these cells beneath the 
urothelium in human bladder that formed a functional syncytium (Sui et al,
188
2002), whilst Shafik et al (2004) also found ICs throughout the dome of the 
human bladder and suggested a vesical pacemaker activity of these cells 
(Shafik et al, 2004).
In mouse urinary bladder, ICs were identified in the outer part of the detrusor 
muscle layer and between the muscle bundles (Lagou et al, 2006). No cGMP 
staining was seen in the suburothelium or the urothelium of the mouse bladder 
(Lagou et al, 2006). No studies have so far reported the location of these cells 
in rat urinary bladder.
6.1.5.3 Functional role of ICs in the urinary bladder of various species
The observation that ICs are immunopositive for connexin 43 and VRL1/TPRV2 
with the previously reported immunopositivity for cGMP, and their close 
proximity to nitregic and peptidergic nerve fibres, suggests a functional role for 
these cells (Smet et al, 1996; Van der Aa et al, 2004; Lagou et al, 2006b). It has 
been suggested that ICs may function as a sensing network, receiving/sending 
signals from/to the urothelium, modulating afferent bladder innervation and/or 
activating a spinal or intramural reflex arc (Van der Aa et al, 2004). It has also 
been shown that ICs in the bladder are capable of generating Ca2+ transients 
(Hashitani et al, 2004), but do not have an obvious role in pacemaking. Instead 
these cells might modulate communication between subgroups of smooth- 
muscle cells in the bladder and thus might help to explain the micromotions of 
the bladder wall (Hashitani et al, 2004).
ICs in the outer muscle layer also seem to be involved in muscarinic-induced 
SA of mouse urinary bladder, demonstrating a further functional role of ICs in 
the bladder (Lagou et al, 2006).
6.1.6 Implications of ICs in overactive bladder
As described in chapter 1, both a myogenic and a neurogenic basis of DO have 
been proposed, although both factors may be implicated and are often 
comorbid. Recent studies have added ICs, as a new component, into the 
complexity of the pathophysiology of DO (Kubota et al, 2008).
In overactive detrusors increased electrical coupling between smooth muscle 
cells may explain the enhanced excitability. Therefore, spontaneous action
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potentials that result in spontaneous contractions may spread further and cause 
synchronous contractions of multiple smooth muscle bundles which results in 
elevation of intravesical pressure. It has been reported that micromotions of the 
bladder wall are enhanced in a rat model of DO (Drake et al, 2003b). This 
abnormality of increased SA in overactive detrusor may result from changes in 
the properties of ICs, as well as increased coupling between smooth muscle 
cells. In a bladder outlet obstructed (BOO) guinea-pig model, it was 
demonstrated that ICs were more widely distributed in the suburothelial layers 
than normal animals (Kubota et al, 2008). Since it has been shown that these 
cells form a dense electrical network in the space between afferent nerves and 
the urothelium, it was suggested that these cells may cause altered signal 
transmission from the urothelium to afferent nerves which results in DO. It was 
also shown that suburothelial connective tissue ICs increase in BOO bladders 
and that initial changes in suburothelial ICs may contribute to ‘neurogenic’ DO. 
BOO progresses ‘myogenic’ DO may result from an increased population of 
muscular ICs subsequent to changes in suburothelial ICs (Kubota, 2008).
An increased number of c-kit positive cells in patients with idiopathic and 
neurogenic DO has also been reported (Biers et al, 2006). However, ICs can 
also decrease in number or be completely abolished in conditions such as 
megacystis microcolon intestinal hypoperistalis syndrome in infants, which 
results in distended non-functional, nonobstructed bladders (Piotrowska et al, 
2004). These studies, again, suggest a link between ICs and contractile activity 
and thus, inhibitors of these cells such as Glivec could be used to inhibit 
undesired SA and subsequent DO.
Although there are various reports on the role of ICs in mediating detrusor SA in 
normal and pathological conditions, no studies have reported the presence of 
these cells in rat urinary bladder, and therefore there are no reports on the 
functional implications of ICs in mediating SA of the STZ-diabetic rat bladder.
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6.2 Aim of the chapter
The aim of this chapter was to identify and characterise ICs in control (non­
diabetic) and STZ-diabetic rat bladder using molecular, immunological and 
functional methods.
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6.3 Material and Methods
6.3.1 Investigation of c-kit expression in rat bladder using RT-
PCR
Total cellular RNA was extracted from control (non-diabetic) (n=5) and 1-week 
diabetic (n=6) rat bladders according to the protocol described in chapter 3.
RNA integrity and quantity was analysed using the Experion automated 
electrophoresis system as described in chapter 3.
cDNA synthesis was carried out as described in chapter 3.
6.3.1.1 Primer design
The sequence of rat -c-kit tyrosine kinase mRNA (Rattus norvegicus mRNA for 
c-kit receptor tyrosine kinase. Accession no: D12524.1) was retrieved from 
"NCBI" website: "http://www.ncbi.nlm.nih.gov" (Figure 60) and primers specific 
to this sequence were designed using primer 3 (web) software. The parameters 
used for primer design were:
• 15-20bp primer length
• Primer GC content of 40-60%
• Primer Tm of 57-63°C
• The primer Tm for both primers were within 2-3 °C of each other
• The amplified region between the two primers was set at 400-500 base
pairs.
The programme returned a range of sequences meeting the parameters, from 
which the primer pair (sequence demonstrated in Table 16) was selected and 
subsequently synthesised (Invitrogen, UK). The synthesised primers were then 
reconstituted with nuclease free water at concentration of 200pM and kept at - 
20°C until use. The amplification region between the set of primers is 
demonstrated in Figure 60.
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Target gene Accession
no Primer sequence
Start
base Tm P.S
c-kit tyrosine 
kinase 
receptor
D12524.1 F : 5 '  GGCCTAGCCAGAGACATCAG 3 ' 
R : 5 '  GAGAGGCTGTGTGGAAGAGG 3 '
2481
2960
59.97
59.99
480
bp
Table 16) Primer sequences for the rat c-kit gene. Tm=melting temperature. bp= base pairs; 
P.S=product size, F=forward R=reverse.
2481ggcctagccagagacatcaggaatgattcgaattacgtggtaaaaggaaatgcacg
GCTGCCCGTGAAGTGGATGGCACCGGAGAGCATTTTCAACTGCGTGTACACATTTGAAA
GTGACGTCTGGTCCTATGGGATTTTCCTCTGGGAGCTATTCTCTCTAGGAAGCAGCCCC
TACCCAGGGATGCCGGTCGATTCCAAGTTTTACAAGATGATCAAGGAAGGTTTCCGAAT
GCTCAGCCCTGAGCACGCGCCTGCCGCAATGTATGAAGTTATGAAGACTTGCTGGGATG
CTGATCCCCTGAAAAGGCCAACATTCAAGCAGGTTGTTCAGCTCATTGAGAAGCAGATC
TCAGACAGCAGCAAACATATTTACTCCAACTTAGCAAACTGTAACCCCAACCCAGAGAA
CCCCGTGGTGGTGGACCATTCTGTGAGGGTCAATTCCGTCGGCAGCAGCACCTCTTCCA
CACAGCCTCTC2960
Figure 60) Partial sequence of Rattus norvegicus mRNA for c-kit receptor tyrosine 
kinase. Accession no: D12524.1. The primer sequence are indicated in red. The sequence of 
the amplified region is highlighted in grey.
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6.3.1.2 Polymerase chain reaction (PCR)
A 25jjI PCR reaction consisting of the components described in Table 17 was 
prepared to the indicated end concentrations.
Reagent Stock concentration Final concentration 
in the reaction
Volume added
PCR mastermix 
(Abgene)
1.1x 1x 22.5|jl
Forward primer 5pM 0.2|jM 1|j|
Reverse primer 5pM 0.2pM 1 pi
cDNA 0.5pg/ul O.OIpg/ul 0.5|jl
Total Volume= 25 pI
Table 17) The PCR reaction components used for amplification of cDNA samples 
obtained from control (non-diabetic) and diabetic rat bladders with c-kit and GAPDH 
primers.
Each control (non-diabetic) and diabetic sample was first amplified using 
GAPDH primers (Table 4) to confirm the presence of amplifiable cDNA after 
reverse transcription (positive control). In the negative control, sterile water was 
added instead of the cDNA template. After confirmation of the presence of 
amplifiable cDNA, samples were then amplified using the designed c-kit primers 
(Table 16).
The PCR reaction was carried out in a GeneE thermocycler (Techno Cambridge 
Ltd) with the following cycle parameters:
Initial denaturation at 95°C for 5 mins
15 seconds denaturation at 95°C N
1 min annealing step at 59°C
1min elongation step at 72°C
Final elongation step at 72°C for 10 min
PCR products were then analysed on a 1% (w/v) agarose gel containing 
0.5ng/ml ethidium bromide. Electrophoresis was carried out at 100 V for 45min. 
Gel images were obtained using a UVP Bioimaging system (Upland, USA).
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► x35 cycles
PCR products were identified by comparison with a DNA ladder covering the 
range of 100-1000bp. Specific PCR bands were excised from the gel and were 
then purified with QIAquick Gel extraction kit (Qiagen) according to 
manufacturer's protocol. The absorbance of DNA solution was determined by 
spectrophotometer at 260nM wavelength and the concentration was determined 
using the following formula:
Concentration (fig/ml) = (A2m reading) x 50 x diiution factor 
1 absorbance unit (A260) = 50pg/ml of DNA
The PCR products purified from the agarose gel were sent to GATC-Biotech 
(Germany) for direct sequencing to confirm the identity of amplified products. 
The sequenced data was then downloaded from www.GATC-biotech.com.
The sequenced data was identified by comparison with genome database using 
the BLAST tool from NCBI website (http://blast.ncbi.nlm.nih.gov/blast.cgi) which 
is a basic logical alignment tool and finds regions of similarity between 
biological sequences.
6.3.2 Immunohistochemistry for detection of c-kit protein 
expression in rat urinary bladder
6.3.2.1 Tissue Preparation
Immunohistochemistry to identify c-kit expression in the rat urinary bladder was 
carried out according to that described by McCloskey & Gurney (2002), with 
modifications.
Whole mount preparations of the bladder from control (non-diabetic) rats were 
prepared for immunohistochemistry. Briefly, the bladder was cut into two 
longitudinal sections. The top and the bottom of each longitudinal strip were 
removed and the mucosa was removed by dissection with curved scissors. 
Bladder preparations were fixed in ice cold acetone for 10mins followed by 
3x5min washes in PBS (phosphate buffered saline) (Sigma, Dorset, UK). 
Tissues were blocked for 1-hour in PBS containing 1%(v/v) donkey serum 
(Sigma, Dorset, UK) before being incubated with 1:200 v/v of anti c-kit goat
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polyclonal IgG primary antibody (C-19)(Santa-Cruz, Heidelberg, Germany) 
diluted in PBS containing 1% donkey serum for 1 hour at room temperature. For 
negative controls, tissues were incubated in PBS containing 1% donkey serum 
only. Following incubation with the primary antibody, tissues were washed 
3x10mins with PBS, and were then incubated with the secondary donkey anti 
goat IgG fluorescent antibody (Alexa 488) (Invitrogen, Paisely, UK) diluted 
(1pg/ml) in PBS containing 5% donkey serum and 0.05% (v/v) Tween, for 1.5 
hour at room temperature. After 3x5min washes in PBS, tissues were mounted 
on L-polylysine-coated slides using aqueous mounting media (70% Glycerol / 
30% PBS).
6.3.2.2 Confocal image analysis
Images were captured using a Zeiss 510 confocal scanning laser microscope 
equipped with krypton/ argon laser as the source of the ion beam. Alexa 488 
labeled antibodies were visualised by excitation at 488nm with a 506-538 band­
pass emission filter. Acquiring 10-20 optical sections in the Z-plane and running 
the series-scanning mode from the deepest focus point to the highest focus 
point allowed a projected image and data set to be generated from which 
composite projected images were saved. Images were analysed using Zeiss 
LSM5 software.
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6.3.3 Functional investigation of the role of ICs in mediating 
SA of detrusor strips from control (non-diabetic) and diabetic rats
Longitudinal mucosa-intact and denuded strips of smooth muscle (2-4 x 6- 
12mm) were isolated from the body of rat bladders from, 1-week, 4-week, and 
12-week diabetic animals and their age-matched controls (non-diabetics), and 
suspended in 15ml organ baths as described in chapter 2. Following 
equilibration (60mins in Krebs), tissues were stimulated with 0.1 pM CCH to 
induce SA as previously described by Ng et al (2006). In the continuous 
presence of CCH, increasing cumulative concentrations of Glivec (1-50pM) 
were added to the tissues and the effects of this drug on the amplitude and the 
frequency of SA was assessed. The tissues were incubated with each 
concentration of Glivec for a period of 10-15mins.
6.3.3.1 Data analysis
To calculate the amplitude and the frequency of SA, a slightly modified method 
to that proposed by Imai et al (2001) was used to define a single spontaneous 
contraction event, as described in section 4.3.3. SA was expressed as the 
mean contraction amplitude/mg tissue and frequency ± SEM during a 5mins 
period within a 10-15mins interval. The percentage change in the amplitude and 
the frequency of SA at each concentration of Glivec relative to that of SA in the 
absence of Glivec i.e. in the presence of 0.1 pM CCH only, was calculated for 
both control (non-diabetic) and diabetic tissues.
6.3.3.2 Statistical analysis
Statistical analysis was performed using repeated measures ANOVA followed 
by Dunnett’s post hoc test for intra-tissue variations and unpaired Student’s t- 
test for inter-tissue variations.
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6.4 Results
6.4.1 Investigation of c-kit expression in rat bladder using 
PCR
6.4.1.1 Identification of c-kit gene expression in control (non-diabetic) 
and diabetic rat bladders.
RT-PCR revealed the expression of c-kit in cDNA samples from both control 
(non-diabetic) and 1-week diabetic rat bladders, at the expected product size of 
480bp (Figure 61). The expression of GAPDH was also confirmed in the cDNA 
samples by observing a band at ^ITObp.
500bp
400bp
200bp
100bp
GAPDH
Figure 61) c-DNA samples from control (non-diabetic) and 1-week diabetic rat bladders 
amplified with c-kit primers. The gel shows amplified products of c-kit and GAPDH. Lane 1: 
100bp ladder. Lane 2: Positive control amplified with GAPDH primers (*171 bp). Lane 3: 
negative control (water). Lane 4: 1-week diabetic rat bladder sample amplified with c-kit primers 
(=480bp). Lane 5: Control (non-diabetic) rat bladder sample amplified with c-kit primers.
6.4.1.2 Sequencing of the PCR products for confirmation of c-kit 
expression in rat urinary bladder
PCR products from both control (non-diabetic) and 1-week diabetic rat bladder 
samples amplified with c-kit primers were isolated from the gel and dispatched 
to GATC-biotech for direct sequencing. Partial sequences (272bp for 1-week
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diabetic and 113bp for control (non-diabetic) samples) obtained from the direct 
sequencing showed homology with R.rattus mRNA for c-kit receptor tyrosine 
kinase isoform (accession no: D12524.1) confirming the expression of c-kit 
tyrosine receptor kinase in rat urinary bladder (Figure 62).
c
24 b lCAGGAATATCCTCCTCACTCACGGGCGGATCACAAAGATTTGCGATTTCGGCCTAGCCAGAGACATC
a g g a a t g a t t c g a a t t a c g t g g t a a a a g g a a a t g c a c g g c t g c c c g t g a a g t g g a t g g c a c c g g a g a g c a
TTTTCAACTGCGTGTACACATTTGAAAGTGACGTCTGGTCCTATGGGATTTTCCTCTGGGAGCTATTCTC
TCTAGGAAGCAGCCCCTACCCAGGGATGCCGGTCGATTCCAAGTTTTACAAGATGATCAAGGAAGGTTTC
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Figure 62) Partial sequence of Rattus norvegicus mRNA for c-kit gene amplified by 
designed primers in control (non-diabetic) (C) and 1-week diabetic rat bladder samples.
Amplified mRNA sequence with c-kit primers is highlighted in Grey. Bases of the c-kit primers 
are in red. The sequenced product sent back by GATC-biotech is indicated in blue.
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6.4.2 Immunohistochemistry for detection of c-kit protein
expression in rat urinary bladder
Using immunohistochemistry, a network of c-kit-positive cells could be identified 
in the rat urinary bladder. Figures 63 and 64 demonstrate immunostaining for c- 
kit on a network of connected cells on the edge, as well as between smooth 
muscle bundles in the rat urinary bladder. No immunostaining for c-kit could be 
seen in the negative control (minus the primary antibody) (Figure 63).
Figure 63) c-kit positive cells in the rat urinary bladder. Whole mount denuded preparations 
of control (non-diabetic) rat bladder blocked with donkey 1% serum and incubated overnight 
with 1:50 dilution of c-Kit antibody (C-19). i) c-kit immunoreactivity can be seen as a network of 
cells within the rat detrusor, ii) A c-kit positive cell with elongated cell body and several slender 
processes, iii) c-kit positive cells found between smooth muscle bundles iv) Negative control.
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Figure 64) C-kit positive cells in rat urinary bladder. Whole mount denuded preparations of 
control (non-diabetic) rat bladder blocked in donkey 1% serum and incubated with 1:50 dilution 
of c-kit antibody (C-19) overnight. White arrows indicate the c-kit positive cells between (i, ii & iv) 
smooth muscle bundles and (iii) outside of smooth muscle bundles.
6.4.3 Induction of spontaneous activity by CCH in bladder 
strips from control (non-diabetic) and diabetic rats.
The non-selective muscarinic agonist CCH (0.1 pM) induced spontaneous 
contractions in bladder strips from control (non-diabetic) and diabetic rats 
(Figure 65).
As demonstrated in Figure 66, the amplitude/mg tissue of SA in 1-week 
diabetic tissues was significantly greater than in the age-matched controls 
(non-diabetic) group. There was no significant difference in the amplitude of 
CCH-stimulated SA of the detrusor strips from 4-week and 12-week diabetic 
rats vs. their aged matched control (non-diabetic) tissues.
In contrast to amplitude, the frequency of SA in 1-week diabetic tissues was 
significantly less than in the age-matched control (non-diabetic) tissues. 
However, no significant difference was seen between 4-week diabetics and 
12-week diabetic tissues vs. their aged matched control (non-diabetic) tissues.
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Figure 65) Typical recordings of spontaneous activity induced by 0.1pM CCH in control 
(non-diabetic) (C) and diabetic (D) bladder strips.
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Figure 66) The amplitude and frequency of SA in detrusor strips from diabetic (D) and 
age-matched control (non-diabetic) rats (C) upon stimulation with 0.1 pM CCH. * p<0.05, 
*** p<0.001 vs. the relevant age-matched control (non-diabetic) groups (unpaired t-test). Data is 
presented as mean±SEM. .
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6.4.4 Functional investigation of the role of ICs in mediating
the SA of detrusor strips from control (non-diabetic) and diabetic 
rats
Glivec inhibited the amplitude and frequency of CCH-induced SA in a 
concentration-dependent manner. Typical chart recordings of the effect of 
Glivec on CCH-induced SA in control (non-diabetic) and 1-week, 4-week and 
12-week diabetic bladder strips are demonstrated in Figure 67.
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0.1 hM CCH 10pM Glivec
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Figure 67) Typical chart recordings of the effect of increasing concentrations of Glivec 
and vehicle (H20 ) on CCH-induced SA in detrusor strips from representative control 
(non-diabetic) (C) & diabetic (D) rats.
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The effect of vehicle (time control) was non significant in all groups (Figure 67).
6.4.4.1 Effects of Glivec on CCH-stimulated SA in detrusor strips from 
1-week diabetic rats
Glivec significantly inhibited the amplitude of SA in detrusor strips from 1-week 
diabetic and aged-matched control (non-diabetic) rats at all concentrations 
(Figure 68).
Glivec also significantly inhibited the frequency of SA in detrusor strips from 
control (non-diabetic) animals at all concentrations (Figure 68). However, in 1- 
week diabetic tissues, only 10pM and 50pM Glivec significantly inhibited the 
frequency of SA (Figure 68).
When the amplitude of SA at each concentration of Glivec was calculated as a 
percentage inhibition relative to SA in the absence of Glivec (i.e. 0.1 pM CCH 
only), there was no significant difference between control (non-diabetic) and 
diabetic tissues (Figure 69).
When the reduction in the frequency was calculated as a percentage inhibition 
relative to SA in the absence of Glivec (i.e. 0.1 pM CCH only), there was a 
significant difference between control and diabetic tissues only at 10pM Glivec 
(Figure 69).
6.4.4.2 Effects of Glivec on CCH-stimulated SA in detrusor strips from 
4-week diabetic rats
Glivec significantly decreased the amplitude of SA in age-matched control (non­
diabetic) tissues at all concentrations apart from 1pM (Figure 70). In 4-week 
diabetic tissues Glivec significantly decreased the amplitude of SA only at 10pM 
and 50pM (Figure 70).
A significant decrease in the frequency of SA in 4-week control (non-diabetic) 
tissues was detected at all concentrations of Glivec apart from 1pM (Figure 70). 
However, Glivec only had a significant effect on the frequency of SA in 4-week 
diabetic tissues at the highest concentration tested (i.e. 50pM) (Figure 70).
When the amplitude of SA at each concentration of Glivec was calculated as a 
percentage inhibition relative to SA in the absence of Glivec (i.e. 0.1 pM CCH
2 0 6
only), there was no significant difference between control (non-diabetic) and 
diabetic tissues (Figure 71).
When the reduction in the frequency was calculated as a percentage inhibition 
relative to the SA in the absence of Glivec (i.e. 0.1 pM CCH only), there was a 
significant difference between control (non-diabetic) and diabetic tissues only at 
5pM Glivec (Figure 71).
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Figure 68) Effect of increasing concentrations of Glivec on the amplitude and the 
frequency of SA induced by 0.1 pM CCH in control (non-diabetic) (C) & 1-week diabetic (D) 
tissues. C: n=17 (top-panel) & 1-week D: n=15 (lower panel). *p<0.05 & **p<0.01 vs. 0.1 pM 
CCH response in absence of Glivec. Data is presented as mean±SEM.
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Figure 69) Percentage decrease in the amplitude and the frequency of SA in detrusor 
strips from control (non-diabetic) versus 1-week diabetic (non-diabetic) rats in presence 
of Glivec. i) Percentage decrease in amplitude & ii) percentage decrease in frequency. *p<0.05 
vs. the control (non-diabetic) tissues. Data is presented as mean±SEM.
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Figure 70) Effect of increasing concentrations of Glivec on the amplitude and the 
frequency of SA induced by 0.1 pM CCH in control (non-diabetic) (C) & 4-week diabetic (D) 
tissues. C: n=13 (top-panel) & 4-week D: n=8 (lower panel) **p<0.01 vs. 0.1 pM CCH response 
in absence of Glivec. Data is presented as mean±SEM
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6.4.4.3 Effects of Glivec on CCH-stimulated SA in detrusor strips from 
12-week diabetic rats
Glivec significantly decreased the amplitude of SA in age-matched control (non­
diabetic) tissues at all concentrations apart from 1pM (Figure 72). However, 
Glivec significantly decreased the amplitude of SA in 12-week diabetic tissues 
only at 50pM.
10pM and 50pM Glivec decreased the frequency of SA in 12-week control (non­
diabetic) tissues (Figure 72). However, in 12-week diabetic tissues a significant 
effect on the frequency of SA was seen only at the highest concentration tested 
(i.e. 50pM).
When the percentage decrease in the amplitude of SA in the presence of all 
concentrations of Glivec relative to SA in the absence of Glivec (i.e. 0.1 pM CCH 
only) was compared, there was no significant difference between control and 
diabetic tissues (Figure 73).
When the reduction in the frequency was calculated as a percentage inhibition 
relative to the SA in the absence of Glivec (i.e. 0.1 pM CCH only), there was no 
significant difference between control and diabetic tissues (Figure 73).
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6.4.5 The role of the mucosa on the inhibitory action of Glivec 
on CCH-stimulated SA in detrusor strips from the rat.
To examine whether the urothelium plays a role in mediating the inhibitory 
responses to Glivec, the effect of increasing concentrations of this drug on 
CCH-stimulated SA was compared in mucosa-intact and denuded detrusor 
strips from control (non-diabetic) and 1-week diabetic rats.
The changes in the amplitude and the frequency of CCH-stimulated 
spontaneous contractions in the presence of Glivec were compared between 
mucosa-intact and denuded detrusor strips from control (non-diabetic) animals. 
The mucosa had no significant effect on the changes in amplitude and 
frequency of SA in the presence of increasing concentrations of Glivec (Figure 
74).
In 1-week diabetic rats, the mucosa also had no significant effect on the 
changes in amplitude and the frequency of SA in the presence of increasing 
concentrations of Glivec (Figure 75).
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6.5 Discussion
It is speculated that in addition to structural and functional changes to nerve and 
muscle in DO, alterations may also occur in the network of ICs in the bladder, 
leading to increased bladder sensation and afferent output from the detrusor 
and subsequent symptoms of urgency and frequency (De Jongh et al, 2007). 
Since in the detrusor of the STZ-diabetic rat, increased basal and CCH-induced 
SA was seen, it was postulated that ICs may be present in the rat urinary 
bladder and their function might be changed in the diabetic state, accounting for 
these changes in the SA. Since no studies have so far reported the existence of 
ICs in the rat urinary bladder, the first aim of this chapter was to identify the 
expression of the c-kit gene, the proto-oncogene that encodes the tyrosine 
receptor kinase c-kit, which is a specific marker for these cells.
6.5.1 Identification of c-kit positive cells in the rat urinary
bladder
Amplified products obtained from RT-PCR experiments showed homology to 
the Rattus norvegicus c-kit receptor tyrosine kinase gene, confirming c-kit 
mRNA expression in the rat urinary bladder, c-kit positive cells were also 
identified in the rat urinary bladder by use of immunohistochemistry. c-kit 
immunoreactivity was detected on a network of cells between smooth muscle 
bundles and at the edge of the bundles. Thus, using the current data, it can be 
confirmed that c-kit positive cells are present between smooth muscle bundles 
(interbundle interstitial cells (IC-IB)) as well as on the boundary of the bundles 
(intramuscular IC (IC-IM)) in the rat urinary bladder. Morphological studies on 
guinea-pig and human bladders have similarly identified ICs on the boundary of 
smooth muscle bundles (IC-IMs) and in the spaces between the bundles (IC- 
IBs) (McCloskey & Gurney, 2002; Van der AA et al, 2004; Shafik et al, 2004). In 
addition, these studies have confirmed the presence of ICs in the 
suburothelium/lamina propria region. We were unable to confirm this in the 
present chapter due to removal of the mucosal layer. Although care was taken 
during the course of the experiments to maintain the orientation of the tissues, it 
was difficult to be absolutely certain about the presence of ICs in the sub­
mucosa and the wall of the urinary bladder, and thus caution was taken on 
concluding the location of ICs in rat urinary bladder, other than their immediate
detected sites within the bladder wall. However, the presence of ICs in the sub­
mucosa and on the outer wall of rat bladder can not be ruled out.
6.5.2 Functional investigation of the role of ICs in mediating
the SA of detrusor strips from control (non-diabetic) and diabetic 
rats
To investigate the role of ICs in mediating the spontaneous contractions of rat 
bladder detrusor, in vitro functional pharmacological studies using Glivec (a c-kit 
tyrosine kinase inhibitor) were performed. As both development and 
maintenance of ICs require c-kit, Glivec can be used as a specific blocker for 
the function of ICs and allows characterisation of the role of these cells in 
mediating detrusor spontaneous contractility.
SA was induced in detrusor strips from control (non-diabetic) and diabetic 
bladders by a low concentration of CCH (0.1 pM). In response to the low 
concentration of CCH, there was a significant increase in the amplitude and a 
decrease in the frequency of spontaneous contractions respectively in 1-week 
diabetic tissues compared to their aged-matched controls (non-diabetics), 
further confirming the results observed in chapter 4.
Following induction of SA, increasing concentrations of Glivec were added to 
the tissues to assess the effect of this drug in mediating the spontaneous 
detrusor contractions. Glivec inhibited the amplitude and frequency of SA in a 
concentration-dependent manner in both control (non-diabetic) and diabetic 
tissues, confirming a role for c-kit positive cells in mediating SA in rat bladder 
detrusor.
Glivec has been shown to suppress contractile activity in various phasic smooth 
muscles, including guinea-pig bladder (Kubota et al, 2004, 2006), stomach 
(Hashitani et al, 2008) and gallbladder (Lavoie et al, 2007); mouse small 
intestine (Shimojima et al, 2005); human uterus and small intestine (Popescue 
et a l , 2006); and human bladder (Biers et al, 2006). However, there are reports 
questioning the specificity of Glivec, particularly at the higher concentrations of 
this drug. Some studies have suggested that acute application of Glivec in vitro 
is unlikely to suppress IC activity through its inhibition of c-kit signalling, and 
instead Glivec may suppress SA of the guinea-pig stomach by inhibiting
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G liv e c  is  in d e e d  a c t in g  v ia  in h ib it io n  o f  th e  c -k it  ty ro s in e  k in a s e  re c e p to r .
H o w e v e r , it is  p o s s ib le  th a t  G liv e c  m a y  a c t o n  o th e r  re c e p to rs  a n d  c e ll ty p e s  
p re s e n t w ith in  th e  t is s u e  a n d  th a t  th is  m a y  re s u lt  in  th e  d i f fe re n c e s  in  th e  
s e n s it iv it ie s  o f  v a r io u s  t is s u e s  to  th e  d ru g . It is  k n o w n  th a t  G liv e c  c a n  in h ib it  n o t 
o n ly  th e  c -k it  ty ro s in e  k in a s e  re c e p to r  b u t a ls o  P D G F R  a n d  m a s t c e lls  (w h ic h  
h a v e  b e e n  s h o w n  to  e x p re s s  c -k it )  (P o p e s c u e  et al, 2 0 0 6 ) . S ig n a l lin g  th ro u g h  
th e  P D G F R  is  a p o te n t  a c t iv a to r  o f  D N A  s y n th e s is  in  b la d d e r  s m o o th  m u s c le  
(A d a m , 2 0 0 6 ) , w h e re a s  m a s t  c e lls  a re  im p o r ta n t  in  in te rs t it ia l c y s t it is ,  in  w h ic h  
th e ir  n u m b e r  in c re a s e s  (B o u c h e r  et al, 1 9 9 5 ). In  o rd e r  to  ru le  o u t  th e  ro le  o f  
P D G F R  in  m e d ia t in g  th e  c o n tra c t i le  a c t iv i ty  o f  s m o o th  m u s c le  t is s u e s ,  
P o p e s c u e  et al (2 0 0 6 ) , h a v e  u s e d  n e u tra lis in g  a n t ib o d ie s  a g a in s t  P D G F R  to  
re d u c e  th e  a c t iv i ty  o f  th is  re c e p to r . It w a s  fo u n d  th a t  th e s e  a n t ib o d ie s  d o  n o t 
h a v e  a n  e f fe c t  o n  u te r in e  s m o o th  m u s c le  S A . T h e y  a ls o  ru le d  o u t  th e  ro le  o f  
m a s t c e lls  in  g e n e ra t io n  o f  S A  in  h u m a n  m y o m e tr iu m  b y  u s e  o f  K e to t ife n  (a n  
in h ib ito r  o f  d e g ra n u la t io n  o f  th e s e  c e lls ) .  It w a s  th e n  s u g g e s te d  th a t  th e  
in h ib ito ry  e f fe c t  o f  G liv e c  o n  S A  is  m e d ia te d  v ia  o th e r  m e a n s  (B ie rs  et al, 2 0 0 6 ; 
P ro p e s c u  et al, 2 0 0 6 ) . In  o rd e r  to  ru le  o u t  w h e th e r  s o m e  o f  th e  e f fe c t  o f  G liv e c  
o n  U B S M  S A  in  th e  p re s e n t  s tu d y  is  m e d ia te d  th ro u g h  P D G F R s  a n d  m a s t c e lls , 
fu r th e r  e x p e r im e n ts ,  u s in g  s p e c if ic  in h ib ito rs  o f  th e s e  w o u ld  b e  n e e d e d .
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6.5.3 Comparison of the effect of Glivec in inhibition of SA in
detrusor strips from control (non-diabetic) and diabetic animals.
G liv e c  re d u c e d  th e  a m p litu d e  a n d  th e  f r e q u e n c y  o f  S A  in  c o n tro l (n o n -d ia b e t ic )  
a n d  d ia b e t ic  t is s u e s  in  a c o n c e n tr a t io n -d e p e n d e n t  m a n n e r . H o w e v e r ,  a lth o u g h  
n o n -s ig n if ic a n t ,  d e t r u s o r  s tr ip s  fro m  a ll d ia b e t ic  g ro u p s  s h o w e d  a t re n d  to w a rd s  
b e in g  le s s  s e n s it iv e  to  G liv e c  th a n  th e  c o n tro l (n o n -d ia b e t ic )  t is s u e s . In c o n tra s t  
to  th is , s tu d ie s  in v e s t ig a t in g  th e  s p o n ta n e o u s  c o n tra c t io n s  o f  h u m a n  o v e ra c t iv e  
d e tru s o rs  h a v e  s h o w n  th a t  G liv e c  h a s  a m o re  p ro fo u n d  e f fe c t  in re d u c in g  th e  
S A  in  o v e ra c t iv e  d e t r u s o r  th a n  n o rm a l t is s u e s  (B ie rs  et al, 2 0 0 6 ) .  In  a s tu d y  b y  
S u i et al (2 0 0 8 ) , G liv e c  a ls o  re d u c e d  th e  S A  in b la d d e r  s h e e ts  fro m  s p in a l c o rd -  
t r a n s e c te d  (S C T ) ra ts , b u t n o t in  n o rm a l ra ts . T h e  re a s o n  fo r  th e s e  
d is c re p a n c ie s  is  n o t  c le a r , a l th o u g h  it m a y  b e  d u e  to  s p e c ie s  a n d  m o d e l 
d if fe re n c e s , a s  w e ll a s  d iv e rs ity  in th e  e x p e r im e n ta l p ro c e d u re s  a n d  t is s u e  
p re p a ra t io n  te c h n iq u e s .  F o r  e x a m p le  in  th e  s tu d y  b y  S u i et al (2 0 0 8 ) , th e  e f fe c t  
o f  a s in g le  d o s e  o f  G liv e c  (3 0 p M ) o n  re d u c t io n  o f  b a s a l S A  in  s h e e ts  o f  ra t 
w h o le  b la d d e r  w a s  a s s e s s e d , w h ils t  in  th e  p re s e n t  s tu d y  th e  e f fe c t  o f  in c re a s in g  
c o n c e n tra t io n s  o f  G liv e c  o n  C C H -s t im u la te d  S A  w a s  m e a s u re d . A ls o  c h a n g e s  
in  th e  d if fu s ib i l i ty  o f  th e  d ru g  in  th e  d ia b e t ic  ra t  d e tru s o r  a s  a re s u lt  o f  in c re a s e d  
b la d d e r  m a s s  m ig h t re n d e r  th e s e  t is s u e s  re la t iv e ly  in s e n s it iv e  to  G liv e c , 
a lth o u g h  th e re  is  n o  d a ta  in  th e  lite ra tu re  to  s u g g e s t  th is . In  a d d it io n ,  a ll t is s u e s  
w e re  e x p o s e d  to  e a c h  c o n c e n tra t io n  o f  G liv e c  fo r  o n ly  1 0 m in s  b e fo re  th e  n e x t 
c o n c e n tra t io n  o f  d ru g  w a s  a d d e d . T h is  m a y  n o t b e  a s u f f ic ie n t  le n g th  o f  t im e  fo r  
G liv e c  to  h a v e  a n  e f fe c t  o n  th e  d ia b e t ic  b la d d e rs . D if fe re n c e s  in  th e  s e n s it iv ity  o f  
n o rm a l a n d  o v e ra c t iv e  d e tru s o r  fro m  v a r io u s  s p e c ie s  to  G liv e c  m a y  a ls o  b e  
e x p la in e d  b y  th e  p ro p o s e d  n o n -s p e c if ic  a c t io n s  o f  G liv e c , s u c h  a s  in h ib it io n  o f  
V D C C s  a n d  K +-s e le c t iv e  o u tw a rd  c u r re n ts  a n d /o r  b y  a n  in h ib ito ry  e f fe c t  o n  o th e r  
p a r t ic ip a t in g  c e lls  (e .g . m a s t c e lls )  a n d  re c e p to rs  (P D G F R ) w ith in  th e  d e tr u s o r  
w h ic h  m a y  h a v e  b e e n  a lte re d  a s  a re s u lt  o f  b la d d e r  d y s fu n c t io n .
T h e  t re n d  to w a rd s  a re d u c e d  s e n s it iv ity  o f  d ia b e t ic  t is s u e s  to  G liv e c  c o u ld  a ls o  
b e  d u e  to  a  re d u c t io n  in  th e  p o p u la t io n  o f  IC s , o r  c h a n g e s  in  th e  lo c a t io n  o f  
th e s e  c e lls  in  th e  ra t b la d d e r , re s u lt in g  in  fe w e r , o r  a lte re d , a v a i la b le  ta r g e ts  fo r  
G liv e c . In p re v io u s  s tu d ie s  (K a n a i et al, 2 0 0 7 ; S u i et al, 2 0 0 8 ; K u b o ta  et al,
2 0 0 8 )  it h a s  b e e n  p ro p o s e d  th a t  IC s  p ro v id e  th e  fo c u s  fo r  g e n e ra t io n  o f  S A  a n d  
th a t  a n  in c re a s e  in  th e ir  n u m b e r  w o u ld  e n h a n c e  th is  c o o rd in a t io n .  A  d e c re a s e  in
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th e ir  n u m b e r  m a y  a ls o  le a d  to  d e c re a s e d  S A  a n d  s e n s it iv ity  to  G liv e c . H o w e v e r ,  
th e  p o p u la t io n  o f  IC s  in  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  ra t  b la d d e rs  w e re  n o t 
in v e s t ig a te d  in  th is  s tu d y  a n d  th u s  fu r th e r  c o n c lu s io n s  o f  th e  ro le  o f  a lte re d  
p o p u la t io n  o f  th e s e  c e lls  in  th e  d ia b e t ic  ra t  b la d d e r  c a n  n o t b e  m a d e .
R e m o v a l o f  th e  u ro th e liu m /m u c o s a  fro m  c o n tro l (n o n -d ia b e t ic )  a n d  1 -w e e k  
d ia b e t ic  ra t  b la d d e rs  d id  n o t h a v e  a  s ig n if ic a n t  e f fe c t  o n  th e  re s p o n s iv e n e s s  a n d  
s e n s it iv ity  o f  d e tru s o r  s tr ip s  to  G liv e c . T h is  m a y  s u g g e s t  th a t  re m o v a l o f  th e  
m u c o s a  d o e s  n o t e f fe c t  th e  p o p u la t io n  o f  c -k it  p o s it iv e  IC s  a n d  th a t  in  th e  ra t 
u r in a ry  b la d d e r  th e  ta rg e ts  o f  G liv e c  a re  s itu a te d  e ls e w h e re . T h is  h y p o th e s is  is  
s u p p o r te d  b y  th e  s tu d ie s  th a t  s u g g e s t  th a t  IC s  in  th e  b la d d e r  b e lo n g  to  
m u lt ip o te n t  g ro u p  o f  fu n c t io n a l re g u la to ry  c e lls  ( re v ie w e d  b y  D ra k e  et al, 2 0 0 6 ) . 
It h a s  b e e n  d e m o n s tra te d  th a t  th e  s u b u ro th e lia l IC s /m y o f ib ro b la s ts  h a v e  
im m u n o re a c t iv i ty  fo r  v im e n t in  a n d  c o n n e x in  4 3  ( r e v ie w e d  b y  D ra k e  et al, 2 0 0 6 ; 
R o o s e n  et al, 2 0 0 8 ) . S o m e  o f  v im e n t in  p o s it iv e  c e lls  b e n e a th  th e  u ro th e liu m  a re  
c -k it  p o s it iv e  b u t a re  to o  s p a rs e ly  d is tr ib u te d .  O th e r  c -k it  p o s it iv e  IC s  a re  fo u n d  
b e tw e e n  s m o o th  m u s c le  b u n d le s  w h e re  th e y  a re  b e lie v e d  to  p re c ip ita te  c a lc iu m  
w a v e s  a n d  g e n e ra t io n  o f  p a c e m a k in g  a c t iv i ty  ( r e v ie w e d  b y  D ra k e  et al, 2 0 0 8 ) . 
In  th is  s tu d y , w e  d id  n o t m a n a g e  to  c h a ra c te r is e  th e  IC s  in  th e  s u b u ro th e liu m  o f  
th e  ra t  b la d d e r  b u t th e  d a ta  fro m  th e  e f fe c t  o f  G liv e c  o n  d e n u d e d  s tr ip s  a s  w e ll 
a s  im m u n o h is to c h e m is tr y  d a ta  s u g g e s ts  th a t  c -k it  p o s it iv e  IC s , w h ic h  a re  th e  
ta rg e ts  fo r  th e  in h ib ito ry  e f fe c t  o f  G liv e c , m a y  b e  s itu a te d  b e tw e e n  s m o o th  
m u s c le  b u n d le s  a s  w e ll a s  b e tw e e n  s m o o th  m u s c le  c e lls  ra th e r  th a n  in  th e  
s u b u ro th e lia l re g io n . F u r th e r  c h a ra c te r is a t io n  o f  th e s e  c e lls  u s in g  P C R  to  
in v e s t ig a te  th e  e x p re s s io n  o f  c -k it  in th e  m u c o s a  a s  w e ll  a s
im m u n o h is to c h e m is tr y  w o u ld  a id  u n d e rs ta n d in g  o f  th e  ro le  a n d  lo c a t io n  o f  IC s  in  
th e  ra t b la d d e r .
2 2 2
6.6 Summary
In  th is  c h a p te r , th e  p re s e n c e  o f  IC s  w a s  c o n f irm e d  in  th e  ra t u r in a ry  b la d d e r  b y  
d e m o n s tra t in g  th e  e x p re s s io n  o f  c -k it  m R N A  a n d  its  p ro te in  p ro d u c t ,  c -k it ,  (a 
s p e c if ic  m a rk e r  o f  IC s ) b y  m e a n s  R T -P C R  a n d  im m u n o h is to c h e m is tr y .
T h e  fu n c t io n a l ro le  o f  th e s e  c e lls  in  m e d ia t in g  ra t d e t r u s o r  S A  w a s  c o n f irm e d  b y  
th e  u s e  o f  th e  ty ro s in e  k in a s e  in h ib ito r  G liv e c , u s in g  in vitro t is s u e  b a th  
e x p e r im e n ts .  G liv e c  in h ib ite d  b o th  th e  a m p litu d e  a n d  th e  f r e q u e n c y  o f  S A  in 
c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  t is s u e s . D ia b e t ic  t is s u e s  w e re  s lig h t ly , 
a lth o u g h  n o t s ig n if ic a n t ly ,  le s s  s e n s it iv e  to  G liv e c .
T h e  re m o v a l o f  th e  m u c o s a  h a d  n o  e f fe c t  o n  th e  s e n s it iv ity  o f  c o n tro l (n o n ­
d ia b e t ic )  a n d  d ia b e t ic  t is s u e s  to  G liv e c .
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Chapter 7: General 
discussion
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In  re c e n t  d e c a d e s , o n e  o f  th e  m a jo r  fo rc e s  d r iv in g  lo w e r  u r in a ry  t r a c t  re s e a rc h  
h a s  b e e n  th e  a im  o f  d is c o v e r in g  th e  o r ig in s  o f  d e tru s o r  o v e ra c t iv i ty  (D O ) a n d  
o v e ra c t iv e  b la d d e r  s y n d ro m e  (O A B S ) , a s  w e ll a s  e f fe c t iv e  w a y s  to  t r e a t  th e s e  
c o n d it io n s  (G il le s p ie , 2 0 0 5 ) . T h e  c o n s e q u e n c e  o f  th e s e  s tu d ie s  h a s  b e e n  th e  
e m e rg e n c e  o f  n e w  in s ig h ts  in to  th e  p h y s io lo g ic a l fa c to rs  c o n tro ll in g  th e  h u m a n  
b la d d e r . It is  n o w  b e c o m in g  c le a r  th a t  th e  g e n e ra l v ie w  o f  th e  c o n tro l o f  b la d d e r  
fu n c t io n  is  fa r  m o re  c o m p lic a te d  th a n  o n c e  th o u g h t  a n d  in v o lv e s  c o m p le x  
in te ra c t io n s  b e tw e e n  s m o o th  m u s c le  c e lls , u ro th e liu m , s u b u ro th e lia l 
m y o f ib ro b la s ts ,  in te rs t it ia l c e lls  ( IC s )  a n d  s e n s o ry  n e rv e s . T h e s e  c o m p le x  
in te ra c t io n s  m u s t b e  e x p lo re d  a n d  ta k e n  in to  a c c o u n t,  e s p e c ia l ly  w h e n  
c o n s id e r in g  n e w  th e r a p e u t ic  ta rg e ts  fo r  t r e a tm e n t  o f  b la d d e r  d y s fu n c t io n .  O n e  
e x a m p le  o f  th is  is  th e  d e v e lo p m e n t  o f  a n t im u s c a r in ic  d ru g s  to  t r e a t  D O  a n d  
u rg e n c y . T h e  in it ia l c l in ic a l ra t io n a le  fo r  u s in g  th e s e  a g e n ts  w a s  th a t  th e y  
e x e r te d  th e ir  e f fe c ts  b y  a c t in g  s o le ly  o n  m u s c a r in ic  re c e p to rs  o f  th e  u r in a ry  
b la d d e r  s m o o th  m u s c le  (U B S M ), a n d  it w a s  th o u g h t  th a t  a lte ra t io n s  in  th e s e  
re c e p to rs  m a y  o c c u r  in  b la d d e r  d y s fu n c t io n  a s s o c ia te d  w ith  D O . T h is  c o n c e p t  
h a s  n o w  b e c o m e  c o n tro v e rs ia l a n d  re c e n t ly  it h a s  b e e n  h y p o th e s is e d  th a t  
a n t im u s c a r in ic  d ru g s  m a y  a c t v ia  o th e r  m e c h a n is m s  re la te d  to  th e  a f fe re n t  
m e c h a n o s e n s o ry  p a th w a y s  ra th e r  th a n  th e  e f fe re n t  s y s te m .
O th e r  e x a m p le s  o f  th e  o v e rs im p lif ie d  v ie w  o f  b la d d e r  fu n c t io n  in c lu d e  th e  la c k  o f  
c le a r  p h y s io lo g ic a l ro le s  fo r  p u r in e rg ic ,  a d re n e rg ic ,  n it re rg ic  n e rv e s , th e  
in tra m u ra l a n d  p e lv ic  g a n g lia ,  th e  u ro th e liu m , io n  c h a n n e ls  a n d  s p e c ia lis e d  c e ll 
ty p e s  s u c h  a s  IC s . F o r a  fu ll p ic tu re  o f  th e  p h y s io lo g y  o f  th e  b la d d e r  a n d  its  
c o n tro l m e c h a n is m s , a ll o f  th e s e  c o m p o n e n t s y s te m s  s h o u ld  b e  c o n s id e re d .  In 
th is  re s p e c t, e x p e r im e n ts  u s in g  a n im a l m o d e l to  in v e s t ig a te  th e  in te g ra te d  
c o n tro l o f  b la d d e r  fu n c t io n  c a n  b e  e x tre m e ly  u s e fu l.  A  c o m m o n  a n im a l m o d e l to  
in v e s t ig a te  th e  p h y s io lo g y  a n d  th e  p a th o p h y s io lo g y  o f  u r in a ry  b la d d e r  
d y s fu n c t io n  a n d  D O  is  th e  s tre p to z o to c in  (S T Z ) -d ia b e t ic  ra t. T h is  a n im a l m o d e l 
w a s  u s e d  in  th e  p re s e n t  s tu d y , a t d if fe r e n t  d u ra t io n s  p o s t S T Z  in je c t io n  in  an  
a t te m p t to  u n d e rs ta n d  th e  u n d e r ly in g  m e c h a n is m s  m e d ia t in g  n o rm a l a n d  
a b n o rm a l d e tru s o r  c o n tra c t i l i ty .
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7.1 Cholinergic mediation of contractile function in rat
urinary bladder
A n t ic h o lin e rg ic  d ru g s  a re  th e  f ir s t  lin e  o f  p h a rm a c o th e ra p y  fo r  t r e a tm e n t  o f  D O  
a n d  c h a n g e s  in  e x p re s s io n  a n d  fu n c t io n  o f  m u s c a r in ic  re c e p to rs ,  w h ic h  m e d ia te  
th e  m a in  c o n tra c t i le  p a th w a y  o f  th e  d e tru s o r ,  h a v e  lo n g  b e e n  th o u g h t  to  be  
a s s o c ia te d  w ith  th e  p a th o lo g y  o f  D O . T h e re fo re ,  in a n  a t te m p t to  e lu c id a te  th e  
u n d e r ly in g  m e c h a n is m s  o f  b la d d e r  d y s fu n c t io n  in  th e  S T Z -d ia b e t ic  ra t, in  th e  
in it ia l s ta g e s  o f  th e  p re s e n t  s tu d y  (C h a p te r  3 ) th e  ro le  o f  m u s c a r in ic  r e c e p to r  
s u b ty p e s  in  m e d ia t in g  th e  d e tru s o r  c o n tra c t io n  w a s  in v e s t ig a te d . In  th e  c u r re n t  
s tu d y , a n  e n h a n c e d  c o n tra c t i le  re s p o n s e  to  c h o l in e rg ic  s t im u la t io n  w a s  o n ly  
d e te c te d  in 1 -w e e k  d ia b e t ic  ra ts , w ith  th e  d e tru s o r  s tr ip s  fro m  o th e r  d ia b e t ic  
g ro u p s  d e m o n s tra t in g  n o  c h a n g e  in  th e ir  s e n s it iv ity  o r  fu n c t io n a l re s p o n s e s  to  
c h o l in e rg ic  s t im u la t io n .  T h is  e n h a n c e d  fu n c t io n a l re s p o n s e  in  d e t r u s o r  s t r ip s  
fro m  1 -w e e k  d ia b e t ic  ra ts  w a s  m e d ia te d  v ia  th e  M 3 -m u s c a r in ic  r e c e p to r  s u b ty p e  
o n ly , s im ila r  to  c o n tro l (n o n -d ia b e t ic )  a n d  o th e r  d ia b e t ic  t is s u e s  (4 -w e e k , 8 -w e e k  
a n d  1 2 -w e e k  d ia b e t ic s ) ,  w ith  th e  ro le  o f  M 2 -m u s c a r in ic  r e c e p to r  re m a in in g  
u n c le a r . R e s u lts  o f  th is  th e s is  a re  in l in e  w ith  a re c e n t  s tu d y  in v e s t ig a t in g  th e  
ro le  o f  m u s c a r in ic  re c e p to r  s u b ty p e s  in  p a t ie n ts  w ith  id io p a th ic  D O  (S te v e n s  e t 
a l, 2 0 0 7 ) . In  th is  re c e n t  s tu d y  it w a s  d e m o n s tra te d  th a t  a lth o u g h  d e tr u s o r  fro m  
p a t ie n ts  w ith  id io p a th ic  D O  d e m o n s t ra te s  a n  e n h a n c e d  c o n tra c t i le  re s p o n s e  to  
c h o l in e rg ic  s t im u la t io n , th e  m a in  re c e p to r  m e d ia t in g  th e  d e tr u s o r  c o n tr a c t io n  is  
th e  M 3 -m u s c a r in ic  re c e p to r  s u b ty p e  (S te v e n s  e t a l, 2 0 0 7 ) .
A n  in c re a s e d  e x p re s s io n  o f  b o th  M 2 -  a n d  M 3 -m u s c a r in ic  r e c e p to rs  w a s  a ls o  
d e te c te d  a t th e  m R N A  le v e l in  b la d d e rs  fro m  1 -w e e k  d ia b e t ic  ra ts  w h ic h  c o u ld  
p o te n t ia l ly  e x p la in  th e  in c re a s e d  re s p o n s e s  to  c h o l in e rg ic  s t im u la t io n  in  th e s e  
t is s u e s . I f  th is  in c re a s e  in  e x p re s s io n  o f  b o th  M 2 -  a n d  M 3 -m u s c a r in ic  r e c e p to rs ’ 
m R N A  is  in d e e d  t r a n s la te d  a t th e  p ro te in  le v e l, it c o u ld  s h if t  th e  c o n tr a c t i le -  
re la x a n t  n e u ro lo g ic a l b a la n c e  to w a rd s  in c re a s e d  c o n tra c t i l i ty  in  th e s e  t is s u e s . 
H o w e v e r , c o n f irm a t io n  o f  th e  e x p re s s io n  o f  th e s e  re c e p to rs  a t th e  p ro te in  le v e l 
is  re q u ire d .
A s  d e s c r ib e d  e a r l ie r ,  it w a s  in it ia l ly  p o s tu la te d  th a t  a n t im u s c a r in ic  d ru g s  b lo c k e d  
m u s c a r in ic  re c e p to rs  o n  th e  d e tru s o r ,  w h ic h  a re  n o rm a lly  s t im u la te d  v ia
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a c e ty lc h o lin e  (A C H ) re le a s e d  fro m  p a ra s y m p a th e t ic  n e rv e s ; th e re b y  th e y  
d e c re a s e  th e  a b il i ty  o f  th e  b la d d e r  to  c o n tra c t.  H o w e v e r , it is  n o w  s p e c u la te d  
th a t  a n t im u s c a r in ic s  m ig h t h a v e  a p u ta t iv e  s e n s o ry  m o d e  o f  a c t io n  a n d  it is 
p o s s ib le  th a t  a t  le a s t p a r t  o f  th e  th e ra p e u t ic  e f fe c t  o f  th e s e  a g e n ts  c o u ld  b e  v ia  
m o d u la t io n  o f  s e n s o ry  p a th w a y s  (F in n e y  e t  a l, 2 0 0 6 ) ; e s p e c ia l ly  s in c e  n e w  
e v id e n c e  h a s  le d  to  th e  s u g g e s t io n  th a t  a n t im u s c a r in ic s  m a y  a c t b y  b in d in g  to  
m u s c a r in ic  re c e p to rs  w ith in  th e  m u c o s a  (M a n s f ie ld  e t  a l, 2 0 0 8 ) . It  h a s  b e e n  
p o s tu la te d  th a t  m u s c a r in ic  re c e p to rs  o n  th e  m u c o s a  a n d  th e  U B S M  c e l ls  a re  th e  
ta r g e t  o f  e n d o g e n o u s  A C H  re le a s e d  fro m  n o n -n e u ro n a l s o u rc e s  s u c h  a s  th e  
u ro th e liu m  (Y o s h im u ra  e t a l, 2 0 0 3 ; N g  e t a l, 2 0 0 6 ) . A c t iv a t io n  o f  th e  m u s c a r in ic  
re c e p to rs  w ith in  th e  b la d d e r  v ia  th is  e n d o g e n o u s  A C H  re le a s e  is  b e lie v e d  to  b e  
p a r t ly  re s p o n s ib le  fo r  g e n e ra t io n  o f  s p o n ta n e o u s  c o n tra c t io n s  d e te c te d  d u r in g  
th e  f i l l in g  p h a s e  o f  th e  m ic tu r it io n  c y c le . S p o n ta n e o u s  c o n tra c t io n s  o f  th e  u r in a ry  
b la d d e r  a re  b e lie v e d  to  be  im p o r ta n t  in m a in ta in in g  b la d d e r  to n e  u n d e r  n o rm a l 
c o n d it io n s , b u t a re  e n h a n c e d  in  p a th o lo g ic a l s ta te s  le a d in g  to  D O . T h e  o r ig in  o f  
s u c h  S A  a n d  th e  m e c h a n is m s  th a t  fa c i l ita te  it a re  u n k n o w n  a n d  m a y  b e  
c o o rd in a te d  b y  c o m p le x  in te ra c t io n s  b e tw e e n  s m o o th  m u s c le , u ro th e lia l,  
s u b u ro th e lia l c e lls  a n d  o th e r  n o n -n e u ro n a l s t r u c tu re s  w ith in  th e  b la d d e r  w a ll 
s u c h  a s  IC s . In  th is  s tu d y , d u r in g  th e  e q u i lib ra t io n  o f  in vitro is o la te d  d e t r u s o r  
s tr ip s , b o th  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  t is s u e s  d e m o n s t ra te d  b a s a l S A . 
T h e  a m p litu d e  o f  th is  b a s a l S A  w a s  s ig n if ic a n t ly  h ig h e r  in  1 -w e e k  d ia b e t ic  
t is s u e s  c o m p a re d  to  d e tru s o r  s tr ip s  fro m  c o n tro l (n o n -d ia b e t ic )  a n d  o th e r  
d ia b e t ic  (4 -w e e k , 8 -w e e k  a n d  1 2 -w e e k )  ra ts  w h ic h  m a y  d e m o n s t ra te  h y p e r ­
c o n tra c t i l i ty  o f  th e  b la d d e r  in  th e s e  ra ts . H o w e v e r , a t 1 2 -w e e k s  p o s t S T Z -  
in je c t io n , b a s a l S A  c o u ld  n o t b e  d e te c te d  in  th e  d ia b e t ic  t is s u e s  w h ic h  m a y  
re f le c t  h y p o -c o n t ra c t i l i ty  o f  th e  b la d d e r  in  th e s e  a n im a ls  (C h a p te r  4 ).
It h a s  p re v io u s ly  b e e n  re p o r te d  th a t  a tr o p in e  (a  n o n -s e le c t iv e  a n t im u s c a r in ic  
a g e n t)  c a n  in h ib it  th e  S A  o f  d e tru s o r  s tr ip s  fro m  S T Z -d ia b e t ic  ra ts  (S te v e n s  e t 
a l, 2 0 0 6 ) . T h e re fo re , it w a s  h y p o th e s is e d  th a t  th e  s p o n ta n e o u s  c o n tr a c t io n s  
d e te c te d  in  d e t r u s o r  s tr ip s  fro m  d ia b e t ic  ra ts  in  th e  c u r r e n t  s tu d y  m a y  b e  
m o d u la te d  b y  e n d o g e n o u s  A C H  re le a s e  f ro m  n o n -n e u ro n a l s o u rc e s  w ith in  th e  
b la d d e r . T o  fu r th e r  e x p lo re  th e  c h o l in e rg ic  m o d u la t io n  o f  S A  in c o n tro l ( n o n ­
d ia b e t ic )  a n d  d ia b e t ic  ra ts , d e tru s o r  s tr ip s  fro m  th e s e  a n im a ls  w e re  s t im u la te d  
w ith  lo w  c o n c e n tra t io n s  o f  th e  m u s c a r in ic  a g o n is t  C C H . C C H  in d u c e d
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s p o n ta n e o u s  c o n tra c t io n s  in  d e t r u s o r  s tr ip s  o f  b o th  c o n tro l ( n o n -d ia b e t ic )  a n d  
d ia b e t ic  ra ts , c o n f irm in g  th e  im p o r ta n c e  o f  c h o l in e rg ic  m o d u la t io n  o f  S A  in  
n o rm a l a n d  d is e a s e d  b la d d e rs . In d e t r u s o r  s t r ip s  fro m  1 -w e e k  d ia b e t ic  ra ts  th is  
C C H - in d u c e d  S A  w a s  s ig n if ic a n t ly  e n h a n c e d  re le v a n t  to  c o n tro ls  (n o n -d ia b e t ic ) .  
In  a d d it io n , a c le a r  d i f fe re n c e  in  b a s a l a n d  C C H - in d u c e d  S A  w a s  d e m o n s t ra te d  
in  th e  d e tr u s o r  s tr ip s  fro m  1 -w e e k  a n d  1 2 -w e e k  d ia b e t ic  ra ts . 1 -w e e k  d ia b e t ic  
ra ts  d e m o n s tra te d  s ig n if ic a n t ly  h ig h e r  a m p litu d e  o f  s p o n ta n e o u s  c o n tra c t io n s  
c o m p a re d  to  1 2 -w e e k  d ia b e t ic  t is s u e s . T h e  a lte re d  e x p re s s io n  o f  M 2 -  a n d  M S - 
m u s c a r in ic  re c e p to rs  o b s e rv e d  in  th e  p re s e n t s tu d y  c o u ld  b e  a n  im p o r ta n t  fa c to r  
in  m e d ia t in g  th e s e  d if fe re n c e s  b e tw e e n  1 -w e e k  a n d  1 2 -w e e k  d ia b e t ic  t is s u e s . 
H o w e v e r , a d d it io n a l p o s s ib le  u n d e r ly in g  re a s o n s  fo r  th e  d if fe re n c e s  in  th e  S A  o f  
d e tru s o r  s tr ip s  fro m  1 -w e e k  a n d  1 2 -w e e k  d ia b e t ic  t is s u e s  w e re  d is c u s s e d  in  
c h a p te r  4.
H ig h  a m p litu d e  S A  h a s  b e e n  a s s o c ia te d  w ith  D O  (N g  e t a l, 2 0 0 6 ) , s in c e  it m a y  
re s u lt  in  s y n c h ro n is a t io n  o f  th e  b la d d e r ’s  a u to n o m o u s  a c t iv ity ,  in c re a s e d  
a f fe re n t  o u tp u t  a n d  th e  s u b s e q u e n t in c re a s e  in  in tra v e s ic a l p re s s u re  a n d  
s y m p to m s  o f  u rg e n c y  a n d  f r e q u e n c y  a s s o c ia te d  w ith  D O . T h e re fo re ,  it a p p e a rs  
th a t  b la d d e rs  fro m  1 -w e e k  d ia b e t ic  ra ts  m a y  p ro v id e  a g o o d  m o d e l fo r  th e  s tu d y  
o f  D O  in th e s e  a n im a ls .
S in c e  s t im u la t io n  o f  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  t is s u e s  w ith  C C H  
re s u lte d  in  a n  in c re a s e d  S A , it w a s  im p o r ta n t  to  e lu c id a te  th e  m u s c a r in ic  
r e c e p to r  ta rg e ts  fo r  th is  a g e n t  in  th e  u r in a ry  b la d d e r  o f  th e  ra t. S in c e  m u s c a r in ic  
re c e p to rs  a re  k n o w n  to  b e  e x p re s s e d  in  th e  m u c o s a  ( re v ie w e d  b y  d e  G ro a t, 
2 0 0 4 ) , th e ir  ro le  in  m e d ia t in g  th e  S A  o f  d e t r u s o r  s tr ip s  fro m  c o n tro l (n o n ­
d ia b e t ic )  a n d  d ia b e t ic  ra ts  w a s  in v e s t ig a te d . C C H -s t im u la te d  S A  w a s  m e a s u re d  
in  in ta c t a n d  m u c o s a -d e n u d e d  d e t r u s o r  s t r ip s  fro m  c o n tro l ( n o n - d ia b e t ic )  a n d  
d ia b e t ic  ra ts . H o w e v e r ,  re m o v a l o f  th e  m u c o s a /u ro th e l iu m  d id  n o t  a l te r  th e  
C C H - in d u c e d  S A  o f  d e tru s o r  s tr ip s  fro m  e ith e r  c o n tro l ( n o n -d ia b e t ic )  o r  d ia b e t ic  
ra ts , e x c e p t  fo r  1 2 -w e e k  d ia b e t ic  t is s u e s .  T h e re fo re ,  it  w a s  c o n c lu d e d  th a t  
m u s c a r in ic  re c e p to rs  o n  th e  m u c o s a  a re  n o t  im p o r ta n t  in  m e d ia t in g  th e  p h a s ic  
d e tru s o r  c o n tra c t io n s  in  c o n tro l (n o n -d ia b e t ic )  o r  y o u n g e r  d ia b e t ic  ra ts  (1 -w e e k , 
4 -w e e k  a n d  8 -w e e k ) . In  1 2 -w e e k  d ia b e t ic  t is s u e s , re m o v a l o f  th e  m u c o s a  
re s u lte d  in  in c re a s e d  s p o n ta n e o u s  c o n tra c t io n s  c o m p a re d  to  in ta c t  t is s u e s .
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U D IF  is  k n o w n  to  b e  re le a s e d  u p o n  m u s c a r in ic  s t im u la t io n  o f  th e  m u c o s a  a n d  
h a s  b e e n  re p o r te d  to  in h ib it  b la d d e r  c o n tra c t io n s  (H a w th o rn  et al, 2 0 0 0 ). 
T h e re fo re , th e  re le a s e  o f  U D IF  m a y  b e  im p o r ta n t  in  in h ib it in g  th e  S A  o f  th e  
d e tru s o r  a t la te r  d u ra t io n s  o f  d ia b e te s  i.e . 1 2 -w e e k s .
Im m u n o c y to c h e m ic a l e v id e n c e  fro m  ro d e n ts  h a s  d e m o n s tra te d  th e  p re s e n c e  o f  
m u s c a r in ic  re c e p to rs  o n  s p e c ia lis e d  ty p e s  o f  c e lls  s u c h  a s  IC s  in  th e  
s u b u ro th e lia l re g io n  o f  th e  b la d d e r . It is  p o s s ib le  th a t  th e s e  c e l ls  c o u ld  b e  a n  
a d d it io n a l ta r g e t  fo r  m u s c a r in ic  re c e p to r  a g o n is ts  s u c h  a s  C C H  w ith in  th e  
b la d d e r , a n d  c o u ld  c o n tr ib u te  to  th e  in c re a s e d  S A  o f  th is  t is s u e . In o rd e r  to  
c h a ra c te r is e  th e  ro le  o f  IC s  in  m e d ia t in g  th e  c h o l in e rg ic  in d u c e d  S A  o f  ra t 
u r in a ry  b la d d e r , th e  e f fe c t  o f  in h ib it io n  o f  th e s e  c e lls , u s in g  th e  c -k it  ty ro s in e  
k in a s e  in h ib ito r  G liv e c , w a s  in v e s t ig a te d  in  d e t r u s o r  s tr ip s  fro m  c o n tro l (n o n ­
d ia b e t ic )  a n d  d ia b e t ic  ra ts  (c h a p te r  6 ). G liv e c  in h ib ite d  C C H - in d u c e d  S A  o f  
d e tru s o r  s tr ip s  fro m  b o th  g ro u p s  s u g g e s t in g  a n  in v o lv e m e n t o f  IC s  in  re g u la t io n  
o f  S A  in  th e  ra t b la d d e r . T h is  h y p o th e s is  is  s u p p o r te d  b y  s tu d ie s  d e m o n s t ra t in g  
th e  ro le  o f  IC s  in m e d ia t in g  th e  S A  in  h u m a n  b la d d e rs  (B ie rs  e t  a l, 2 0 0 5 ) . S in c e  
IC s  b e lo n g  to  a m u lt ip o te n t  g ro u p  o f  fu n c t io n a l re g u la to ry  c e l ls  a n d  it is  
h y p o th e s is e d  th a t  s o m e  o f  th e s e  c e lls  m a y  b e  s itu a te d  in  th e  s u b u ro th e lia l 
re g io n  a n d  s o m e  w ith in  th e  m u s c le  b u n d le s  a n d  a ro u n d  s m o o th  m u s c le  c e lls . 
T h u s , it is  im p o r ta n t  to  d e te rm in e  w h ic h  p o p u la t io n  o f  th e s e  c e lls  is  m o re  
im p o r ta n t  in  m e d ia t in g  th e  c h o l in e rg ic  m e d ia te d  S A  in  ra t b la d d e r . In  th e  c u r r e n t  
s tu d y , th e  ro le  o f  s u b u ro th e lia l  IC s  in  m e d ia t in g  th e  S A  in  ra t  b la d d e r  c a n  b e  
ru le d  o u t to  s o m e  e x te n t , s in c e  re m o v a l o f  th e  m u c o s a  d id  n o t a f fe c t  th e  
d e tru s o r  re s p o n s e s  to  G liv e c  in  e ith e r  c o n tro l (n o n -d ia b e t ic )  o r  d ia b e t ic  ra ts . 
T h is  s u g g e s ts  th a t  IC s  w ith in  th e  s m o o th  m u s c le  b u n d le s  a n d  b e tw e e n  s m o o th  
m u s c le  c e lls  m a y  b e  m o re  im p o r ta n t  in  m e d ia t in g  th is  a c t iv i ty  in  ra t  u r in a ry  
b la d d e r  a n d  th a t  th e  s u b u ro th e lia l IC s  ( i f  th e y  e x is t  in ra t  b la d d e r )  m a y  b e  m o re  
im p o r ta n t  in  s e n s o ry  tr a n s d u c t io n  a n d  c o m m u n ic a t io n  b e tw e e n  a f fe re n t  n e rv e s , 
u ro th e lia l c e lls  a n d  s m o o th  m u s c le  c e lls .
S in c e  c h a n g e s  in  m u s c a r in ic -m e d ia te d  c o n tra c t io n s  o f  th e  d e t r u s o r  h a v e  b e e n  
s u g g e s te d  to  b e  im p o r ta n t  in  p a th o lo g ic a l c o n d it io n s , it w a s  a ls o  im p o r ta n t  to  
d e te rm in e  w h ic h  m u s c a r in ic  re c e p to r  s u b ty p e  w a s  im p o r ta n t  in  m e d ia t in g  th e  
S A . S tu d ie s  h a v e  d e m o n s tra te d  a n  in c re a s e d  e x p re s s io n  o f  b o th  M 2 -  a n d  M S - 
m u s c a r in ic  re c e p to rs  in  th e  d e tru s o r  a n d  th e  u ro th e liu m  o f  th e  S T Z -d ia b e t ic  ra t
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(T o n g  e t a l, 1 9 9 9 , 2 0 0 2  &  2 0 0 6 ; C h e n g  e t  a l, 2 0 0 7 ) . W e  w e re  u n a b le  to  
c o m m e n t  o n  th e  e x p re s s io n  le v e ls  o f  m u s c a r in ic  re c e p to rs  o n  th e  u ro th e liu m  o f  
S T Z -d ia b e t ic  ra ts , b u t w e  d id  d e m o n s t ra te  th a t  th e  e x p re s s io n  o f  M 2 -m u s c a r in ic  
re c e p to r  m R N A  w a s  in c re a s e d  in  th e  d e tru s o rs  o f  a ll d ia b e t ic  ra ts  e x c e p t  1 2 - 
w e e k  d ia b e t ic  t is s u e s , w h ic h  d e m o n s tra te d  n o  c h a n g e  in  th e  e x p re s s io n  le v e l o f  
th is  re c e p to r  s u b ty p e . T h e  e x p re s s io n  le v e ls  o f  M 3 -m u s c a r in ic  re c e p to rs  w e re  
d e c re a s e d  in  a ll d ia b e t ic  t is s u e s  e x c e p t  1 -w e e k  d ia b e t ic  t is s u e s , w h ic h  
d e m o n s tra te d  a n  in c re a s e d  e x p re s s io n  o f  th is  re c e p to r  s u b ty p e . It m u s t  b e  
n o te d  th a t  le v e ls  o f  m R N A  w ill n o t a lw a y s  re f le c t  th e  le v e l o f  th e  e n c o d e d  
p ro te in . F o r  e x a m p le  it h a s  b e e n  d e m o n s tra te d  in  h u m a n s  th a t  le v e ls  o f  M 3 -  
a n d  M 4 -m u s c a r in ic  re c e p to rs  m R N A  d o  n o t c o r re la te  w ith  th e ir  p ro te in  
d e n s it ie s ,  a lth o u g h  M 2 -m u s c a r in ic  re c e p to r  e x p re s s io n  d id  s h o w  a p o s it iv e  
c o r re la t io n  b e tw e e n  a m o u n t o f  m R N A  e x p re s s e d  a n d  its  t r a n s c r ip t io n  (A r r ig h i et 
al, 2 0 0 8 ) . T h e s e  re s u lts  a re  in  l in e  w ith  th o s e  re p o r te d  b y  B ra v e rm a n  &  R u g g ie r i
(2 0 0 6 ) , w h o  h a v e  s h o w n  th a t  M 2 -m u s c a r in ic  re c e p to r  p ro te in  d e n s ity  c o r re la te s  
d ire c t ly  w ith  th e  re s p e c t iv e  t r a n s c r ip ts ,  w h ils t  n o  c o r re la t io n  e x is ts  b e tw e e n  th e  
p ro te in  a n d  t r a n s c r ip t  le v e ls  o f  th e  M 3 -m u s c a r in ic  re c e p to r  s u b ty p e  in  ra t  u r in a ry  
b la d d e r . In d e e d  i f  th is  is  tru e , th e n  th e  d e c re a s e d  e x p re s s io n  o f  M 3 -m u s c a r in ic  
re c e p to rs  fo u n d  in 4 -w e e k  to  1 2 -w e e k  d ia b e t ic  ra t b la d d e rs  in  th e  p re s e n t  s tu d y  
m a y  n o t b e  re f le c te d  a t th e  p ro te in  le v e l. T h is  m a y  a ls o  m e a n  th a t  th e  in c re a s e d  
S A  d e te c te d  in  d ia b e t ic  ra t  b la d d e rs  (e x c e p t  1 2 -w e e k  d ia b e t ic s )  m a y  b e  
m e d ia te d  v ia  a c o m b in a t io n  o f  b o th  re c e p to rs .  T h e  la t te r  h y p o th e s is  is  
s u p p o r te d  b y  a re c e n t  s tu d y  d e m o n s tra t in g  th a t  a c t iv a t io n  o f  M 2 -  a s  w e ll a s  M S - 
m u s c a r in ic  re c e p to rs  b y  e n d o g e n o u s  A C H  c a n  e n h a n c e  s p o n ta n e o u s  
c o n tra c t io n s  in w h o le  b la d d e r  p re p a ra t io n s  f ro m  n e o n a ta l a n d  p o s tn a ta l ra ts  (N g  
e t  a l, 2 0 0 6 ) . M u k e r ji  e t  a l (2 0 0 6 )  a ls o  s h o w e d  in c re a s e d  im m u n o s ta in in g  fo r  M 2 -  
a n d  M 3 -m u s c a r in ic  re c e p to rs  in  s u b u ro th e lia l m y o f ib ro b la s t- l ik e  c e lls  in  p a in fu l 
b la d d e r  s y n d ro m e s  a n d  id io p a th ic  D O , w h ic h  c o r re la te d  w ith  c l in ic a l s c o re s  o f  
u rg e n c y , s u g g e s t in g  a ro le  in  p a th o p h y s io lo g y .  F u r th e r  s tu d ie s  lo o k in g  a t th e  
e x p re s s io n  le v e ls  o f  th e s e  re c e p to rs  a t th e  p ro te in  le v e l in  th e  d e tru s o r ,  m u c o s a  
a n d  IC s  a n d  u s in g  m o re  s p e c if ic  m u s c a r in ic  re c e p to r  a g o n is ts  a n d  a n ta g o n is ts  
w o u ld  e n h a n c e  o u r  u n d e rs ta n d in g  o f  th e ir  ro le  in  m e d ia t in g  d e tr u s o r  
c o n tra c t io n s  in  th is  a n im a l m o d e l.
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E n d o g e n o u s  A C H  re le a s e d  in  th e  b la d d e r  m a y  a ls o  in d u c e  th e  re le a s e  o f  o th e r  
n e u ro t ra n s m it te rs ,  s u c h  a s  A T P , b y  s t im u la t io n  o f  m u s c a r in ic  re c e p to rs  in  th e  
u ro th e liu m . T h is  c o u ld  in d u c e  D O  b y  s t im u la t in g  p u r in e rg ic  r e c e p to rs  e x p re s s e d  
o n  th e  a f fe re n t  n e rv e s  a n d  IC s , fu r th e r  a d d in g  to  th e  c o m p lic a te d  in te ra c t io n s  
b e tw e e n  d i f fe re n t  c o m p o n e n ts  o f  th e  b la d d e r  w a ll m e d ia t in g  d e tr u s o r  
c o n tra c t i l i ty  (W u  e t  a l, 2 0 0 4 ; re v ie w e d  b y  F o w le r  e t  a l, 2 0 0 8 ) . T h e  ro le  o f  A T P  
a n d  p u r in e rg ic  re c e p to rs  w a s  n o t in v e s t ig a te d  in  th e  ra t  b la d d e r  in  th is  s tu d y , b u t 
m a y  b e  w o r th  fu tu re  in v e s t ig a t io n .
7.2 Smooth muscle cell excitability mediating contractile 
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A s  w e ll a s  c h a n g e s  in  c h o l in e rg ic  m o d u la t io n  o f  b la d d e r  c o n tra c t i l i ty ,  c h a n g e s  in 
U B S M  a n d  1C e x c ita b i l i ty  m a y  a ls o  b e  im p o r ta n t  in  b la d d e r  d y s fu n c t io n ,  
e s p e c ia l ly  s in c e  o v e r  re c e n t y e a rs  it h a s  b e c o m e  c le a r  th a t  S A  o f  th e  u r in a ry  
b la d d e r  is  d e p e n d e n t  u p o n  e le c tr ic a l p ro p e r t ie s  o f  s m o o th  m u s c le  c e lls . 
C h o lin e rg ic  s t im u la t io n  o f  U B S M  c o n tra c t io n  a n d  M 3 - m u s c a r in ic  r e c e p to r  
p a th w a y , a s  w e ll a s  th e  e le c tr ic a l p ro p e r t ie s  o f  s m o o th  m u s c le  c e lls  a n d  IC s , a re  
d e p e n d e n t  u p o n  io n  c o n d u c ta n c e  a c ro s s  th e  c e ll m e m b ra n e . It h a s  b e e n  
d e m o n s tra te d  th a t  M 3 -m u s c a r in ic  re c e p to r  a c t iv a t io n  re s u lts  in  u r in a ry  b la d d e r  
s m o o th  m u s c le  (U B S M ) m e m b ra n e  d e p o la r is a t io n  a s  a re s u lt  o f  C a 2+ e n try  
th ro u g h  v o lta g e  d e p e n d e n t C a 2+ c h a n n e ls  (V D C C s )  (E k m a n  e t  a l, 2 0 0 6 ; E k m a n  
e t a l, 2 0 0 9 ) . C a 2+ e n tr y  th ro u g h  V D C C s  le a d s  to  a n  in c re a s e  in  g lo b a l 
in t ra c e l lu la r  C a 2+, w h ic h  is  im p o r ta n t  in  in it ia t io n  o f  a c t io n  p o te n t ia ls  th a t  u n d e r l ie  
th e  s p o n ta n e o u s  c o n tra c t io n s  (E k m a n  e t a l, 2 0 0 9 ) . T h e  re p o la r is a t io n  p h a s e  o f  
th e  U B S M  a c t io n  p o te n t ia l,  re g u la t io n  o f  C a 2+ e n tr y  a n d  s u b s e q u e n t  re la x a t io n  
o f  U B S M  is  m e d ia te d  b y  th e  a c t iv i ty  o f  v a r io u s  K + c h a n n e ls ,  e s p e c ia l ly  B K Ca 
c h a n n e ls .  S in c e  o p e n in g  o f  K + c h a n n e ls  le a d s  to  re la x a t io n  o f  th e  d e tru s o r ,  
a g e n ts  th a t  m e d ia te  th e  a c t iv a t io n  o f  th e s e  c h a n n e ls  a re  b e in g  c o n s id e re d  a s  a n  
a lte rn a t iv e  th e ra p e u t ic  t r e a tm e n t  fo r  D O  a n d  O A B S  ( re v ie w e d  b y  S e lle rs  &  
M c K a y , 2 0 0 7 ).
T h e  ro le  o f  K + c h a n n e ls  is  n o t o n ly  im p o r ta n t  in  m e d ia t in g  th e  re p o la r is a t io n  o f  
U B S M  a c t io n  p o te n t ia ls  a n d  re la x a t io n , b u t it h a s  a ls o  b e e n  s h o w n  th a t  th e ir  
in h ib it io n  v ia  th e  M 2 -m u s c a r in ic  re c e p to r  p a th w a y  c o n tr ib u te s  to  U B S M
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c o n tra c t io n  (N a k a m u ra  e t a l, 2 0 0 2 ) , h ig h lig h t in g  th e  c o m p le x  in te ra c t io n s  o f  
th e s e  c h a n n e ls  w ith  v a r io u s  c o m p o n e n ts  o f  s ig n a ll in g  p a th w a y s  m e d ia t in g  
U S B M  c o n tra c t i le  a c t iv ity . 1C c e lls  w ith in  th e  b la d d e r  h a v e  a ls o  b e e n  s h o w n  to  
p o s s e s s  C a 2+-a c t iv a te d  a n d  v o l ta g e -d e p e n d e n t  K + c u r re n ts  (M c C lo s k e y , 2 0 0 5 ) . 
T h e s e  s tu d ie s  h ig h lig h t  th e  im p o r ta n c e  o f  K + c h a n n e ls  in  m e d ia t in g  d e tr u s o r  
c o n tra c t i l i ty .  T h u s , th e  ro le  o f  K + c h a n n e ls  in  m e d ia t in g  C C H - in d u c e d  S A  w a s  
in v e s t ig a te d  in th is  s tu d y .
In  a n  a t te m p t  to  e lu c id a te  th e  ro le  o f  la rg e  c o n d u c ta n c e  C a 2+ a c t iv a te d  K + B K c a 
c h a n n e ls  in  m o d u la t in g  b a s a l a n d  C C H - in d u c e d  S A  in  d e t r u s o r  s tr ip s  fro m  
c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  ra ts , t is s u e s  w e re  in c u b a te d  w ith  a  b lo c k e r  
( ib e r io to x in  ( IB T X ))  o r  a n  o p e n e r  (N S 1 6 1 9 )  o f  th is  c h a n n e l re s p e c t iv e ly  (c h a p te r  
5 ). It w a s  d e m o n s tra te d  th a t  o p e n in g  o f  B K Ca c h a n n e ls  re d u c e s  o n ly  th e  
a m p litu d e  o f  S A  in  d e tru s o r  s tr ip s  fro m  b o th  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  
ra ts  a n d  th a t  th is  e f fe c t  w a s  s e e n  o n ly  a t  th e  h ig h e s t  c o n c e n tra t io n  o f  N S 1 6 1 9 . 
T h e  la c k  o f  fu n c t io n a l re s p o n s e s  o f  d e t r u s o r  s t r ip s  fro m  c o n tro l ( n o n -d ia b e t ic )  
a n d  d ia b e t ic  ra ts  to  N S 1 6 1 9  in  th is  s tu d y  a re  in  l in e  w ith  a  re c e n t  re p o r t  
d e m o n s tra t in g  th a t  m o d u la t io n  o f  B K Ca c h a n n e ls  is  n o t im p o r ta n t  in  m e d ia t in g  
C C H - in d u c e d  S A  o f  d e tru s o rs  fro m  n e w b o rn  a n d  a d u lt  m ic e  (E k m a n  e t  a l,
2 0 0 9 ) . T h e  p o s s ib le  re a s o n s  fo r  th is  la c k  o f  fu n c t io n a l re s p o n s e  o f  d e t r u s o r  
s tr ip s  fro m  th e  ra t to  N S 1 6 1 9  in  th e  c u r re n t  s tu d y  c o u ld  b e  th a t  m o d u la t io n  o f  
c h a n n e ls  u n d e r  th e  c u r re n t  e x p e r im e n ta l s e t  u p  m a y  n o t  n e c e s s a r i ly  t r a n s la te  to  
a fu n c t io n a l p h y s io lo g ic a l re s p o n s e . In  th is  s tu d y  th e  m e a s u re d  v a r ia b le  is  th e  
c o n tra c t i le  re s p o n s e  o f  d e tru s o r  s tr ip s , w h ic h  is  m o d u la te d  b y  v a r io u s  
c o m p lic a te d  m e c h a n is m s  a n d  s ig n a ll in g  p a th w a y s . F o r  e x a m p le  a s  w e ll a s  
s m o o th  m u s c le  c e lls , IC s  w ith in  th e  b la d d e r  in  g u in e a -p ig s  a n d  h u m a n s  a ls o  
d e m o n s tra te  B K  c u r re n ts  (S u i e t  a l, 2 0 0 4 ; M c C lo s k e y , 2 0 0 5 )  a n d  it c o u ld  b e  
s p e c u la te d  th a t  IC s  m a y  a ls o  b e  in v o lv e d  in th e  fu n c t io n a l re s p o n s e s  o f  ra t  
b la d d e rs  to  B K Ca c h a n n e l m o d u la to rs .  T h e s e  c o m p le x  in te ra c t io n s  m a y  a c t 
to g e th e r  to  p ro d u c e  th e  f in a l re s u lt: c o n tra c t io n  o f  th e  b la d d e r .  T h e re fo re ,  in  
o rd e r  to  u n d e rs ta n d  th e  ro le  o f  N S 1 6 1 9  in  m o d u la t in g  th e  S A  o f  th e  b la d d e r ,  
e a c h  o f  th e s e  c o n tr ib u t in g  fa c to rs  m u s t  b e  d is s e c te d  a n d  s tu d ie d  in d iv id u a lly .
A lth o u g h  o p e n in g  o f  B K Ca c h a n n e ls  h a d  lim ite d  e f fe c t  in  m e d ia t in g  th e  S A , 
in h ib it io n  o f  th e s e  c h a n n e ls  b y  th e  s p e c if ic  B K Ca c h a n n e l b lo c k e r  IB T X  d id  
s ig n if ic a n t ly  a f fe c t  th e  b a s a l S A  o f  d e t r u s o r  s t r ip s  fro m  c o n tro l ( n o n - d ia b e t ic )
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a n d  d ia b e t ic  ra ts , d e m o n s tra t in g  th a t  th e s e  c h a n n e ls  m a y  b e  im p o r ta n t  in 
m o d u la t in g  th e  b a s a l m e m b ra n e  e x c ita b i l i ty  in  U B S M  o f  th e  ra t. T h e s e  re s u lts  
a re  fu r th e r  s u p p o r te d  b y  v a r io u s  s tu d ie s  d e m o n s tra t in g  th a t  B K c a c h a n n e l 
b lo c k a d e  in  U B S M  c e lls  re s u lts  in in c re a s e d  b a s a l S A  in d e tru s o rs  fro m  v a r io u s  
s p e c ie s  ( Im a i e t  a l, 2 0 0 1 ; B u c k n e r  e t  a l, 2 0 0 2 ; D a rb la d e  e t a l, 2 0 0 6 ; N g  e t a l, 
2 0 0 7 ) . 1 -w e e k  d ia b e t ic  t is s u e s  a p p e a re d  to  b e  m o re  s e n s it iv e  to  m o d u la t io n  b y  
IB T X , w h ils t  1 2 -w e e k  d ia b e t ic  t is s u e s  w e re  re la t iv e ly  in s e n s it iv e  to  th is  b lo c k e r , 
a g a in  h ig h lig h t in g  th e  c le a r  d if fe re n c e s  in  b la d d e r  fu n c t io n  b e tw e e n  1 -w e e k  a n d  
1 2 -w e e k  d ia b e t ic  ra ts . T h e  u n d e r ly in g  re a s o n s  fo r  th e  d i f fe re n c e s  in th e  
s e n s it iv ity  o f  1 -w e e k  a n d  1 2 -w e e k  d ia b e t ic  t is s u e s  to  IB T X  a re  d is c u s s e d  in 
C h a p te r  5, b u t m a y  b e  d u e  to  d if fe re n t  u n d e r ly in g  m e c h a n is m s  c o n tro ll in g  th e  
m e m b ra n e  p o te n t ia l o f  U B S M  c e lls  o r  a lte re d  le v e ls  o f  U B S M  a c t iv i ty  a n d  
e x c ita b i l i ty  in  th e s e  ra ts . T h e  ro le  o f  IC s  in  m o d u la t in g  th e  b a s a l S A  in  ra t 
b la d d e r  m u s t a ls o  b e  c o n s id e re d . W h a te v e r  th e  u n d e r ly in g  c a u s e , th e  in c re a s e d  
s p o n ta n e o u s  c o n tra c t io n s  a s  a re s u lt  o f  B K Ca c h a n n e l in h ib it io n  m a y  re s u lt  in  
in c re a s e d  a ffe re n t  o u tp u t  f ro m  th e  b la d d e r  a n d  c a u s e  D O .
A n  im p o r ta n t  f in d in g  fro m  th e  c u r re n t  s tu d y  w a s  th a t  th e  m R N A  e x p re s s io n  o f 
B K Ca c h a n n e l s u b u n its  d e c re a s e d  w ith  d u ra t io n  in d ia b e t ic  t is s u e s .  T h is  
o b s e rv a t io n  d id  n o t c o r re la te  w ith  th e  p a tte rn  o f  S A  d e te c te d  in  1 -w e e k -1 2 -w e e k  
d ia b e t ic  t is s u e s , b u t c o u ld  e x p la in  th e  a lte re d  le v e ls  o f  U B S M  a c t iv i ty  a n d  
e x c ita b il i ty .  M e a s u r in g  th e  B K c a c u r re n ts  a t s in g le  c e ll le v e l in  U B S M  c e lls  a n d  
IC s  u s in g  e le c tro p h y s io lo g y  in  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  t is s u e s  c o u ld  
fu r th e r  c la r ify  th e  ro le  o f  th e s e  c h a n n e ls  in  m e d ia t in g  th e  S A  o f  th e  d e tru s o r .
In te rm s  o f  th e  ro le  o f  o th e r  C a 2+ a c t iv a te d  K + c h a n n e ls ,  o n ly  th e  e f fe c t  o f  
b lo c k in g  s m a ll c o n d u c ta n c e  C a 2+ a c t iv a te d  K + (S K c a)c h a n n e ls  o n  b a s a l S A  w a s  
in v e s t ig a te d  in c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  t is s u e s . S K c a c h a n n e ls  d id  n o t 
p la y  a ro le  in  m e d ia t in g  th e  U B S M  m e m b ra n e  p o te n t ia l a n d  S A  in  th e s e  ra ts , 
w h ic h  is  in  c o n tra s t  to  th e  re s u lts  o f  o th e r  s tu d ie s  d e m o n s tra t in g  th e  im p o r ta n c e  
o f  S K Ca c h a n n e ls  in  m o d u la t in g  th e  S A  in  d e t r u s o r  s tr ip s  o f  v a r io u s  s p e c ie s  
(H e r re ra  et al, 2 0 0 3 ; H o u g a rd  et al, 2 0 0 9 ) . H o w e v e r , to  c o n f irm  th is , fu r th e r  
a n a ly s is  w ith  v a r io u s  S K c a c h a n n e l o p e n e rs  a n d  s tu d y in g  th e  e x p re s s io n  le v e ls  
o f  th e s e  c h a n n e ls  in  U B S M  w o u ld  a id  o u r  u n d e rs ta n d in g  o f  th e  ro le  o f  th e s e  
c h a n n e ls  in ra t  u r in a ry  b la d d e r .
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T h e  ro le  o f  A T P  s e n s it iv e  K + ( K A t p )  c h a n n e ls  in  m o d u la t in g  C C H - in d u c e d  a n d  
b a s a l S A  w a s  a ls o  in v e s t ig a te d  in  d e t r u s o r  s tr ip s  fro m  c o n tro ls  (n o n -d ia b e t ic )  
a n d  d ia b e t ic  ra ts . In  c o n tra s t  to  th e  e f fe c t  o f  th e  B K c a c h a n n e l o p e n e r  N S 1 6 1 9 , 
o p e n in g  o f  K At p  c h a n n e ls  b y  c ro m a k a lim  in h ib ite d  th e  f r e q u e n c y  o f  S A  o n ly , 
d e m o n s tra t in g  th a t  o p e n in g  o f  th e s e  c h a n n e ls  in  U B S M  m a y  b e  a f fe c t in g  a c t io n  
p o te n t ia l a c t iv a t io n  a n d  f ir in g . D e tru s o r  s tr ip s  fro m  d ia b e t ic  ra ts  d e m o n s t ra te d  a 
t re n d  to w a rd s  b e in g  le s s  s e n s it iv e  to  in h ib it io n  b y  c ro m a k a lim  th a n  d e tru s o r  
s tr ip s  fro m  c o n tro l (n o n -d ia b e t ic )  t is s u e s . T h is  m a y  b e  d u e  to  d o w n re g u la t io n  o f  
K a t p  c h a n n e l a c t iv i ty  in th e  d ia b e t ic  t is s u e s  a s  a re s u lt  o f  d e c re a s e d  e x p re s s io n  
o f  K a t p  c h a n n e l s u b u n its ,  w h ic h  w a s  d e te c te d  a t th e  m R N A  le v e l in  th e  c u r re n t  
s tu d y . R e g u la t io n  o f  K ATp c h a n n e l fu n c t io n  a n d  e x p re s s io n  b y  h y p e rg ly c a e m ia  in 
v a r io u s  c e ll ty p e s  h a s  b e e n  re p o r te d  p re v io u s ly  (A c o s ta -M a r t in e z  &  L e v in e , 
2 0 0 7 ; K in o s h ita  e t  a l, 2 0 0 8 ) . F o r  e x a m p le  in  th e  s tu d y  b y  A c o s ta -M a r t in e z  &  
L e v in  (2 0 0 7 ) , it w a s  d e m o n s tra te d  th a t  h y p e rg ly c a e m ia  re d u c e s  th e  e x p re s s io n  
o f  K ATp c h a n n e ls  in  b ra in  c e lls  a n d  n e u ro n s , a n d  th is  re d u c t io n  m a y  re s u lt  in 
a lte re d  e x c ita b i l i ty  o f  th e s e  c e lls . T h e  s a m e  m e c h a n is m  c o u ld  b e  p o s tu la te d  in 
U B S M  c e lls  o f  d ia b e t ic  ra t b la d d e r . H o w e v e r ,  m e a s u r in g  th e  g lu c o s e  le v e ls  in 
U B S M  c e lls  a n d  i ts ’ ro le  in  m e d ia t in g  v a r io u s  re g u la to ry  p a th w a y s  le a d in g  to  
d e tru s o r  c o n tra c t i l i ty  a n d  e x c ita b i l i ty  w e re  b e y o n d  th e  s c o p e  o f  th is  th e s is  a n d  
c o u ld  b e  in v e s t ig a te d  in fu tu re  re s e a rc h . F u r th e r  e x p e r im e n ts  e lu c id a t in g  th e  
e x p re s s io n  o f  K ATp c h a n n e ls  a t  th e  p ro te in  le v e l c o u ld  a ls o  b e  u s e fu l.  A ls o  s in c e  
th e  S A  w a s  in d u c e d  b y  s t im u la t io n  o f  th e  t is s u e s  w ith  C C H , it c o u ld  b e  
p o s tu la te d  th a t  m u s c a r in ic  re c e p to r  a c t iv a t io n  m a y  in h ib it  K ATp c h a n n e l a c t iv ity ,  
e s p e c ia l ly  w h e re  a n  in c re a s e d  e x p re s s io n  o f  M 2 -  a n d  M 3 - m u s c a r in ic  re c e p to rs  
m R N A  h a s  b e e n  d e te c te d  (1 -w e e k  d ia b e t ic  ra ts ) . In o th e r  w o rd s  c h o l in e rg ic  
s t im u la t io n  o f  m u s c a r in ic  re c e p to rs  m a y  in it ia te  a c a s c a d e  o f  e v e n ts  in  U B S M  
le a d in g  to  d e c re a s e d  a c t iv ity  o f  K ATp c h a n n e ls ,  a n d  s in c e  th e re  is  a n  in c re a s e d  
e x p re s s io n  o f  m u s c a r in ic  re c e p to rs  in  1 -w e e k  d ia b e t ic  t is s u e s , th is  in h ib ito ry  
e f fe c t  o n  th e  K ATp c h a n n e ls  m a y  b e  e n h a n c e d , re s u lt in g  in  a d e c re a s e d  
fu n c t io n a l re s p o n s e  to  K ATp c h a n n e l o p e n e r ,  c ro m a k a lim .
In c o n tra s t  to  th e  e f fe c t  o f  c ro m a k a lim , th e  K ATp c h a n n e l b lo c k e r  g lib e n c la m id e ,  
fa i le d  to  h a v e  a s ig n if ic a n t  e f fe c t  on  th e  b a s a l S A  in  b o th  c o n tro l (n o n - d ia b e t ic )  
a n d  d ia b e t ic  t is s u e s , in d ic a t in g  th a t  th e  b lo c k a d e  o f  K ATp c h a n n e ls  a t  s in g le  
c h a n n e l le v e l m a y  n o t b e  a d e q u a te  to  re s u lt  in  a n  a lte re d  m e a s u ra b le  fu n c t io n a l
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re s p o n s e  in  t is s u e  b a th  e x p e r im e n ts . A n o th e r  p o s s ib il ity  m a y  b e  th a t  b lo c k in g  
K atp c h a n n e ls  is  n o t im p o r ta n t  in re g u la t in g  th e  S A  u n d e r  b a s a l c o n d it io n s .
S in c e  o p e n in g  o f  B K Ca c h a n n e ls  re s u lte d  in  in h ib it io n  o f  th e  a m p litu d e  o f  S A  a n d  
o p e n in g  o f  th e  K a tp  c h a n n e ls  in h ib ite d  th e  f r e q u e n c y  o f  S A , it c o u ld  b e  
p o s tu la te d  th a t  B K Ca a n d  K a tp  c h a n n e ls  o n  s m o o th  m u s c le  a c t  to g e th e r  v ia  
c o m p le x  m e c h a n is m s , w h ic h  m a y  a ls o  in v o lv e  in te ra c t io n s  w ith  IC s  a n d  o th e r  
s ig n a ll in g  p a th w a y s  a s s o c ia te d  w ith  m u s c a r in ic  re c e p to r  s t im u la t io n  in  U B S M  
c e lls , to  m o d u la te  th e  S A  in  ra t u r in a ry  b la d d e r .
IK Ca a n d  K v c h a n n e ls  m a y  a ls o  b e  im p o r ta n t  in  m e d ia t in g  th e  U B S M  m e m b ra n e  
p o te n t ia l a n d  th e  S A  o f  th e  d e tru s o r  fro m  c o n tro l (n o n -d ia b e t ic )  a n d  d ia b e t ic  
ra ts . T h u s , fu tu re  in v e s t ig a t io n s  o n  th e  ro le  o f  th e s e  c h a n n e ls  m a y  a ls o  b e  
u s e fu l.
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7.3 Summary and conclusions
In  c o n c lu s io n  th e  re s u lts  o f  th e  p re s e n t s tu d y  d e m o n s t ra te  th a t  in  o rd e r  to  
u n d e rs ta n d  th e  m e c h a n is m s  u n d e r ly in g  n o rm a l a n d  a b n o rm a l d e t r u s o r  
c o n tra c t io n s , it is  im p o r ta n t  to  c o n s id e r  n o t o n ly  th e  p a th w a y s  th a t  m e d ia te  
d ire c t  U B S M  c e ll c o n tra c t io n , b u t a ls o  th e  c o m p le x  in te ra c t io n  o f  v a r io u s  
m e c h a n o s e n s o ry  c o m p o n e n ts  o f  th e  u r in a ry  b la d d e r  w a ll s u c h  a s  th e  m u c o s a , 
a f fe re n t  n e rv e s  a n d  IC s , th a t  h a v e  re c e n t ly  b e c o m e  a  fo c u s  o f  in te re s t  in  th is  
a re a .
In  th is  th e s is ,  th e  p h y s io lo g y  a n d  p a th o p h y s io lo g y  o f  d e tru s o r  in  n o rm a l a n d  
d ia b e t ic  ra t b la d d e rs  w e re  e x p lo re d . It w a s  d e m o n s tra te d  s o m e  c h a n g e s  w ith in  
th e  c h o l in e rg ic  p a th w a y s  m e d ia t in g  d e tr u s o r  c o n tra c t io n  in  th e  a n im a l m o d e l, 
e s p e c ia l ly  th o s e  m e d ia t in g  th e  s p o n ta n e o u s  c o n tra c t io n s  o f  th e  b la d d e r  in  th e s e  
a n im a ls .  M a rk e d  d if fe re n c e s  w e re  d e te c te d  in  S A  o f  th e  b la d d e rs  fro m  1 -w e e k  
d ia b e t ic  a n d  1 2 -w e e k  d ia b e t ic  a n im a ls .
T h is  s tu d y  a ls o  id e n t if ie d  a  n e tw o rk  o f  s p e c ia lis e d  c e lls  ( IC s )  in  th e  ra t  u r in a ry  
b la d d e r  a n d  it w a s  d e m o n s tra te d  th a t  th e s e  IC s  h a v e  a ro le  in  m e d ia t in g  th e  
s p o n ta n e o u s  c o n tra c t io n s  o f  th e  d e t r u s o r  u n d e r  n o rm a l a n d  d ia b e t ic  s ta te s .
T h e  ro le  o f  v a r io u s  K + c h a n n e ls  m o d u la to rs  o n  m o d u la t in g  th e  c h o l in e rg ic  
in d u c e d  S A  w a s  in v e s t ig a te d . S o m e  c h a n g e s  w e re  d e te c te d  in  th e  d ia b e t ic  
t is s u e s  in  th e ir  re s p o n s e  to  K + c h a n n e l m o d u la t io n .
S in c e  th e  d e tr u s o r  s tr ip s  fro m  1 -w e e k  d ia b e t ic  a n im a ls  d e m o n s tra te d  th e  m o s t 
s tr ik in g  c h a ra c te r is t ic s ,  s o m e  o f  w h ic h  h a v e  a ls o  b e e n  d e m o n s t ra te d  in  
o v e ra c t iv e  b la d d e rs , th e n  it c a n  b e  c o n c lu d e d  th a t  d ia b e t ic  a n im a ls  a t  th is  
d u ra t io n  o f  d ia b e te s  c o u ld  b e  u s e d  a s  a m o d e l o f  D O .
T h e  d a ta  p re s e n te d  in  th is  th e s is  in d ic a te s  th a t  c o m p le x  m e c h a n is m s  s e rv in g  
b a s ic  p h y s io lo g ic a l p ro c e s s e s  a re  p re s e n t  in  th e  u r in a ry  b la d d e r . H o w e v e r ,  it is  
c le a r  th a t  n o t e n o u g h  is  k n o w n  a b o u t th e  d e ta i le d  in te g ra te d  p h y s io lo g y  o f  th e  
b la d d e r  w a ll a n d  th e  s tr u c tu re s  in v o lv e d . In  th e  c a s e  o f  s p o n ta n e o u s  
c o n tra c t io n s  o f  th e  b la d d e r , d a ta  a re  h ig h ly  s u g g e s t iv e  th a t  th is  s y s te m  p la y s  a n  
im p o r ta n t  ro le  in g e n e ra t in g  a n d  m o d u la t in g  s e n s a t io n s  o r ig in a t in g  in  th e
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b la d d e r  w a ll a n d  in v o lv e s  c o m p le x  in te ra c t io n s  b e tw e e n  v a r io u s  c o m p o n e n ts  
p re s e n t  in  th e  u r in a ry  b la d d e r . It w o u ld  o n ly  b e  p o s s ib le  to  g a in  a  b e t te r  
p e rs p e c t iv e  o f  th is  s e n s o ry  s y s te m  fro m  d e ta ile d  a n a ly s is  o f  th e  in te g ra te d  
w h o le  is o la te d  o rg a n . S u c h  c o m p le x  e v e n ts  c a n  n o t b e  p re d ic te d  fro m  d a ta  o n  
s m a ll p ie c e s  o f  t is s u e  o b ta in e d  fro m  h u m a n  p a tie n ts , e m p h a s is in g  th e  
im p o r ta n c e  o f  a n im a l m o d e ls  in re v e a lin g  b a s ic  p r in c ip le s  o f  b la d d e r  fu n c t io n  
a n d  c o n tro l.
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